An investigation into determinants of adherence to anti-psychotic medication by Satti, F.
              
City, University of London Institutional Repository
Citation: Satti, F. (2017). An investigation into determinants of adherence to anti-
psychotic medication. (Unpublished Doctoral thesis, City, University of London) 
This is the accepted version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  http://openaccess.city.ac.uk/21747/
Link to published version: 
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
 1 
 
Portfolio of  
Doctorate in  
Health Psychology 
 
 
Faisal Satti 
 
 
 
 
For the qualification of 
Professional Doctorate in Health Psychology 
 
 
 
City, University of London  
School of Health Sciences  
Northampton Square 
London 
EC1V 0HB 
 
 
 
 
Submitted 
June, 2017. 
 2 
 
  
City, University of London 
Northampton Square 
London 
EC1V 0HB 
United Kingdom 
T +44 (0)20 7040 5060
www.city.ac.uk   Academic excellence for business and the professions
THE FOLLOWING PART OF THIS THESIS HAS BEEN REDACTED 
FOR COPYRIGHT AND DATA PROTECTION REASONS:
Pages: 181, 204, 205, 208, 211, 260-263, 285, 283-293, 306-317, 318-334
 3 
 
TABLE OF CONTENTS 
 
SECTION A 
Acknowledgements ............................................................................7 
Preface ...............................................................................................9 
References .......................................................................................15 
 
 
SECTION B Research  
An Investigation into determinants of adherence to anti-psychotic  
medication ………………………………………………………………. 17  
Abstract.............................................................................................18 
 
Section 1 Introduction ................................................................... 20 
Chapter 1: Adherence……………..................................................... 20 
Chapter 2: Demographic Factors and adherence …………………... 37 
Chapter 3: Illicit substance use and adherence ……......................... 41 
Chapter 4: Side effects and adherence............................................. 47 
Chapter 5: Social support and adherence........................................ 53 
Chapter 6: Illness perceptions and adherence.................................. 60 
Chapter 7: Purpose of study, Aims, Rationale, Research Question and 
Hypothesis ………………………………………................................. 68  
 
Section 2 Methodology and Results ............................................. 72 
Chapter 8: Methodology……………………....................................... 72 
Chapter 9: Results…………………………….................................... 88 
 
Section 3 Discussion ................................................................... 107 
Chapter 10: Insight and Treatment Control ..……........................... 113 
Chapter 11: Use of the Self Regulation Model & measures of illness 
perception ………..…..................................................................... 116 
Chapter 12: Importance of the therapeutic relationship upon treatment 
control in psychosis …..………………............................................ 119 
Chapter 13: Demographic findings..……........................................ 122 
Chapter 14: Patient perspectives in identifying side effects and the im-
portance of professionals ……….……………................................. 126 
Chapter 15: Measures of side effects…………............................... 128 
Chapter 16: Drug use and adherence………………………………  130 
 
Section 4 Clinical Implications, Future Research, Limitations and 
Conclusions………………………………………………….…….….133 
Chapter 17: Clinical Implications …................................................ 133 
Chapter 18: Future Research……………………………................. 143 
Chapter 19: Limitations and challenges ……………………........... 146 
Chapter 20: Conclusion ……………………………..….................... 151 
References ………………...……...……………………..……….…… 154 
 
 
 
 4 
 
SECTION C Professional Practice…………………………..……..213 
     
Unit 1   Generic Professional Competence: Supplementary 
Report ………………..…………………......…………. 214   
   
Unit 3  Consultancy Case Study: ………….………………… 235     
 
Unit 4  Teaching and Training Case Study A: Behaviour 
Change, Communication skills and Healthy Eating Work-
shops in mental health care settings ……..……….… 265   
 
Teaching and Training Case Study B: MSc Lecture -   
Social and Psychological Consequences of Alopecia 
………………………………..…………………………  293  
     
Unit 5  Behaviour Change Intervention Case Study: Implement-
ing health eating interventions for individuals with schiz-
ophrenia ……………………………………….………. 335 
     
 
 
 
SECTION D Systematic Review .…………………………….…….  401 
 
“Psychological and Social consequences of 
Autoimmune Alopecia” 
Abstract ………………………………..…………………...………….. 402 
Background ………………..……………………………...…………... 404  
Aims …………………………………………………………………..…407 
Method ..………………………………………………………………. 407 
Study Selection .……………………………………....…………........ 409  
Results …....…………………………………………..……………..... 426 
Discussion .....……….……………………………..………………..... 437  
Conclusion …………………………………………………………….. 442 
References .………...….…….....……………………………...........   443 
 
  
 5 
 
LIST OF TABLES AND ILLUSTRATIONS 
  
 
  
TABLES  
 
  
SECTION B RESEARCH   
 
Table 1. Summary of demographic data ……………...……………… 93  
Table 2. Summary of descriptive statistics ………………..…………. 95  
Table 3. Summary of changes in baseline and T2 scores for all varia-
bles…………………………………………..………………..…………. 98  
Table 4. Associations between demographic factors at baseline and 
adherence at baseline ..………………………………………………. 100  
Table 5. Associations between demographic factors at T2 and adher-
ence at T2 ………………………………..…………..…………………101  
Table 6. Correlations between potential predictors and Adherence at 
baseline and six-month follow up …….......................…………..…. 103  
Table 7. Regression model of baseline Independent variables with 
Baseline Adherence as dependent variable ……..…..…………….. 106  
 
 
SECTION C Behaviour Change Intervention Case Study 
 
Table 1.  Activities within each session ….……………..………….. 343 
Table 2.  Pre & Post Intervention Scores …..……………………….. 351 
 
 
SECTION D SYSTEMATIC REVIEW 
   
Table 1.  Data Extraction Tool ……………………………………….. 410 
      
  
  
 
  
  
 6 
 
ILLUSTRATIONS 
  
 
 
SECTION D SYSTEMATIC REVIEW   
 
Figure 1: Prisma Flowchart ……………………………...…………… 426  
  
 7 
 
Acknowledgments 
 
 
I would like to express my sincere gratitude to my academic supervisor Dr. Angeliki 
Bogosian, for her sustained support and guidance throughout this process. Angeliki 
has been an unlimited source of advice and encouragement. She has always been 
available to provide insight, offer practical direction and has been extremely gener-
ous in sharing her time, experience and expertise. I will remain deeply appreciative 
of all her help during the training.  
 
I would also like to express my gratitude to Dr Hayley McBain for her help with the 
final stages and to the academic staff team at City, University of London, as well as 
to all of the participants who gave up their time to take part in this study. 
 
 My eternal appreciation goes to my wife Basia, without whom it would not have been 
possible to complete this process. I would like to thank her for all the help, patience 
and consideration during the training. Most of all, I will remain everlastingly grateful 
that I have been able to share some of the best moments of my life with her over the 
last three years. 
 
My sincerest thanks go out to all the friends and family who have supported me 
throughout the training, particularly my father, Iftikhar Satti for teaching me how to 
take the time to appreciate the finer things in life. Special thanks go to my sister, 
Nusrat Ahmed for all her help with the proof reading.  
 
I dedicate this thesis to my son Mikael, whose arrival provided me with the final spur 
required in the acquisition of the qualification and to the two Sofia’s; My mother, who 
has always taught me to believe in myself while providing me with unconditional love 
and support and my daughter, who has, and always will, inspire me to be the best 
that I can be.  
 8 
  
 9 
SECTION A:  PREFACE 
____________________________________________________ 
This Portfolio documents completion of the required competencies for the award of 
Professional Doctorate in Health Psychology. It demonstrates the process of the ac-
quisition of skills and knowledge while undertaking Health Psychology training. It fo-
cuses on reflections of linking the theoretical awareness that occurred during this 
process with applied areas of practice. 
 
The majority of the training illustrated in this portfolio involved the application of 
Health Psychology theories and frameworks within a community based mental health 
project. Evidence suggests that on average, individuals with serious mental health 
illnesses such as schizophrenia, die twenty years earlier when compared with the 
general population. They are also twice as likely to develop diabetes, twice as likely 
to develop hypertension, three times more likely to die from coronary heart disease, 
ten times more likely to die from respiratory disease and four times more likely to die 
prematurely (Rethink Mental Illness, 2013). Additionally, weight gain is a common 
unwanted side effect of anti-psychotic medication (Kurzthaler & Fleischhacker, 
2001). This has been identified as a crucial issue as many patients with schizophre-
nia are exposed to serious health risks due to excessive body weight (Acil, Dogan, 
& Dogan, 2008). The clinical implications of these factors are pronounced, particu-
larly when the financial connotations are considered. Hospital treatment and anti-
psychotic medication can be both costly and prolonged in long-term mental health 
disorders (Allison et al., 2009). Additionally, research suggests that a lack of 
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knowledge of the positive aspects of healthy living is prevalent on many mental 
health wards (Acil et al., 2008). Furthermore, individuals diagnosed with mental ill-
ness often display a lack of engagement and trust towards health care professionals. 
Due to this, their physical health and overall well-being can often be overlooked (Acil 
et al., 2008). Developing an effective therapeutic relationship is often considered a 
cornerstone to effective treatment (Lehrer & Lorenz, 2014), and communication has 
been identified as having a significant impact on therapeutic relationships for individ-
uals diagnosed with schizophrenia. Communication styles and effective health pro-
motion could therefore potentially have a profound impact upon patients.  
 
The training was conducted within the context of these factors. The aim was to utilise 
this opportunity to introduce the benefits of the application of Health Psychology the-
ory, within a community based mental health setting. Improving the health of this 
population was at the centre of many aspects of the portfolio. It was hoped that this 
could impact on overall well-being, enhancing standards and delivery of psychiatric 
care and conceivably serving as a pathway, which could potentially result in an up-
take of Applied Health Psychologists working within this field.   
 
The research thesis explored the concept of adherence to anti-psychotic medication. 
Anti-psychotic medication is the most common form of treatment for various forms of 
psychosis. However, many individuals avoid terms such as psychotic or schizo-
phrenic, with some individuals rejecting their clinical diagnosis altogether. Therefore, 
the decision was made for terminology to focus purely on the medication rather than 
a particular condition. This was an effort to avoid labelling and to make the research 
as inclusive as possible while maximising patient participation. The aim was for the 
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research to benefit from a focus on patient perspectives in addition to clinical per-
spectives.  
 
Anti-psychotic medication can deliver considerable improvements in symptoms. Yet, 
the estimated rate of non-adherence to anti-psychotics is reported to be 56% (Lacro, 
Dunn, Dolder, Leckband, & Jeste, 2002). Non-adherence to anti-psychotic medica-
tion is associated with a range of detrimental outcomes including an increased risk 
of relapse and rehospitalisation, increased use of emergency psychiatric services, 
detrimental mental functioning and increased risk in suicide (Beck, Cavelti, Kvrgic, 
Kleim, & Vauth, 2011). Investigating ways of improving adherence was thus seen as 
a crucial element of future research (Acosta, Hernández, Pereira, Herrera, & 
Rodríguez, 2012). The aim was for the thesis to be written in a manner which would 
be accessible not only to Health Psychologists but also to those working within men-
tal health settings. The potential real-world impact is presented in the wider context 
of the value of the theoretical frameworks of Health Psychology in exploring these 
phenomena. The implications of how the Self-Regulation Model provides a useful 
framework for understanding how a patient’s representation of their illness inﬂuences 
their adherence to anti-psychotic medication is a key element of the results of this 
study. The findings from the research thesis are due to be presented at the BPS 
Division of Health Psychology conference in September 2017.   
 
Having identified issues surrounding the prevalence of physical health and weight 
gain amongst individuals prescribed anti-psychotic medication, it was apparent that 
a healthy eating behaviour change intervention would be of considerable benefit in 
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optimizing well-being of service users within a community based mental health set-
ting. To this end the behaviour change competency focused on the development and 
implementation of Health Psychology based behaviour change workshops. This pro-
vided service users with an opportunity that they might not otherwise receive and 
further amplified the real-world potential and benefits of the application of Health 
Psychology theory and input within a mental health setting. 
 
Health Psychology and health promotion are complimentary and proved to be an 
antecedent to first component of the teaching and training competency. During dis-
cussions with a director at a community mental health service, the impact of the be-
haviour change competency was assessed. It was agreed that raising awareness of 
the benefits of healthy eating, focusing specifically on aiding service users within 
mental health settings, would be of great use to staff members within the organisa-
tion. The director was eager for training on Health Psychology perspectives to be 
rolled out to the multi-disciplinary staff team. Training was adapted to focus on com-
munication styles and introduced Motivational Interviewing as a useful technique in 
helping people change health related behaviour in mental health settings.  
 
Throughout the course of the training there were numerous opportunities to lecture 
on various undergraduate and postgraduate psychology programmes. The case 
study included in this portfolio focuses on a lecture on the Research in Action mod-
ule, which explored the psychological impact of Alopecia (the area of the systematic 
review), as this lecture was designed purely from the research undertaken while car-
rying out work for this portfolio. The process of designing and conducting a lecture 
which helped disseminate findings to post graduate psychology students proved to 
 13 
be an extremely worthwhile and enjoyable experience. It provided the opportunity to 
develop new skills and was a particular highlight of the training process. 
 
The concept for the systematic review, developed from an interest in the promotion 
and engagement of psychological interventions for relatively obscure conditions. 
This stemmed from a conversation with an Alopecia patient in which their experi-
ences of the condition were described. It was highlighted how family members had 
suggested that it was vain to focus on physical appearance. While healthcare pro-
fessionals emphasised that it did not involve physical pain, and had expressed how 
the individual should be grateful that the hair loss was not due to a more serious 
illness such as cancer. This was paralleled with the experience of working with indi-
viduals diagnosed with mental health conditions. Some of whom had described frus-
trations at how, many of their symptoms such as lack of motivation, were often 
viewed as behavioural issues and not as symptoms of their illness. Alopecia is not 
life threatening, it does not involve loss of mobility or physical pain. However, it can 
have a profound negative impact on one’s psychological health (Williamson, Gonza-
lez, & Finlay, 2001). A systematic review was conducted to develop a more detailed 
understanding of the psychological and social impact of Autoimmune Alopecia and 
the psychological treatments currently available for this impact.  
 
The consultancy involved the opportunity to work with a different client group in the 
area of smoking cessation. Smoking is a complex health behaviour involving an 
amalgamation of biological, psychological and social processes (Marks, Murray, Ev-
ans, & Willig, 2000). Addiction to smoking and the process of cessation is an im-
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portant area for Health Psychology practice and research, and a priority for the gov-
ernment in reducing health inequalities, while improving overall health. Although the 
trainee was experienced and qualified in providing specialist smoking cessation sup-
port amongst mental health populations, working with a completely different client 
group afforded the option to develop new skills, expand upon communication tech-
niques and hone pre-existing skills. The Consultancy, Teaching and Training and 
Systematic Review thus provided an opportunity to work with different populations. 
This has demonstrated that although there was a core emphasis during the training, 
there has also been variety, highlighting the scope of Health Psychology to be ap-
plied within a diverse range of settings.  
 
This portfolio demonstrates the consolidation of learning and experience on the doc-
toral Health Psychology training programme. The varying competencies illustrate the 
process of the application of theory to practice and assessing and critiquing the evi-
dence base to address challenges. The main focus was on the application of Health 
Psychology principles, while working as a Trainee Health Psychologist in a commu-
nity based mental health project. Working within this setting provided innovative 
ways to expand upon the boundaries of its implementation, expounding the numer-
ous benefits of its applications, and illustrating the positive role that Health Psychol-
ogy can play in addressing key public health challenges.   
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Abstract 
 
Introduction 
Adherence to prescribed medication is crucial to effective treatment in many chronic 
conditions, and particularly for individuals diagnosed with psychosis. Health Psychol-
ogy has traditionally provided robust models that have been employed to explore 
adherence in numerous chronic conditions. However, research using these models 
to explore adherence to anti-psychotic medication is scarce. This study looked to 
implement the science and evidence base of Health Psychology while exploring de-
terminants of adherence to anti-psychotic medication. 
 
Method 
In this longitudinal questionnaire study, data was collected at two-time points, six 
months apart. One hundred and ten individuals participated in the baseline stage. 
Adherence to antipsychotic medication was measured using the Medication Adher-
ence Rating Scale. Social support, illness perceptions, illicit drug use and side effects 
were assessed using the Duke Functional Social Support Questionnaire, The Brief 
Illness Perception Questionnaire, The Drug Abuse Screening Test and The Glasgow 
Anti-Psychotic Side Effect Scale Questionnaires respectively. Analysis of Variance 
and Correlation analyses were conducted to explore associations between these 
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factors and adherence, while the potential predictive capacity of these factors was 
examined through Multiple Regressions.  
 
Results 
Social Support, Treatment Control and Personal Control were significantly associ-
ated with adherence, while Treatment Control (β=.407 [.405-.095], p=.000) and So-
cial Support (β=.282 [.682-.214], p=.002) were demonstrated to be a significant de-
terminant of adherence to anti-psychotic medication.   
 
Conclusion 
Adherence to anti-psychotic medication presents with a unique set of challenges and 
is a complex phenomenon influenced by a number of parameters. Levels of social 
support and treatment control are significant determinants of adherence to anti-psy-
chotic medication. Efforts to enhance social support and personal control can be 
employed in future interventions designed to increase adherence. Treatment Control 
is an important factor and the Self-Regulation Model has the aptitude to be employed 
in future research. There is potential for prospective research to apply Health Psy-
chology theories, frameworks and principles to not only scrutinise adherence within 
mental health settings but also develop behaviour change interventions that target 
identified risk factors for non-adherence.  
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SECTION 1. INTRODUCTION 
CHAPTER 1. Adherence 
 1.1 Adherence and Health Psychology. 
Non-adherence is an intricate, multi-factorial issue with a variety of forms. The chal-
lenges of patients not following prescribed treatment is not new. Indeed, it was com-
mented upon by Hippocrates in the 4th century BC (Lerner, 1997). It is a problem in 
all areas of medication but the very nature of psychiatric illness, which can have an 
impact upon judgment, places psychiatric patients at increased risk of non-adher-
ence (Srinivasan & Thara, 2002). 
Adherence is a behaviour that is difficult to detect and individuals may be fully or 
partially non-adherent (Schennach-Wolff et al., 2009). Researchers have suggested 
that adherence to medication ranges on a spectrum. From patients who take none 
of their prescribed medication, to those who take every dose exactly as described, 
with various levels in between which can be termed as partial adherence (Haddad, 
Brain, & Scott, 2014). In research, adherence is often dichotomised for analysis re-
quirements and a distinction made at missing 20% of medication, as this termination 
point has been demonstrated to have validity in predicting subsequent rehospitalisa-
tion in psychosis (Karve et al., 2009). However, others have argued that adherence 
should be viewed as continuously disturbed rather than naturally dichotomous, as 
complete adherence or non-adherence is uncommon (Razali & Yusoff, 2014). 
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Health Psychology has proposed various models to explain the psychological factors 
affecting non-adherence, several which will be discussed in this study. Leventhal’s 
(1980) Self-Regulation Model has frequently been utilised to explain adherence in 
long-term conditions. More recently, the Necessity-Concerns Framework (Horne et 
al., 2013) has expanded upon previous research and outlined how common sense 
evaluations of prescribed medication influence the motivation to adhere to treatment. 
Models such as Leventhal’s Self-Regulation model and the Necessity-Concerns 
Framework have been used to explore adherence in numerous long-term conditions. 
However, research into the application of Health Psychology frameworks amongst 
individuals diagnosed with psychosis remains scarce, and there is a deficiency of in-
depth, longitudinal reviews of the unique factors surrounding adherence amongst a 
population of individuals prescribed anti-psychotic medication. This study looked to 
implement the science and evidence base of Health Psychology and Health Behav-
iour Change into the world of adherence to anti-psychotic medication.  
 
1.2 Adherence and Anti-psychotic medication. 
Antipsychotic medications are primarily indicated for the treatment of the symptoms 
of psychoses. Psychosis is the term used to refer to the experience of hallucinations 
(sensory perceptions of phenomena that are not actually present) and delusions 
(false beliefs held despite evidence to the contrary) and the resulting behaviour that 
may occur as a consequence of these experiences. Illnesses involving symptoms of 
psychosis include schizophrenia and other psychotic disorders such schizoaffective 
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disorder, delusional disorder and bipolar affective disorder, Antipsychotic medica-
tions may also be used to treat the psychosis associated with other medical condi-
tions, such as dementia (Lally & MacCabe, 2015).  
 
According to statistics released in 2015 by the Health and Social Care Information 
Centre, one in four people in the UK report being diagnosed with at least one mental 
health problem (The Health & Social Care Information Centre, 2015). Schizophrenia 
is the traditional term for more severe psychoses. Schizophrenia is one of the most 
common severe mental health conditions, for many it is a chronic psychotic disorder, 
which causes a range of different psychological symptoms and has substantial emo-
tional and financial impact (Popp, Manea, & Moraru, 2014). It is a disorder that affects 
thinking, feeling and behaviour. Symptoms can include delusions, hallucinations 
such as hearing voices, and loss of interest, energy and emotions. The cost and 
impact of psychosis, both to the individual and at a societal level can be immense 
(Zou et al., 2013). Periods of remission and relapse are often precipitated by dysau-
tonomia (i.e. dysfunction of autonomic nervous system), isolation and financial de-
pendence (Popp et al., 2014).  
This research will examine adherence to anti-psychotic medication in general rather 
than focus on a particular medication or condition due to patients’ preference to avoid 
labelling and difficulties with accurate diagnosis. During the Patient and Public In-
volvement (PPI) groups conducted as part of this study (refer to chapter 8.4), it was 
highlighted that patients often felt labelled and stigmatised by terms such as “schiz-
ophrenic” and often disassociate from such terminology, many reported that they 
would feel more comfortable taking part in research focusing on their medication 
rather than their condition. Furthermore, a diagnosis of schizophrenia is made based 
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on psychiatric evaluation identifying the presence of two or more of the following 
symptoms for over 30 days; hallucinations, delusions, disorganized speech, cata-
tonic behaviour or negative symptoms (emotional flatness, apathy, lack of speech). 
As symptoms and Community Mental Health teams had varied over time, feedback 
from the PPI suggested that it was common to have multiple diagnoses at a particular 
time or to be diagnosed with different conditions by different psychiatrists during the 
course of treatment. In addition, it was highlighted that the majority of patients were 
treated with a combination of different anti-psychotic medications rather than just one 
and that it was relatively common for the psychotropic medication to be changed 
numerous times during treatment. Therefore, this study will focus on patients’ illness 
perceptions and adherence to medication in general and will not make any distinction 
of the specific medication taken. This was an effort to avoid labelling and to make 
the research as inclusive as possible while maximising patient participation.  
 
1.3 Unique aetiology of psychosis.  
An important point to consider when investigating adherence to anti-psychotic medi-
cation is the unique aetiology of the condition. Historically, treatments for those suf-
fering from psychoses were often ineffectual and many remained in asylums for 
lengthy periods. However, the introduction of anti-psychotic medications in the 
1950’s enabled those diagnosed with mental health disorders to be treated in the 
community. The conception of typical antipsychotic medication and subsequent in-
troduction of atypical antipsychotics has resulted in improved outcomes for patients, 
moving away from Victorian modes of treatment in outdated wards and instigated 
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the introduction of community care (Coffey, 1999). Anti-psychotic medication is con-
sidered a cornerstone in the treatment and recovery of severe mental health illnesses 
such as schizophrenia (McCann, Boardman, Clark, & Lu, 2008). Overwhelming evi-
dence suggests that anti-psychotic medication is extremely efficacious in treating the 
symptoms of psychosis (Thornley & Adams, 1998). It has the potential to reduce the 
risk of relapse substantially (Klingberg, Schneider, Wittorf, Buchkremer, & 
Wiedemann, 2008). Numerous studies have highlighted that the key element of fa-
vourable long-term outcomes is continuous adherence to anti-psychotic treatment 
(Robinson et al., 2002; Malla et al., 2006).  
 
The development, progression, consequences and outcomes in psychosis vary 
greatly between individuals (Ram, Bromet, Eaton, Pato, & Schwartz, 1992). A rela-
tively low percentage of people diagnosed experience a single episode and fully re-
cover. For the majority, it is a chronic condition. However, the prognosis is favourable 
when treated with anti-psychotic medication (Haddad et al., 2014). Research sug-
gests that long-term treatment adherence to anti-psychotic medication coincides with 
considerable improvements in symptoms and functioning and it therefore has a sub-
stantial advantage over no treatment or non-adherence (Lee, Kane, Sereika, Cho, & 
Jolley, 2011). Despite the evidence suggesting that anti-psychotic medication is im-
perative in the successful treatment of psychosis, it is reported that schizophrenia is 
the second most difficult condition in which to obtain suitable adherence, with the 
most difficult being weight reduction therapy (Keith & Kane, 2003). The estimated 
rate of non-adherence in schizophrenia is reported to be 56% (Lacro, Dunn, Dolder, 
Leckband, & Jeste, 2002). However, prevalence rates vary according to clinical set-
ting, assessments used, duration, and study population characteristics (Novic et al., 
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2010). In the first two years subsequent to a psychotic episode, the non-adherence 
rate is reported to be 55% and is linked to a fivefold increase in rehospitalisation 
within one year (Barkhof, Meijer, de Sonneville, Linszen, & de Haan, 2012).  
 
In severe psychiatric conditions where insight is often impaired, and the necessity of 
treatments may not be recognised by the patient (Emsley, 2010), non-adherence can 
be a convoluted, severe issue. In fact, a recent review highlighted several features 
that make non-adherence especially challenging for psychiatric patients. These fac-
tors not only include a lack of illness awareness (which refers to illness perceptions 
and insight as well as beliefs and attitudes concerning the composition of the illness), 
the direct impact of symptoms (which can include cognitive impairments, depression 
and both positive and negative symptoms), comorbid substance misuse, social iso-
lation, stigma and increasing disintegration of mental health services in many socie-
ties (Haddad et al., 2014). However, while a number of studies have investigated 
these concepts separately there is relatively scarce longitudinal research exploring 
the interaction between these factors. 
 
1.4 Research impediments and distinction between Com-
pliance & Adherence 
 
There are also complexities in the definition of compliance or non-adherence and the 
criteria by which it becomes clinically relevant (Kikert et al., 2008). In general termi-
nology, adherence to a medication regime is viewed as the extent to which the indi-
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vidual’s behaviour corresponds with agreed recommendations from a health profes-
sional (Lehane & McCarthy, 2009). The term “non-adherent” may refer to other treat-
ment recommendations and not just medication. This is recognised by the World 
Health Organisation (Haddad, Brain & Scott, 2014). In secure mental health wards, 
the term compliance is often used rather than adherence. Compliance refers to “the 
extent to which the patient’s behaviour (in terms of taking medications, following di-
ets, or executing other lifestyle changes) coincides with medical recommendations” 
(Haynes, 1979). Adherence refers to “the extent to which the patient’s behaviour (in 
terms of taking medications, following diets, or executing other lifestyle changes) 
coincides with medical recommendations jointly agreed between the patient and the 
prescriber” (Barofsky, 1978). The difference between the two terms mainly involves 
the responsible clinicians’ degree of authority and any other distinction is negligible 
(Acosta et al., 2012). However, the term adherence emphasises patient autonomy 
whereas the term compliance is often criticised as being overly authoritarian, illus-
trating a hegemony in the relationship. In spite of this, the term compliance remains 
in consistent use in mental health setting parlance (Ziguras et al., 2001). The term 
concordance has been used to outline mutual agreement while encompassing pa-
tient support in taking medication. A range of alternative terms have been proposed 
including treatment compliance and fidelity, however adherence is generally pre-
ferred due to its neutrality (Haddad, Brain & Scott, 2014). For this reason, the term 
adherence will be used throughout this study.  Additionally, adherence is a behaviour 
that is difficult to detect and individuals may be fully or partially non-adherent (Wolf 
et al., 2009).  
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It is also difficult to distinguish between intentional and non-intentional non-adher-
ence. Individual perception and practicalities can impede a distinction between un-
intentional non-adherence, which is non-adherence due to lack of capacity, re-
sources and other practical factors and intentional non-adherence which is non-ad-
herence due to motivational beliefs, preferences and other perceptual factors 
(Horne, 2001). Unintentional non-adherence to treatment may be due to lack of un-
derstanding of the treatment regime. Based on this premise, the target is to enhance 
knowledge, skills and awareness, which is necessary and beneficial. Another reason 
for unintentional non-adherence may be due to retrospective memory. Patients for-
get the details of the treatment regime. If that is the case, patients may benefit from 
written or even illustrative examples of the regime. A third reason for unintentional 
non-adherence may be that patients forget their postponed intention of what to do at 
the time when they are supposed to recall their intention to do it (Park and Kidder, 
1996). Retrieval can be improved by event based retrieval or time based retrieval. 
Or making an implementation intention, delegating control to the environment by 
specifying where, when and how to adhere to medication. The focus of the present 
study will be on intentional adherence. The problem with targeting unintentional ad-
herence is that education, knowledge and memory cues do not often predict better 
adherence when non-adherence is deliberate.  The predictors of intentional adher-
ence have been modelled in the same way as other health behaviours. In the present 
study cognitive determinants of adherence as well as demographics and social sup-
port will be explored.   
 
Researchers (Haddad, Brain & Scott, 2014) suggest that adherence to medication 
ranges on a spectrum, from patients who take none of their prescribed medication, 
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to those who take every dose exactly as described, with numerous other levels in 
between which can be termed as partial adherence. However, in research adherence 
is often dichotomised for analysis requirements and a distinction made at missing 
20% of medication as this termination point has been demonstrated to have validity 
in predicting subsequent rehospitalisation (Karve et al., 2009). Conversely, others 
have argued that adherence should be viewed as continuously disturbed rather than 
naturally dichotomous as complete adherence or non-adherence is uncommon 
(Razali & Yusoff, 2014). Therefore, for the purpose of this research, adherence is 
considered to be on a continuous spectrum rather than dichotomised. 
 
 
1.5 Depot neuroleptics provided in long-acting injections. 
Long acting depot injections offered in the form of depot neuroleptic medication were 
identiﬁed as a means of improving adherence and relapse prevention when they 
were first introduced in the United Kingdom in 1966 (Tattan & Creed, 2001). The first 
atypical neuroleptic to be produced in depot form is Risperidone, a commonly pre-
scribed atypical anti-psychotic originally available in oral form. The influence of depot 
risperidone in clinical settings has resulted in other atypical neuroleptics becoming 
available in the form of long-acting injections including paliperidone depots and 
olanzapine depots both of which have the additional advantage of being available on 
a monthly rather than fortnightly basis. Some typical anti-psychotic medications such 
as haloperidol and fluphenazine are also available in long-acting injection formula-
tions. The advantage of depot neuroleptics, in the form of long-acting injections, is 
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the simplification of the administration of the medication. The patient does not ad-
minister the medication themselves, providing opportunities for monitoring, review 
and regular patient contact. There are less associated issues surrounding obtaining 
prescriptions or collecting medication.  
 
There are a range of political reasons for the use of long acting depot injections, as 
it associated with increased cost savings (Aldridge, 2011). Depot injections are nor-
mally administered by a Registered Mental Health Nurse and their administration is 
often used as an opportunity for patient contact, monitoring and termed as a review. 
This can lead to job losses for community social workers and other health care pro-
fessionals who would normally provide these fortnightly reviews. However, there is 
prevalent research suggesting that long acting depot injections are more coercive 
than oral antipsychotics, with considerable ethical concerns regarding the coercion 
and force associated with long acting depot injections in the mental health system, 
which continues to be debated among psychiatrists and nurses (Patel et al. 2010). 
Despite these concerns, British legislation has enhanced authority to mandate ad-
herence with treatment for patients in the community (Molodynski et al. 2010). Su-
pervised community treatment orders (CTOs), were first introduced in 2008. Under 
supervised community treatment, individuals are made subject to a CTO, CTO con-
ditions can be used to legally enforce adherence to a long acting depot injection in 
the community with one of the most frequent CTO conditions involving a requirement 
to adhere to treatment, that often includes anti-psychotic depot injections (Emsley, 
2010). This further politicises the debate as there is a strong CTO focus on antipsy-
chotic depot injections. Breaching CTO conditions through non-adherence to a pre-
scribed depot injection could be used as grounds for recall to hospital even in the 
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absence of relapse (Molodynski et al. 2010). This can also be viewed as the most 
severe potential disadvantage of long-acting depots, as they are often perceived as 
more coercive than oral anti-psychotics and have faced ethical challenges as re-
search indicates that patients report long-acting depot injections as the least pre-
ferred of the various types of psychiatric medications, with some patients finding the 
process demeaning (Aldridge, 2011).  
 
At present, there is limited evidence sourced from randomized controlled trials re-
garding the safety and efﬁcacy of long-acting depot injections compared with placebo 
or oral anti-psychotic medication (NCCMH 2010). It has also been highlighted that 
relapse can occur even when medication is administered by long-acting depot injec-
tions (Aldridge, 2011). An in-depth review also found that one year after hospital 
discharge there were no differences in rates of adherence to depot or oral anti-psy-
chotic medication (Weiden et al., 1996).  
 
Aldridge (2011) suggests that if non-adherence still occurs while patients are pre-
scribed long acting depot injections, a planned non-adherence harm-reduction ap-
proach would potentially reduce harm. This would involve providing information and 
resources on coming off anti-psychotic medication. Monitoring, close support, and 
the use of psychosocial interventions for coping with stress could potentially help to 
lessen possible harm resulting from withdrawal (Wunderink et al. 2007). Aldridge 
(2011), goes on to argue that a harm-reduction approach to non-adherence is more 
in accord with nursing as seen in both the NMC (2008) Code and the Prime Minister’s 
Commission on the Future of Nursing and Midwifery in England (2010). 
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1.6 Temporal Effects of the condition 
Most individuals will be prescribed anti-psychotic medication following a psychotic 
episode and may not yet themselves be acutely aware of the extent of the illness or 
their diagnosis. A common symptom of psychosis is hallucination (both auditory and 
visual), which can make it difficult to distinguish reality from delusion. Individuals di-
agnosed with a psychosis often suffer from impaired insight and may not recognise 
the necessity of treatment (Emsley, 2010). This can have a significant impact as the 
temporal effects can influence beliefs and outcomes in the illness. Patients may have 
suffered from an acute psychotic episode and may not have consented to treatment, 
resulting in sectioning under the Mental Health Act (1983) and in-patient treatment 
against the patient’s will. In such scenarios, non-adherence to anti-psychotic medi-
cation may be exacerbated by their associations with traumatic experiences at in-
patient settings, and of the higher doses of medication required in the acute stages 
of the illness (Coffey, 1999). Furthermore, some patients may find it difficult to dis-
tinguish side effects from the symptoms of psychosis (McCann, Clarke, & Lu, 2009), 
while others may be prescribed numerous anti-psychotic medications (Valenstein et 
al., 2004). Therefore, due to the length of time it takes to have an impact on symp-
toms, some people may not associate anti-psychotic medication with improvements 
in their mental health. There are also issues with the terminology and measures uti-
lised within mental health settings, where individuals who do not adhere to an aspect 
of their treatment programme are termed “non-compliant” and researchers have 
highlighted limitations in the measures utilised to assess compliance (Acosta et al., 
2009). 
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Often the individual will enter the mental health system in a crisis and will be 
treated with anti-psychotic medication. However, although anti-psychotic medica-
tion is effective in reducing symptoms (McCann et al., 2009), this effect can cus-
tomarily take a considerable amount of time to manifest. The individual may there-
fore, not necessarily equate the medication with an improvement in their symp-
toms. Thus, the importance of continuing with the medication may not be obvious to 
patients who may attribute the alleviation in symptoms with other factors and may 
wish to put this distressing episode and its associations behind them (Sapra et al., 
2014).  
 
 
1.7 Impact of non-adherence to anti-psychotic medication. 
Non-adherence is considered the main hindrance in psychosis treatment (Corrigan, 
2002). With medication non-adherence considered a central barrier in the treatment 
of patients suffering from schizophrenia (Jaeger, WeiBhaupt, Flammer, & Steinert 
2014). Prevalence, consequences and associated costs of non-adherence have en-
sured that the analysis of this trend is extremely relevant (Acosta et al., 2012). Non-
adherence to anti-psychotic medication is associated with substantially detrimental 
treatment outcomes including risk of relapse, rehospitalisation, reduced psychoso-
cial functioning (Weiden, Kozma, Grogg, & Locklear, 2004), increased use of emer-
gency psychiatric services, poorer prognoses, detrimental mental functioning and 
increased risk in suicide (Beck, Cavelti, Kvrgic, Kleim, & Vauth, 2011).  
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The consequences of non-adherence can be overwhelming for patients and those 
close to them. Furthermore, research indicates that non-adherence is associated 
with a higher proclivity towards violence and related arrests, victimisations, increased 
illicit substance use, alcohol related problems, and significantly lower life satisfaction 
(Ascher-Svanum et al., 2006). Swartz et al., (1998), reported that non-adherence to 
anti-psychotic medication is linked to a heightened tendency to commit violent acts 
such as homicide or suicide. It is also stated to be a risk factor in completed suicides 
(Emsley, 2010).      
 
Similarly, studies suggest that partial adherence to anti-psychotic medication is just 
as detrimental to mental health and is equally as damaging as non-adherence 
(Llorca, 2008). A review of the effect of partial adherence to anti-psychotic medica-
tion emphasised that the risk of relapse increased even with moderate gaps in med-
ication adherence (Masand, Roca, Turner, & Kane, 2009). Findings also propose 
that numerous adherence measures underestimate the prevalence of non-adher-
ence and that many clinicians underrate poor adherence rates in their patients 
(Emsley, 2010). Adherence rates in individuals may vary over time. It is often higher 
immediately after a hospital discharge and deteriorates gradually (Kane, Kishimoto, 
& Correll, 2013). In a study which measured non-adherence rates in first episode 
psychotic patients, it was reported that one third admitted to hospital were non-ad-
herent six months later (Kamali et al., 2006). A study of male first episode psychotic 
patients found that 53.6%, abandoned their treatment within the first year (Novak-
Grubic & Tavcar, 2002). Studies have posited that the rates of relapse in patients 
with schizophrenia increase almost fivefold after five years and reaches 81.9% 
(Theisen, 2001). In 2007, it was suggested that the annual cost associated with the 
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treatment of schizophrenia in the United States was over $10 billion and that 40% of 
those costs were attributed to non-adherence (Byerly, Nakonezny, & Lescouflair, 
2007). It is also important to note that relapse episodes involve more care related 
costs which in the UK places increasing financial and administrative burden not only 
on the NHS but also on local councils (Acosta et al., 2012).  
 
According to figures from a British Broadcasting Corporation (BBC) report based 
upon research conducted in March 2015 the funding for NHS trusts to provide mental 
health services was £6.6 billion in 2014 (BBC 2015). The Health and Social Care 
Information Centre suggests that the social care expenditure on adults with mental 
health needs in the United Kingdom was £1.2 billion. The average cost of a night in 
a mental health in-patient bed is £321 - meaning a typical admission of 38 days costs 
over £12,000. However, in the current economic climate, these figures have come 
under increasing scrutiny, and reports indicate that funding for NHS trusts to provide 
mental health services have fallen by 8.25 per cent, or £600 million, over the course 
of the last government (BBC 2015). In 2012, the Schizophrenia Commission, a group 
of 12 independent experts, was established to review current understanding of schiz-
ophrenia and recommend priority actions to improve outcomes for patients. The 
commission reported that overall, the condition costs society almost £11.8 billion a 
year and recommended that funds should be reapportioned from secure care to com-
munity-based treatment programmes (The Schizophrenia Commission 2012). Thus, 
there is increasing financial and societal pressure on Community Mental Health 
Team’s (CMHT’s) to enhance adherence to anti-psychotic medication rates for those 
residing in the community. 
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1.8 Current perspectives. 
Non-adherence to anti-psychotic medication is clearly a crucial predicament and fail-
ing to adhere to prescribed treatment is a central factor in relapse (Kane, 2007; 
Llorca, 2008; Masand et al., 2009). The costs of poor adherence are considerable to 
the patient and society. Exploring ways of improving adherence is thus seen as a 
key element of future research (Acosta et al., 2012; Srinivasan & Thara, 2002). The 
dynamics that influence the individual’s level of adherence can be described as an 
interaction among various factors. These factors can be categorised as patient re-
lated, environment/illness related or treatment related (Velligan, et al., 2009). Patient 
related variables include socio-demographic factors, attitudes towards treatment and 
substance misuse. Illness related variables include type and severity of symptoms 
and insight into the illness, while treatment-related variables include the side effects 
of medication (Novick et al., 2010). A number of studies have reported various pre-
dictors of adherence for individuals with psychosis. Demographic factors (Kirkbride 
et al., 2012a), insight into the condition (Novick et al., 2015), comorbid substance 
misuse (Asher & Gask, 2010), and lack of social support (Mas-Expósito, Amador-
Campos, Gómez-Benito, & Lalucat-Jo, 2013) are considered important factors. This 
study will go on to investigate each of these factors in greater detail. 
 
Although Health Psychology has been utilised to explore adherence in various con-
ditions, the perspective of those diagnosed anti-psychotic medication remains rela-
tively unexplored by Health Psychologists. There are various factors that may have 
influenced this. The unique nature of psychosis and schizophrenic illness, obfus-
cates concepts of illness perceptions, decision making and engagement with health 
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care professionals. There are occasions when patients may be considered to be a 
risk to themselves or others, and may require formal admission to hospital under the 
Mental Health Act (1983). Working with patients with the condition is often more as-
sociated with clinical psychologists. However, it is Health Psychologists who are ide-
ally placed to investigate adherence, using well-established techniques to ensure 
that the autonomy of the patient is respected. The purpose of this study is to explore 
potential determinants of adherence to anti-psychotic medication in greater detail 
whilst applying the science of Health Psychology to the unique characteristics of ad-
herence in psychosis.   
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CHAPTER 2. 
Demographic factors and adherence.  
To many, psychosis may often feel like a distant, unfamiliar condition. The stigmati-
sation of the illness and the way in which individuals diagnosed with the condition 
had historically been segregated from the rest of society, has led to some of the 
general public being unfamiliar with the prevalence of the disorder (Haddad et al., 
2014). Indeed, some people may feel that they have not encountered or known an-
yone that is dealing with mental illness and can be unaware that someone they know 
is dealing with the condition. At face value a 1.1% incidence rate may give the im-
pression of a statistically small figure. However, the prevalence rate for schizophre-
nia alone is twice as high as Alzheimer’s which is often considered to be a more 
recognised condition (Popp et al., 2014). According to the WHO statistics, schizo-
phrenia is diagnosed five times as often as multiple sclerosis and six times as often 
as insulin-dependent diabetes (WHO 2006). 
 
2.1 Sociological, Economical & Biomedical Factors 
Despite the relatively low incident rate for psychotic illness, the prevalence rates are 
persistently high (McGrath et al., 2004). The incidence rate for Schizophrenia is re-
ported to be 1.1% of the population over the age of eighteen (Torrey, 2006). The 
average age of onset is eighteen in males and twenty-five in females (Torrey, 2006). 
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A comprehensive systematic review of rates indicated that when compared with fe-
males, males are moderately more likely to be diagnosed with the condition (McGrath 
et al., 2004). Males are also reported to experience more “negative” symptoms of 
psychosis, have a lower chance of making a full recovery and display worse out-
comes when compared statistically with females (McGrath et al., 2004). The illness 
occurs throughout the world in all societies regardless of ethnicity, gender, class, 
religion or culture. However, although incidence levels remain relatively consistent, 
there is some reported variance in rates amongst different groups of people (Saha, 
Chant, Welham, & McGrath, 2005). New episodes are more likely to be reported in 
Black and other minority ethnic communities (Kirkbride et al., 2012a). Research has 
indicated that inner-city areas with high rates of poverty experience higher rates of 
schizophrenia (March et al., 2008). In a 2012 study of participants across several 
ethnically diverse boroughs of London, Kirkbride (Kirkbride et al., 2012a) looked to 
explore the reasons why urban communities have elevated rates of psychotic disor-
ders. The research was supported by the Welcome Trust and the National Institute 
for Health Research (NIHR). Results indicated that rates of schizophrenia and similar 
disorders showed variance after controlling for age, ethnicity, gender and social 
class. Findings highlighted the effects of complex societal factors that underlie the 
onset of mental health disorders and proposed that the risk of psychotic illness could 
be predicted by three environmental factors; increased population density, increased 
deprivation (relating to income, education, employment and crime) and increased 
inequality (disparities between the rich and poor). The study drew attention to the 
way that the socio-economic environment could impact on psychotic illness and its 
recovery. However, although links between social inequality and psychosis have 
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been explored, there is relatively little research into the impact of social inequality on 
adherence to anti-psychotic medication.  
 
Previous research has indicated that health outcomes are optimised when societies 
are more equal (Kirkbride, Stubbins, & Jones 2012b), leading to an expectation that 
there may be demographic differences in adherence to medication regimes. This 
relates to the health inequalities that currently exist within those suffering from psy-
chosis (Cheng et al., 2010). According to 2012 figures released by the Schizophrenia 
Commission (2012), individuals with serious psychiatric illnesses such as schizo-
phrenia are on average twice as likely to develop diabetes, three times more likely 
to develop hypertension, four times as likely to die from coronary heart disease and 
ten times more likely to die from a respiratory illness. Overall, individuals with serious 
mental health illnesses such as schizophrenia, die 20 years earlier when compared 
with the general population (March et al., 2008). Figures have indicated that, of adults 
diagnosed with schizophrenia only 28% live independently, while 25% live with a 
family member, 20% live in Supported Housing, 10% live in nursing homes, 6% live 
in hospitals, 6% live in jails or prisons and around 6% are homeless or live in shelters 
(Torrey, 2006). This is significant as the majority of previous research has explored 
concepts in hospital settings, whereas investigating adherence in the community 
would be more relevant, as this is the setting in which individuals are expected to 
self-medicate rather than have their medication administered or monitored by staff. 
 
There is relatively little research focus on relationships between socio-demographic 
factors and adherence to anti-psychotics. A study (Tsang, Fung & Corrigan, 2009) 
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looked at medication compliance in relation to self-stigma, insight, attitudes towards 
medication, and sociodemographic status in eighty-six Chinese adults diagnosed 
with Schizophrenia. Results identified insight as a significant predictor of adherence 
but also indicated that while living alone was associated with non-adherence, living 
in a supported environment was associated with higher levels of adherence. Previ-
ous research has proposed that socio-demographic factors including gender, age, 
financial status, education, marital status etc. correlate with adherence to anti-psy-
chotic medication (Fenton, Blyler, & Heinssen, 1997; Fleischhacker, Oehl, & Hum-
mer, 2003; Pinikahana, 2005). However, the results of correlations carried out by 
these studies have been inconclusive (Tsang et al., 2009).  Despite these results, it 
is acknowledged that the socio-demographic background of an individual has some 
level of impact upon their level of adherence (Tsang et al., 2009). Thus, although the 
impact of demographic factors in psychosis has been highlighted, there is a scarcity 
of studies that have explored demographic concepts and their impact on adherence 
to anti-psychotic medication extensively. The majority of previous studies were 
cross-sectional and there are no studies looking at the effects of demographic char-
acteristics on adherence over time. The current research will attempt to investigate 
the socio-demographic impact upon adherence in further detail.  
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CHAPTER 3.  
Illicit substance use and adherence. 
Illicit substance use amongst individuals suffering a mental health condition is prom-
inent and considered a prevalent clinical concern. A substantial body of research has 
denoted that in comparison to the general population, people with severe mental 
health conditions such as schizophrenia are at a heightened risk of suffering from a 
substance use disorder (Asher & Gask, 2010; Bahorik Newhill, Queen, & Eack, 2014; 
Margolese, Malchy, Negrete, Tempier, & Gill, 2004; Fowler, Carr, Carter, & Lewin, 
1998).  
 
3.1 Prevalence of dual diagnosis in psychosis. 
The co-occurrence of a mental health and an addictive disorder referred to as a “dual 
diagnosis” is frequent, with a lifetime comorbidity prevalence rate reportedly being 
59% (Fowler et al., 1998). A comprehensive meta-analysis reported that around 1 in 
4 individuals diagnosed with schizophrenia suffered from a cannabis use disorder, 
which is over five times greater than the rate amongst the general population (Asher 
& Gask, 2010). Alcohol dependence, nicotine use and psychostimulant misuse rates 
are all high in individuals suffering from a psychotic disorder, with the most commonly 
used psychostimulants being cocaine and cannabis (Akvardar et al., 2004). In-
creased drug use amongst patients has been linked to earlier onset of the disorder, 
increased rates of relapse, rehospitalisation, homelessness, violence, HIV infection, 
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legal issues, non-adherence to medication, suicide and other unfavourable out-
comes (Asher & Gask, 2010; Akvardar et. al, 2004). However, these studies have 
used a variety of measures to explore drug use, rather than a measure specifically 
validated to explore drug use amongst individuals diagnosed with psychosis. Fur-
thermore, a comprehensive review by Angermeyer (2000) suggested that a dual di-
agnosis is often reported to result in increased management issues from a clinical 
perspective with increased levels of aggression, violence and non-adherence to 
medication. The rates of criminal activity in Single Diagnosis patients were reported 
to be 13.7%, compared to 40.1% in Dual Diagnosis patients. The impact of a Dual 
Diagnosis is vast and may have a profound effect. Dual Diagnosis patients were 
reported to commit more violent crimes, and are allegedly seventeen times more 
likely to commit homicide than the general public. Although the prevalence of drug 
use and its effect on the course of psychotic illness has been widely researched, the 
precise mechanisms as to why this occurs remain subject to debate. Therefore, re-
search into the impact of drug use on treatment and adherence levels to anti-psy-
chotic medication is of high priority. 
 
3.2 Causality.  
Some individuals diagnosed with psychosis have reported using street drugs in an 
effort to “self-medicate” their condition and thus avoid taking their prescribed medi-
cation (Margolese et al., 2004). According to recent information, developed with the 
help of researchers who work at the Institute of Psychiatry Psychology & Neurosci-
 43 
ence (King's College London) and mental health professionals working at South Lon-
don and Maudsley NHS Foundation Trust, some people who have a diagnosis of 
psychosis have reported using illicit drugs to help cope with some of the symptoms 
of their illness. Due to the legal implications involved this can be a highly contentious 
area of enquiry. It also gives rise to the debate surrounding the direction of causality 
between drug use and psychosis. While there is general agreement of an association 
between psychosis and drug use, the direction of causality remains a divisive topic. 
In a comprehensive 2001 literature review, Cantor-Graae, Nordström and McNeil, 
reported that cannabis use had predated the onset of psychotic symptoms in several 
studies but not in others. There was also no consensus on whether substance use 
impacted the age of onset for psychosis. The effect of substance use on the medical 
evolution of psychosis also remained subject to debate. Some of the included studies 
were unable to identify a relationship between substance use and changes in symp-
toms (Cantor-Graae et al., 2001). Other findings included greater premorbid adjust-
ment, higher rates of marital and employment status, less brain structural abnormal-
ities and fewer hospital admissions (Cantor-Graae et al., 2001). This has led to the 
view that patients who habitually use illicit substances may have a less severe form 
of psychosis and greater social skills, yet relatively few studies have investigated the 
long-term relationship of substance use on non-adherence to anti-psychotic medica-
tion.  
 
Conversely, other studies indicate that substance use is closely associated with both 
non-adherence and relapse. Research suggests that patients with schizophrenia 
who use psychostimulants are hospitalised at twice the rate of patients who do not, 
with greater cannabis usage having a significant relationship with relapse rates (Van 
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Dorn, Desmaris, Young, Sellers, & Swartz, 2012).  Alcohol dependence was linked 
with an increased hospital duration of twice as long, with even negligible alcohol use 
reported to be a predictor of rehospitalisation (Angermeyer, 2000). Substance use 
has been indicated as having a relationship with relapse, rehospitalisation, non-ad-
herence to treatment, criminality and suicide (Cantor-Graae et al., 2001). However, 
the effects of illicit drug use to adherence to anti-psychotic medication are still un-
clear. 
 
3.3 Transnational variations. 
The majority of previous research into drug use in mental health populations origi-
nates from the United States and Europe, with the majority of data obtained from 
North America, the UK and Germany. Figures from other areas particularly develop-
ing countries are inadequately represented. In the United States around 70% of in-
dividuals diagnosed with psychosis use nicotine, 45-60% are alcohol dependent, and 
31-42% use cannabis. Whereas the rates for cannabis dependence is reported to be 
27% in France, 18.7% in England and 5-13% in Germany (Margolese et al., 2004). 
The rate for cocaine use amongst people diagnosed with schizophrenia is reported 
to be 15-50% in the United States, 1.5% in France and 1% in Australia, in the UK the 
rate of stimulant use including both cocaine and amphetamines is reported to be 
8.7% (Margolese et al., 2004). The fact that these rates vary so significantly, high-
lights the need for additional global and local information regarding the degree, is-
sues, impact and prevalence of drug use in assorted communities. Studies from 1990 
to 2000 looking at schizophrenia, schizoaffective disorder and substance misuse 
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with a sample size of over thirty participants were reviewed (Cantor-Graae et al., 
2001). The review did not distinguish between substance dependence or abuse. 
However, it did exclude studies if a defining criterion of abuse or dependence was 
not comprehensively quantified. The authors reported that prevalence rates altered 
according to the population of the study and the process used to define abuse. Rates 
of abuse ranged between 40 to 60%. Research that included only one technique of 
determining abuse tended to report lower rates than research that used more than 
one method. Comorbidity rates tended to be higher in samples obtained from clinical 
settings when compared with outpatients. Results indicated that in Australia sub-
stance use rates were particularly high amongst outpatients underlining that drug 
use was not just prevalent in Europe and North America. 
 
3.4 Explanations for prevalence. 
At present, there appears to be very little consensus as to the reasons for the prev-
alence of drug use in people with psychosis. Some research appears to suggest use 
can be linked to a form of self-medication as certain substances have the potential 
to alleviate or target certain symptoms (Margolese et al., 2004). Other research sug-
gests that the choice of a specific substance is principally dependent on obtainability 
and affordability (Cantor-Graae et al., 2001). What is widely accepted is that different 
substances affect psychosis in different ways. Cannabis use has been known to 
cause anxiety, hallucinations, and paranoia (Akvardar et al., 2004). Nicotine has 
been associated with an improvement in negative symptoms and auditory data pro-
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cessing, as well as diminishing the unwanted side effects of anti-psychotic medica-
tion. However, there are complex issues surrounding the effect of nicotine on the 
impact of anti-psychotic medication, particularly clozapine (Bahorik et al., 2014). Pa-
tients have reported attempting to use cocaine as a way of attenuating feelings of 
depression as cocaine use has been reported to lessen both positive and negative 
symptoms of schizophrenia (Akvardar et al., 2004).  
 
There remains a lack of empirical evidence surrounding the reasons for the preva-
lence of illicit substance use and a dearth of studies that have explored the impact 
of illicit substance upon adherence to anti-psychotic medication. This study will at-
tempt to investigate these concepts in greater detail. It will investigate the effects of 
drug use on adherence longitudinally and will explore the effects of drug use in com-
parison with other potential determinants of adherence, in order to view the signifi-
cance of drug use compared to other factors. 
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CHAPTER 4. Side Effects and Adherence. 
Overwhelming evidence has highlighted the efficacy of anti-psychotic medication in 
treating the symptoms of psychosis and bringing about improvements in the course 
and outcome of the condition (Zygmunt, Olfson, Boyer, & Mechanic 2002). A meta-
analysis of 65 randomised control trials reported that patients treated with anti-psy-
chotic medication displayed significantly lowered relapse rates, were less likely to be 
admitted to hospital or drop out of trials for any other reason (Haddad et al., 2014). 
However, anti-psychotic medications are multifarious in their actions and have also 
been associated with a range of side effects. Around 75% of individuals prescribed 
anti-psychotics experience side effects (Coffey, 1999). The nature, severity and ex-
tent of these side effects vary widely among individuals but some are extremely se-
vere (McCann et al., 2009). Traditional anti-psychotic medications, in particular, have 
been associated with a variety of unwanted side effects. Newer atypical anti-psy-
chotic medications were considered to lessen the array of side effects but in some 
cases, the side effects associated with their use are equally debilitating and even life 
threatening (Coffey, 1999). 
 
 
4.1 Typical anti-psychotics.  
Increased Health Psychology research may potentially be useful helping us under-
stand the high rates of non-adherence in psychosis due to the unique nature of anti-
psychotic treatment. Anti-psychotic medication is not always completely effective 
and the complex side-effects of these medications, can increase patients’ concerns 
regarding their treatment. Traditional anti-psychotic medication was first developed 
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in the mid-1950s, and quickly became the treatment of choice for psychosis. They 
are often referred to as ‘typical’ or 'first-generation' anti-psychotics. Although there 
are many different types of typical anti-psychotics they all work in a similar way by 
blocking the action of dopamine receptors in the brain, some more strongly than 
others (Coffey, 1999). Symptoms of psychosis often get divided into “positive and 
negative” symptoms. Positive symptoms refer to variations in behaviour or thoughts, 
including hallucinations or delusions. While negative symptoms refer to withdrawal 
or lack of function, such as appearing emotionless and flat. Typical anti-psychotics 
are reportedly efficacious in treating “positive” symptoms of psychosis such as visual 
and auditory hallucinations. However, there are also some drawbacks associated 
with their use. They are ineffective at reducing the “negative” symptoms of psychosis 
such as social withdrawal, unemotionality or apathy. They are ineffective at reducing 
any symptoms in around 30% of those treated (Zygmunt et al., 2002), and for a large 
section of patients whose symptoms are reduced, many will go on to experience side 
effects which can impact adherence to the medication.  
 
The most common form of side effects of typical anti-psychotics are referred to as 
“extrapyramidal side effects”.  Extrapyramidal side effects are a group of symptoms 
relating to motor control, coordination and involuntary movements. Extrapyramidal 
side effects can include akathisia - which manifests in a sensation of restlessness 
and can result in rocking and pacing up and down, tardive dyskinesia - which involves 
uncontrollable facial movements, dystonia - which causes muscles to involuntarily 
contract and contort leading to unnatural and painful movements and positioning and 
Parkinsonism - the same symptoms as someone with Parkinson's disease, including 
slower thought processes and movements, tremors, rigid muscles, difficulty speaking 
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and facial stiffness (Wolters, Knegtering, Van den Bosch, & Wiersma, 2009). Other 
common side effects of typical anti-psychotics include weight gain, photosensitivity, 
sedation, blurred vision, dizziness, constipation, sexual dysfunction (reduced libido 
or impotence), agranulocytosis (deficiency in a type of white blood cells that in-
creases vulnerability to infections) and neuroleptic malignant syndrome and others 
(Coffey, 1999). 
 
 
4.2 Atypical anti-psychotics. 
Concerns regarding the high number of side effects of typical anti-psychotics re-
sulted in a search for alternatives and led to the development of “atypical” or second 
generation anti-psychotics, which were generally thought to have reduced extrapy-
ramidal side effects. The introduction of new atypical anti-psychotics was expected 
to herald a new era of improved outcomes for those suffering from psychosis. It was 
hoped that they would be associated with fewer extrapyramidal side effects, en-
hanced clinical efficacy and would lead to a marked improvement in rates of adher-
ence to medication (Leucht, Pitschel-Walz, Abraham, & Kissling, 1999). They work 
on different chemical messengers in the brain and have a lower affinity for the D2 
dopamine receptors but a higher affinity for D4 dopamine receptors, than typical anti-
psychotics and also have an effect on serotonergic receptors (Coffey, 1999).  Studies 
have indicated that atypical anti-psychotics are also more effective in dealing with 
the negative symptoms of psychosis (Tsang, et al., 2009). Clozapine is often referred 
to as the primary atypical anti-psychotic but was actually developed in 1959. It 
showed efficacy as being extremely effective for treatment-resistant psychosis, treat-
ment of negative symptoms, reduced anticholinergic effects, reduced extrapyramidal 
 50 
side effects, greater clinical efficacy and improved outcomes (Leucht et al.,1999). 
However, the sale of clozapine was discontinued shortly after its introduction due to 
concerns over its potentially fatal neutropenic side effects. It was later reintroduced 
with strict safeguards and guidelines involving regular white blood cell checks (and 
is now discontinued if these checks are abnormal), it is also associated with a range 
of other side effects (Coffey, 1999). Although other atypical anti-psychotics reduce 
extrapyramidal side effects commonly caused by typical anti-psychotics, these 
symptoms can and do occur with any type of anti-psychotic medication (Wolters et 
al., 2009). Antidepressants and other medications can sometimes cause extrapy-
ramidal side effects as well. Other side effects of atypical anti-psychotics include 
sedation, excessive weight gain, increased likelihood of developing diabetes, pos-
tural hypotension, sexual dysfunction (reduced libido or impotence), excessive sali-
vation and convulsions. Some can affect blood pressure and cause dizziness, while 
in high dose long term use can also cause extrapyramidal side effects (Coffey, 1999).  
 
 
4.3 Symptoms versus sequelae. 
The treatment of psychosis can be viewed as a trade between symptoms and se-
quelae. Some side effects may desist if medication is discontinued. However, ex-
trapyramidal side effects can continue for an indefinite period and some may expe-
rience movement disorders for life after a course of treatment. Clinical concerns re-
garding extrapyramidal side effects are pronounced, as socially debilitating side ef-
fects can lead to enhanced social withdrawal. Around 75% of patients experience 
extrapyramidal side effects and clinical literature appears to ascribe this as a key 
concern, yet there is no clear evidence that patients view it as such (Coffey, 1999). 
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Atypical anti-psychotics have fewer side effects but some of these can be extremely 
debilitating. Atypical anti-psychotics results in a higher rate of sexual dysfunction. 
There has been negligible research into this aspect of side effects and it is often not 
mentioned in clinical practice but there is evidence to suggest that patients them-
selves rate this as the most severe side effect and it therefore has a negative impact 
on adherence (McCann et al., 2009). A community-based study reported that 50% 
of patients reported experiencing side effects which were not rated as severe, but 
the cumulative effect of experiencing a variety of different side effects raised the 
severity considerably. It was also noted that during initial treatment patients had dif-
ficulty differentiating side effects from the symptoms of their condition (McCann et 
al., 2009).  
 
The consequences of side effects to anti-psychotic medication can impact upon 
physical health and personal relationships, destabilise wellbeing, affect morbidity 
and mortality and necessitate the requirement of regular medical supervision 
(Wolters et al., 2009). Despite this, the main concern is often that the severity of side 
effects could lead people to discontinue adherence to anti-psychotic medication 
(McCann et al., 2009). Although newer atypical anti-psychotics are associated with 
clinical advantages such as reduced side effects and increased tolerability, non-ad-
herence rates have remained high (Remington et al., 2007). For individuals diag-
nosed with psychosis, relatively little is known about their perceptions of the severity 
of their condition and their beliefs around effectiveness of the treatment and how 
those beliefs influence their adherence to medication. It is imperative that measures 
used to assess these concepts address all aspects of side-effects to anti-psychotic 
medication as perceived by those prescribed them. Furthermore, there is a paucity 
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of research exploring these concepts over time. Thus, the complex relationship be-
tween adherence to anti-psychotic medication and side effects precepts greater lon-
gitudinal exploration. 
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CHAPTER 5. Social support and adherence.  
Social support is conceptualised as an individual having a person or group of people 
who are available to them, on whom they can rely and who let them know that they 
are cared for, valued and loved (Sarason, Levine, Basham, & Sarason, 1983). It 
refers to the sustenance provided by a support network, such a network can often 
involve friends and family but is not restricted to just them (Mas-Expósito et al., 
2013). Social networks comprise the quality, quantity and strength of relationships 
and the impact, support and structure of these relationships on quality of life (Mac-
donald, Hayes, & Baglioni, 2000). Robust social support is formed through perma-
nency, reciprocity, positivity and regular interaction. It can include financial, emo-
tional, advisory and informational support and companionship. A strong social sup-
port network is consistently associated with improving outcomes across a wide range 
of diverse illnesses and conditions, including individuals suffering from psychosis 
(Macdonald et al., 2000; Norman et al., 2005). Yet, research indicates that individu-
als with severe mental illnesses are more likely to have lowered social support and 
smaller social networks, with limited access to support other than that provided by 
mental health services. These findings go on to highlight associations between the 
reduced levels of social support in individuals suffering from psychosis and increases 
in psychiatric symptoms, relapse, rehospitalisation and lowered levels of self-esteem 
and quality of life. Furthermore, higher levels of social support are considered a cru-
cial component of treatment and recovery (Mas-Expósito et al., 2013). 
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5.1 Impact of social support upon adherence. 
The relationship between social support and adherence has received considerable 
research attention in Health Psychology. While research into the impact upon adher-
ence to anti-psychotic has remained relatively unexplored, there is substantial em-
pirical evidence for the association of social support with adherence in numerous 
other conditions. Meta-analyses performed following a comprehensive literature re-
view covering 122 studies, between the years of 1948 to 2001, correlated structural 
or functional social support with adherence to medication, revealed a significant re-
lationship between adherence and practical, emotional, and one-dimensional social 
support. There were also associations with family cohesiveness and conflict, marital 
status, and living arrangements of adults (DiMatteo, 2004). Social support has been 
purported to impact upon adherence in a range of conditions. A study exploring So-
cial Support and Adherence for individuals diagnosed with Hepatitis C found that 
social support had a significant impact upon adherence. Findings revealed that while 
receiving treatment, individuals experience both supportive and unsupportive reac-
tions from family, friends and healthcare providers. Supportive reactions were found 
to enhance adherence while unsupportive reactions were associated with reduced 
adherence to treatment. The authors went on to argue that in order to support treat-
ment adherence, healthcare professionals should assess sources of support experi-
enced by patients during treatment. When a supportive network is not in place, pa-
tients should be encouraged to attend a support group or seek counselling, while 
exercising empathy and caring to support adherence during treatment (Phillips & 
Barnes, 2016). Similarly, research into weight loss has found social support to be a 
significant factor in adherence (Marquez et al., 2016). 
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The association between social support and health outcomes has received a sub-
stantial amount of devotion in Health Psychology and behavioural medicine re-
search. Social support is reported to guide and enhance the capacity to adjust to and 
live with illness and it is believed that the relationship between social support and 
health may be facilitated by adherence (Dunbar-Jacob & Schlenk, 2001). Backing 
and assistance from a support network of friends and family has been associated 
with enhancing patient adherence by heightening optimism and self-esteem, cush-
ioning the stresses of being ill, reducing depression, improving health-related behav-
iour and providing practical assistance (DiMatteo, 2004). Although the importance of 
social support upon adherence has been demonstrated in numerous conditions in-
cluding psychosis, studies have yet to explore this effect longitudinally for those di-
agnosed with psychosis. 
 
5.2 Community treatment in psychosis.  
In line with the introduction of anti-psychotic medication there have been substantial 
changes in the standards and delivery of psychiatric care, resulting in an increasing 
awareness of the importance and impact of adequate social support. Although the 
importance of social support in relation to adherence has been clearly established, 
there is relatively little information regarding the impact of social support on adher-
ence within individuals with psychosis.   
Social Support is however acknowledged to impact upon mental health and has a 
role in both mental illness prevention and recovery. Research has stressed that it is 
a key influence upon the perceived severity of symptoms, adaptations and health 
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outcomes amongst patients diagnosed with schizophrenia (Hamaideh, Al-Magaireh, 
Abu-Farsakh, & Al-Omari, 2014). It is considered a determinant in advancing recov-
ery, can positively affect both physical and mental health and perhaps most signifi-
cantly, high levels of social support is purported to act as a defensive shield that can 
positively enhance the quality of life of people with psychosis while decreasing the 
severity of their symptoms (Mas-Expósito et al., 2013). Unfortunately, many individ-
uals with psychosis often suffer from social dysfunction and their social relationships 
and networks are reportedly reduced (Macdonald et al., 2000). Yet although the size 
of the network is reportedly reduced that may not necessarily reflect upon the level 
of support. A smaller social network may not affect the level of support that these 
individuals receive. However, in research social support is largely represented by the 
size of the network with some evidence suggesting that reduced networks equate 
with a deficiency of close relationships (Norman et al., 2005). The terms social sup-
port and social networks are subjective and multidimensional and thus difficult to 
quantify and measure. Research into the phenomenon has utilised a variety of 
measures in an attempt to explore these concepts in mental health populations. In-
vestigating these methods to ensure they are robust may offer additional insight into 
adherence. Although the impact of social support upon mental health is recognised, 
its relationship with adherence remains largely unexplored. The measures used in 
this study have been validated as appropriate for the assessment of perceived social 
support in patients diagnosed with psychosis. 
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5.3 Onset of psychotic symptoms & duration of untreated 
psychosis. 
A recent area of research into the effects of social support on psychosis is with regard 
to its predictive capacity on symptom outcomes and hospitalisation rates. The inves-
tigation of prognostic elements has led to increased awareness in the duration of 
untreated psychosis and its associations with a lack of social support. The duration 
of untreated psychosis, refers to the interval between the onset of psychotic symp-
toms and the commencement of appropriate treatment, (Norman et al., 2005). Re-
search indicates that there are often substantial delays in the duration of untreated 
psychosis for individuals with schizophrenia and delays are correlated with added 
severity of symptoms and long-term outcomes (Mas-Expósito et al., 2013). The du-
ration of untreated psychosis is reported to impact upon health outcomes, as com-
prehensive meta-analyses suggest that it has a link with symptomatic and functional 
outcomes (Marshall et al., 2005). It has been reported that individuals with enhanced 
social support pursue treatment for psychosis earlier (Norman et al., 2005).   
 
5.4 Cultural variations in social support. 
Relatively little research has explored how different cultures impact upon social sup-
port for individuals suffering from psychosis. Social support intrinsically involves re-
lationships among individuals and groups of individuals. People from different cul-
tural upbringings may view and be affected by social support differently and their 
relationship patterns are best understood within the context of culturally speciﬁc 
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structures (Kim, Sherman, & Taylor, 2008). This in turn should be reflected in the 
measures utilised to assess support and the development of culturally appropriate 
care (Cheng, Tu, & Yang, 2016). Research exploring social support across various 
societies has identified consistent cultural differences in people’s inclination to utilise 
social support for dealing with stressors. Cultural differences affect the way in which 
individuals view themselves, relationships with others and their sense of self-esteem 
(Cheng et al., 2016).  
 
These cultural differences may impact upon how people view, seek and accept sup-
port within their community, with people in individualistic cultures more likely to seek 
social support (Kim et al., 2008). Thus, in Western culture, where society if often 
considered more disparate and social support tends to be viewed in terms of the size 
of the individual’s social network, individuals diagnosed with psychosis who have 
superior social skills may be more able to develop a larger social network, whereas 
individuals with a more severe and enduring form of psychosis may have less social 
skills and their networks may be smaller. Conversely, in more collectivist cultures, 
including parts of Asia, society is often considered more interdependent, and individ-
uals viewed as connected and bound to a group, with group objectives seen as more 
relevant than personal needs (Kim et al., 2008).  
 
There is a dearth of empirical studies that have explored concepts of social support 
upon adherence to anti-psychotic treatment utilising measures that are validated for 
use amongst individuals diagnosed with psychosis. There also remains a lack of re-
search that have scrutinised these concepts longitudinally. This thesis will explore 
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the impact of social support upon adherence to anti-psychotic medication in light of 
the unique characteristics of adherence in psychosis.  
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CHAPTER 6. Illness perceptions and adher-
ence. 
Poor insight into the condition is considered a core characteristic in psychosis, with 
between 57-98% of individuals diagnosed with schizophrenia unaware of having a 
mental disorder (Lehrer & Lorenz, 2014). Insight into illness has been defined as the 
acceptance of the clinician’s illness model by the patient (Beck et al., 2011). 
 
 
6.1 Illness insight.  
 As poor illness insight is a common feature in psychosis, it has been argued that 
this lack of insight can lead to negative attitudes towards treatment. Lowered insight 
has been linked with lower self-esteem, hopelessness, depression and increased 
internalisation of stigma (Lincoln, Lullmann, & Rief, 2007). Much of the research into 
predictors of insight has utilised samples of chronic patients from in-patient settings, 
but interest has increased in exploring correlates and predictors of insight amongst 
individuals who have been recently experiencing symptoms. Research into first epi-
sode psychosis indicates that insight is associated with advanced negative and dis-
organised symptoms, severe depression, severe unusual thought content and in-
creased severity of overall symptoms (Ayesa-Arriola et al., 2011). Investigations into 
cognitive insight identified an indiscriminate dysfunction of the neural networks that 
undertake decision-making tasks, with a reduced cognitive insight linked to impaired 
insight. Cognitive insight was also reported to have connections to memory (predom-
inantly working memory) and verbal learning (Ayesa-Arriola et al., 2011). 
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The absence of illness insight is purported to be a key factor in medication non-
adherence (Novick et al., 2015). An increasing body of research has been devoted 
to exploring the foundations and effects fundamental to the lack of insight in psycho-
sis. It is believed that enhancing knowledge and awareness of psychotic illness and 
its treatment increases adherence to medication, yet research evidence is varie-
gated. Investigations of the scientific and neurocognitive associations of insight have 
provided capricious results (Ayesa-Arriola et al., 2011). A contemporary meta-anal-
ysis suggested that psychoeducation had no significant effect upon adherence (Lin-
coln et al., 2007). The results of longitudinal studies exploring insight on medication 
adherence have been inconclusive which has intensified reservations of its predictive 
capacity (Beck et al., 2011).  
 
 
6.2 Theoretical perspectives on illness perceptions. 
Health Psychology has provided valuable frameworks to explore concepts of illness 
perception and insight. Illness Perception refers to a set of beliefs concerning how 
individuals make sense of their health status (Mak, Chong, & Wong, 2014). The no-
tion of illness perception has been used to explain how a representation of one’s 
illness is created as a mechanism to make sense of one’s condition and create ade-
quate reactions. For patients with mental health issues, the attributions and percep-
tions of their illness could potentially either hasten or defer pursuing treatment, which 
in turn impacts upon the conduits of clinical care and future prospects. Psychotic 
episodes would thus inform the patient’s beliefs regarding recognising their status 
and the associated personal and social consequences, irrespective of whether the 
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illness itself is acknowledged by the patient or not (Gómez-de-Regil, Kwapil, & Bar-
rantes-Vidal, 2014). It is common to find partial awareness among mental health pa-
tients who refer to symptoms using their own terminology. Illness perception com-
prises of cognitive and emotional representations and does not require recognition 
of the condition as an illness (Moss-Morris et al., 2002).  One of the more inﬂuential 
illness perception models is Leventhal’s Self-Regulation Model of Health and Illness 
Behaviour (Leventhal, Leventhal, & Contrada, 1998: Leventhal, Leventhal, & Cam-
eron, 2001). The Self-Regulation Model interprets illness perceptions as a key com-
ponent of determining how people understand and manage threats to their health 
(Fischer et al., 2010). 
 
Alongside The Theory of Planned Behaviour (Ajzen, 1985), The Self-Regulation 
Model (varyingly referred to as Leventhal’s Theory, The Common Sense Model, the 
Common-Sense Model of Self-Regulation of Health and Illness etc.) have both been 
frequently utilised as health-related decision-making frameworks by Health Psy-
chologists. The Theory of Planned Behaviour originates from rational models of de-
cision-making, and has been extensively used to forecast and explore a variety of 
health behaviours (Sivell, Edwards, Elwyn, & Manstead, 2011). However, the Theory 
of Planned Behaviour has faced increasing challenges in recent times (Ogden, 
2015). Criticisms include that it is not falsifiable, that it creates rather than measure 
cognitions and that its constructs can be tautological (Ogden, 2003). While the The-
ory of Planned Behaviour attempts to forecast patient decisions, the Self-Regulation 
Model scrutinises how the wider representation of a condition helps the patient deal 
with that condition. It offers a framework explaining how patients make sense of their 
condition and their perceptions of accessible treatments, assigning more importance 
 63 
on emotional and coping responses when rationalising illness-related behaviour 
(Wearden & Peters, 2008). The Self-Regulation Model is theoretically derived and 
purports that people create their own representations of their condition that aids mak-
ing sense of their experience and facilitates coping. It outlines the corresponding 
cognitive and emotional processes that intermingle in the way an individual copes 
with and adjusts to their condition, in the same manner that a health risk generates 
both a cognitive representation of the threat and a parallel requirement for processes 
to cope with the risk (Snell, Hay-Smith, Surgenor, & Siegert, 2013).  
 
The Self-Regulation Model identiﬁes the dynamics involved when patients process 
information that help them develop lay perceptions of the illness (Leventhal, Meyer, 
& Nerenz, 1980; Leventhal, Nerenz, & Steele, 1984: Leventhal et al., 2001: Le-
venthal, Weinman, Leventhal, & Phillips, 2008). These perceptions inform coping 
behaviours and outcomes. It theorises that lay perceptions develop in three stages, 
namely; interpretation of the problem (whereby cognitive representations, or an ab-
stract model of the illness are developed by the patient), action plan / coping stage 
(during which the patient identiﬁes and cultivates appropriate coping strategies) and 
the appraisal stage (where patients appraise their strategies to decide whether to 
continue with their current coping strategy or cultivate an alternative). These stages 
endure until the coping strategies implemented are viewed as being effective and a 
state of equilibrium is reached (Sivel at al., 2011). Originally, the self-regulation 
model identiﬁed ﬁve cognitive components of illness representations (Leventhal et 
al., 1984). These are identity (which refers to the illness label used to describe the 
condition and associated symptoms), causal attributions (the individual’s perception 
of what caused the onset of the illness), expected consequences (the anticipated 
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effects and outcome of the illness), perceptions of controllability/curability  (the extent 
to which individuals believe they will be able to recover from or control the illness 
through treatment) and timeline perceptions (the length of time that the individual 
believes their condition will last) (Snell et al., 2013).  Subsequently, three further 
cognitive dimensions were added to the model, these components addressed emo-
tional representations (emotional perceptions related to the illness), cyclical timeline 
beliefs (perceptions related to variations in symptoms and unpredictability of the con-
dition), and coherence (the extent to which the individual coherently understands 
their condition) (Moss-Morris et al., 2002). These components are not independent 
of each other and can often be connected or interrelated. Illness representations can 
be affected by a variety of elements, including past experience, experiences related 
by an acquaintance who underwent treatment, knowing someone diagnosed with the 
illness as well as information provided by friends, relatives, the media and health 
care professionals (Sivel at al., 2011). 
 
Health Psychology offers robust theories and models to explain, describe and predict 
health behaviour and the Self-Regulation Model is appealing to Health Psychologists 
as it theorises that people are problem solvers who take an active role in the man-
agement of their own health (Wearden & Peters, 2008). The self-regulation model 
has been successfully employed by researchers in attempts to further understand-
ings of health outcomes in an assortment of conditions including chronic fatigue syn-
drome (Wearden & Peters, 2008), chronic pain (Snell et al., 2013), cardiovascular 
disease (Sivell et al., 2011), ﬁbromyalgia (Miró et al., 2011), cancer (Dillard, Ferrer, 
Ubel, & Fagerlin, 2012) and traumatic brain injury (Hou et al., 2012), amongst others.  
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6.3 Impact of stigma upon perceptions of illness, coping 
strategies & adherence in psychosis. 
Although illness perceptions and the Self-Regulatory Model have been utilised to 
assess adherence in a variety of health conditions, the perspective of individuals 
diagnosed with psychosis has remained relatively unexplored. Conversely, investi-
gations into the causes and consequences of the lack of insight in schizophrenia 
have become increasingly prominent. Mental illness is a highly stigmatised condition, 
and individuals who have been diagnosed with the condition have reported being the 
subject of both stigma and discrimination. Research has highlighted that the stigma 
experienced by individuals with a mental health illness interferes with recovery efforts 
including adherence (Sarkin et al., 2015). Stigma has been described as biased be-
haviours, negatively predisposed attitudes and prejudiced social structures, that oc-
cur when a substantial collection of society validates negative attitudes towards a 
subgroup (Corrigan, 2000). Stigma has multifaceted and confounding effects on peo-
ple’s welfare and societal circumstances affecting the public’s perceptual, emotive, 
and behavioural responses towards the stigmatised illness and those diagnosed with 
it (Angermeyer, 2000). Stigma has been acknowledged as a key facilitator of psy-
chological and behavioural symptoms, which can have far reaching impact upon the 
individual and society as a whole (Mak et al., 2014). The stigma experienced by 
individuals diagnosed with a mental illness leads to an increased reluctance to dis-
close details regarding their mental health and impacts upon engagement with pro-
fessionals and treatment (Sarkin et al., 2015). There is reported discrimination of 
individuals with mental illness in employment, housing and other social opportunities 
with public opposition to the setting up of rehabilitation facilities in their locality (Mak 
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et al., 2014).  It is theorised that those diagnosed with mental health conditions often 
deny the illness as a coping mechanism, as a way to protect themselves from the 
adversity of the condition (Angermeyer, 2000). A consequence of this coping mech-
anism is poor engagement levels with clinicians and diminished adherence for pa-
tients diagnosed with mental illness (Sarkin, et al., 2015). This fits into the character-
istics of paranoia, grandiose delusions and false beliefs, which are common features 
of psychotic illness (Thornley & Adams, 1998).  
 
6.4 Importance of therapeutic relationships upon illness 
perceptions in Psychosis 
The specialised skills required by mental health practitioners may have impacted the 
relative lack of research conducted by Health Psychologists on adherence to anti-
psychotic medication. Research into the impact of illness insight upon therapeutic 
relationships has enhanced awareness of its influence. A study made up of inpatients 
diagnosed with schizophrenia and schizoaffective disorder suggested that poor ther-
apeutic relationships and poor insight were correlated with low levels of adherence 
(Misdrahi, Petit, Blanc, Bayle, & Llorca, 2012). Studies have explored the relationship 
between therapeutic relationships, insight and adherence (Beck et al., 2011). How-
ever, these studies have faced limitations due to small sample size. Previous re-
search has suggested that the main predictor of engagement levels was mainly de-
mographic (Dunbar-Jacob & Schlenk, 2001). Yet, more recent exploration has indi-
cated that illness beliefs have been used to predict engagement levels, with those 
who associated internal psychological causes to their symptoms, less likely to drop 
out of therapy (Marcus et al., 2014).  Many of these studies have taken place within 
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in-patient settings. However, within these settings professionals will routinely admin-
ister medication. Therefore, research of individuals who reside in the community and 
self-medicate would appear advantageous when investigating adherence. 
A plethora of research has reported evidence for the predictive role of patients’ ill-
ness perceptions in coping responses and health outcomes (Wearden & Peters, 
2008; Snell et al., 2013; Sivell et al., 2011; Gómez-de-Regil et al., 2014; Moss-Morris 
et al., 2002; Mak et al., 2014). Although studies in the general population have ex-
plored the effectiveness of utilising the self-regulation model in examining adherence 
to treatment programmes, the perspective of schizophrenia patients has remained 
largely unexplored. This is a key issue as findings highlight that many patients with 
schizophrenia are exposed to serious health risks due to non-adherence. Thus, in 
spite of the increasing research into the impact of illness perception upon adherence, 
numerous questions endure regarding its causes and impact upon people with psy-
chosis. As yet, very few studies have investigated whether illness perceptions impact 
upon medication adherence amongst individuals with psychosis. With even fewer 
exploring these concepts longitudinally. As it is proposed that the disposition of one’s 
self-regulation is cyclical, it would be insightful to explore whether this impact evolves 
over time utilising concepts provided by the self-regulation model.  
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CHAPTER 7. Purpose of this study, Aims, Ra-
tionale, Research Question and Hypothesis. 
The present study expands upon previous research, while exploring determinants of 
adherence to anti-psychotic medication and relationships between any of the factors 
considered to possibly impact upon attitudes towards adherence. It also attempts to 
highlight methods that could improve these factors in a positive nature. Upon review-
ing past research, it seems clear that non-adherence to anti-psychotic medication 
stands as one of the foremost challenges in psychiatry (Aldridge, 2011). It is linked 
to detrimental treatment outcomes, relapse, rehospitalisation and reduced psycho-
social functioning (Weiden et al., 2004). The consequences of non-adherence can 
be overwhelming for patients, those close to them, society in general and the econ-
omy (Byerly et al., 2007).   
Exploring ways of improving adherence is viewed as a crucial component in future 
research (Acosta et al., 2009; Srinivasan & Thara, 2002). The dynamics which influ-
ence adherence can be described as an interaction between various factors includ-
ing patient related, environment/illness related or treatment related factors (Velligan 
et al., 2009). A number of review studies have reported various predictors, with in-
creasing evidence indicating that the seeds of non-adherence are rooted in factors 
associated with drug use, side effects, social support, illness insight and demo-
graphic factors (Lacro et al., 2002; Masand et al., 2009; Novick et al., 2010). How-
ever, the majority of previous research has been cross-sectional, utilising partici-
pants from in-patient settings and varying, non-standardised measures. There is a 
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dearth of studies that have satisfactorily identified the relative significance of the var-
ious risk factors for non-adherence. Previous studies have mainly focused on one 
risk factor at a time and there is scant research that has explored several risk factors 
simultaneously in order to identify the most significant predictive factor. Many of the 
studies exploring adherence to anti-psychotics were retrospective, cross-sectional 
and conducted prior to atypical anti-psychotic medication becoming available or the 
development of new features such long-acting depot injections (Novick et al., 2010). 
Although some degree of research has looked at factors in isolation, studies utilising 
a longitudinal method to explore which of these factors have the greatest predictive 
capacity in individuals with a mental health impairment are rare. Furthermore, much 
of the previous research in this area appears to be limited to data collected at one 
particular time and to the best of my knowledge there has been no longitudinal study 
in the area exploring the interaction between these concepts. Adherence can vary 
over time and a longitudinal design comparing data obtained from participants at two 
time points is imperative in order to examine if adherence should be viewed as con-
tinuously disturbed rather than naturally dichotomous (Razali & Yusoff, 2014).  
 
There is a paucity of prospective studies that have explored predictive concepts in 
depth and it is currently unclear as to which factors are the best long-term predictors 
of adherence to anti-psychotic medication. The purpose of this paper is to apply the 
science of Health Psychology to exploring determinants of adherence to anti-psy-
chotic medication. It aims to further our understanding of the elements and occur-
rences of the issues involved, while discussing factors that could potentially enhance 
these issues to a positive nature. The objectives of the present study are based on 
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Leventhal’s Self- Regulation Model. The Self-Regulation Model suggests that indi-
vidual’s beliefs about the causes, duration, consequences of the illness, and whether 
or not they have some control over the illness, influences the way the person adjusts 
and copes with that illness (Leventhal, 1985). Extending this model, it is argued that 
the way in which individuals being treated with anti-psychotic medication conceptu-
alise their illness may be an important factor for their adherence. As multiple corre-
lations were undertaken and to avoid type 2 error, only findings at p<0.01 were con-
sidered significant. Similarly, as the analysis looks to determine if there is a relation-
ship between variables in either direction, two-tailed tests are utilized and therefore 
the hypothesis is non-directional. 
 
This study aims to explore the psychosocial, clinical and demographic factors that 
may potentially impact adherence in individuals with psychosis. Two main questions 
will be explored: 
1. Are demographic characteristics, perceived levels of social support, illness 
perceptions, drug use and side effects at baseline associated with adherence 
both at baseline and 6-month follow-up  
2. Which of the baseline factors examined (demographic characteristics, per-
ceived levels of social support, illness perceptions, drug use and side effects) 
are the strongest determinant of adherence both at base line and 6-month fol-
low-up?  
Specifically, it is hypothesised that: 
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a. Demographic characteristics such as age, employment status, marital status 
and educational status at baseline will be associated with adherence to anti-
psychotic medication both at baseline and at 6-month follow-up.  
b. Perceived levels of social support at baseline will be associated with adher-
ence to anti-psychotic medication both at baseline and at 6-month follow-up. 
c. Illness perceptions (Consequences, Illness Timeline, Personal Control, Treat-
ment Control, Identity, Concern, Understanding and Emotional Representa-
tions) at baseline will be associated with adherence to anti-psychotic medica-
tion both at baseline and at 6-month follow-up.  
d. Drug use at baseline will be associated with adherence to anti-psychotic med-
ication both at baseline and at 6-month follow-up. 
e. Side effects of antipsychotic medication at baseline will be associated with 
adherence to anti-psychotic medication both at baseline and at 6-month fol-
low-up. 
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SECTION 2. 
METHODOLGY & RESULTS 
CHAPTER 8 Methodology 
8.1 Design  
This is a longitudinal questionnaire study. Data was collected at two time points. The 
initial stage of data collection (baseline) took place in Autumn 2015, with the second 
phase (T2) taking part six months later, in the Spring of 2016. Ethical Approval was 
sought from City, University of London’s Psychological Research Ethics Committee 
and was granted on 12th of May 2015. Ethics Approval Code; PSYCH (P/F) 14/15 
155 (Refer to Appendix). 
The time scale for the second phase of data collection was set six months later as 
this mirrors current Care Programme Approach (CPA) meeting timescales, Commu-
nity mental health teams (CMHTs), arrange a CPA meeting every six months for 
individuals with psychosis who are treated in the community. During these meetings, 
events over the previous six months are reflected upon and plans for the following 
six months are arranged. Knowledge of potential risk factors that could affect people 
within this time scale is of imperative practical use in developing interventions, ap-
proaches, strategies and planning. 
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8.2 Ethical considerations.  
While composing the procedure, careful consideration was provided to ethical issues 
to ensure that the study met with BPS guidelines. The researcher obtained DBS 
clearance to work with the individuals involved. As the study did not involve NHS 
patients, NHS clinicians or NHS premises, university ethics were considered ac-
ceptable. The study was approved by the university’s psychology ethics committee. 
Approval Code; PSYCH (P/F) 14/15 155 (Refer to Appendix A). Further to the stand-
ard considerations, the researcher ensured that none of the recruited participants 
were currently, nor had previously been under the clinical care of the researcher. 
Participants were recruited from individuals who were not subject to Sections 2, 3, 4 
or 5 of the Mental Health Act (1983). Individuals can be admitted, detained and 
treated under different sections of the Mental Health Act, the term ‘sectioned’ is used 
to describe a compulsory admission to hospital and these sections refer to in-patient 
admissions. Section 2 refers to an admission for assessment. Section 3 refers to an 
admission for treatment, while Section 4 refers to an emergency admission. Section 
5 involves being stopped from leaving hospital as a voluntary or informal patient. The 
reasoning for excluding individuals who were subject to these conditions was due to 
potential debate surrounding issues regarding informed consent. Specifically, the ex-
tent to which individual’s subject to conditions of the Mental Health Act (1983) would 
be able to provide informed consent to participate in the study. Individuals over the 
age of 18 who were subject to Section 117 (after care) or a Community Treatment 
Order were able to take part, as these individuals would have been reviewed by their 
multi-disciplinary team and clinically assessed as able to reside in the community 
and deemed as having individual capacity under the terms of the Mental Capacity 
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Act (1983). They would therefore be able to provide individual consent. The re-
searcher ensured that no form of coercion was used to encourage participation.  
 
All participants were provided with a consent form which they were asked to read 
and sign. They were informed that participation in the study was entirely voluntary 
and that they were entitled to withdraw at any time. It was made apparent that any 
personal information supplied, together with the data resulting from their participa-
tion, would be recorded in an anonymous form, remain anonymised and be stored 
in a secure location. This encouraged participants to be honest when answering the 
questions, but also fulfilled the informed consent requirements. Participants were 
given the option of being accompanied by a key worker or any other appropriate 
adult. They were asked if they had fully understood what had been said and further 
if they would like to continue participation. Participants were also encouraged to 
speak to the researcher or their key worker if they had any concerns. 
 
Participants were fully debriefed following data collection and at this point the edu-
cational value of the study outlined. Participants were able to ask questions and the 
researcher was able to address any questions or issues to ensure that those individ-
uals that continued with participation were content with their involvement.  
 
8.3 Participants. 
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Participants were recruited from a range of locations including community-based 
charities, online forums, social media, community centres, supported accommoda-
tions, sheltered accommodations and support groups. The majority of initial partici-
pants were recruited from a number of registered organisations running community 
based step-down accommodations providing independent group living for individuals 
with mental health needs in the North, North East and West London areas and the 
sample subsequently snowballed via word of mouth. The researcher also attended 
monthly service user forums at the supported care environments in order to explain 
the purpose of the study and recruit participants. Potential participants were given 
an information sheet of the study with researcher’s details to get in touch if they 
wanted to take part. Only participants residing in the community took part. One hun-
dred and twenty-six participants were initially recruited and consented to take part. 
Thirteen of the participants provided partially completed or illegible questionnaires 
while three participants later decided to withdraw from the study resulting in one hun-
dred and ten individuals featuring in the first stage. All participants who took part in 
the initial data collection were contacted again after six months and those who re-
mained eligible were invited to take part in the second stage. Twenty-five individuals 
(22.72%) dropped out from the second stage of data collection. The second stage of 
data collection, comprised of eighty-five individuals who were provided with the same 
set of questionnaires, which they were asked to complete and return to the author. 
The same process and procedures as during the first stage of data collection were 
adhered too.   
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Inclusion criteria  
Participants were eligible for inclusion if they: 
  Were currently prescribed anti-psychotic medication. 
  Were aged over 18. 
  Resided in the community. 
  Were fully discharged and not subject to Sections 2, 3, 4 or 5 of the Mental 
Health Act (1983).  
Exclusion criteria  
Potential participants were excluded if they: 
  Were having medication administered to them by others. 
  Resided in a mental health ward or residential care home and not fully dis-
charged in to the community.  
 
8.4 Patient & Public involvement in choosing question-
naires. 
The researcher has experience working within mental health settings, and has de-
veloped a staged self-medication programme. The author was therefore determined 
to be explicit in detailing previous experiences and circumventing any potential pre-
conceived notions from his prior involvement of working within mental health. In order 
to avoid any form of examiner bias, it was decided to run a focus group in order to 
attain patient and public involvement in finalising which questionnaires to be utilised 
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in this research. This allowed the research to identify & employ measures that par-
ticipants would potentially feel most comfortable completing, while removing any pre-
determined ideas or subconscious agendas based on the researcher’s experience 
of utilising these measures in previous professional practice. 
 
Prior to the collection of data, the researcher had posted an invite for the focus group 
at a recovery club meeting, which took place at a local Community mental health 
group. The group was facilitated by the researcher and lasted for 90 minutes. It was 
attended by seven individuals. Four of these individuals were, or had previously 
been, prescribed anti-psychotic medication, two were carers for individuals pre-
scribed anti-psychotic medication and one was a keyworker for an individual pre-
scribed anti-psychotic medication. The focus group were provided with different 
measures which assessed factors associated with adherence and provided feedback 
on each one, which was then discussed with the group. Wherever possible, the re-
searcher attempted to provide several measures for each factor and attempted to 
establish the process for data collection in a way that would optimise responses and 
participation. In total 11 questionnaires were provided (Refer to Appendix B). These 
included the Medication Adherence Rating Scale (MARS), the Medication Adher-
ence Questionnaire (MAQ), the Drug Abuse Screening Test (DAST-10), the Drug 
Attitude Inventory (DAI), The Liverpool University Neuroleptic Side-Effect Rating 
Scale (LUNSERS), the Systematic Monitoring of Adverse events Related to Treat-
ments (SMARTS), the Glasgow Anti-psychotic medication Side effect Scale (GASS), 
the Illness Perception Questionnaire (IPQ), the Brief Illness Perception Question-
naire (BIPQ), the Social Support Questionnaire (SSQ) and the Duke-UNC Functional 
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Social Support Questionnaire (FSSQ). People were also asked for their thoughts on 
the research in general and reasons why they would or wouldn’t take part. 
 
At this stage, the measures to be used in the study were finalised and the procedure 
for data collection established, based on the feedback received. Several question-
naires were rejected based on comments received. Six of the seven focus group 
members stated that they felt the Illness Perception Questionnaire was overly 
lengthy and therefore the Brief Illness Perception Questionnaire was chosen, as it 
was felt that this adequately addressed relevant aspects of the condition. Although 
three individuals also felt that the Glasgow Anti-Psychotic Side Effect Scale was time 
consuming, all seven individuals agreed that it adequately addressed sexual side-
effects for both males and females which the other questionnaires did not, and was 
therefore considered to be the most suitable for use in the study. As observations 
included the fact that completing numerous questionnaires could negatively impact 
upon concentration, it was decided to keep the demographic questionnaire brief. The 
final questionnaires selected for use in this study are the Medication Adherence Rat-
ing Scale (MARS), the Brief Illness Perception Questionnaire (BIPQ), the Glasgow 
Anti-psychotic side effect scale (GASS), the Drug Abuse Screening Test (DAST-10) 
and the Duke-UNC Functional Social Support Scale (FSSQ).  
 
Aspects of medication taking were discussed and it was mentioned that individuals 
living in mental health wards or residential care homes might be required to adhere 
to their medication programme as a condition of the stay. Some individuals residing 
in residential care would have their medication administered by staff and compliance 
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monitored. For others, professionals would often prompt/remind them to take medi-
cation even when the individual concerned was self-medicating. Therefore, it was 
decided that the study should target individuals who lived independently or in the 
community. It was also decided that the study should be as inclusive as possible and 
should focus on all individuals who were prescribed anti-psychotic medication rather 
than focusing on a particular condition or medication. This was because individuals 
often rejected terms such as “schizophrenic”, and individuals were often prescribed 
several types of anti-psychotic medication during the course of their treatment. 
 
8.6 Measures. 
The following assessments were administered in one session. All participants who 
completed the assessments and who remained legible under the inclusion criteria 
were invited to undertake the assessment process again twenty-four weeks later.   
 
Outcome variable 
Medication Adherence Rating Scale (MARS) 
In order to assess medication adherence, this study utilised the Medication Adher-
ence Rating Scale (Thompson, Kulkarni, & Sergejew, 2000). The MARS was devel-
oped to address perceived deficiencies of previously used adherence measures. It 
expanded upon widely used psychiatric research measures such as the Drug Atti-
tude Inventory (DAI) and the Medication Adherence Questionnaire (MAQ) in an at-
tempt to cultivate a medication adherence tool with enhanced validity, reliability and 
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clinical utility (Thompson et al., 2000). Upon creation, the authors assessed the 
measure utilising a sample of sixty-six patients the majority of whom had been diag-
nosed with schizophrenia and it was reported to be a reliable and valid quantifier of 
adherence for psychoactive medication. This has been endorsed by supplementary 
research with a large-scale validation study (n=277) of the MARS, which attempted 
to establish the psychometric properties in psychosis, reporting good internal con-
sistency, concurrent and predictive validity (Fialko et al., 2008). The MARS is a ten 
item self-report measure. It consists of either “yes” or “no” answers, specifically de-
signed to assess adherence in psychosis and takes approximately eight minutes to 
complete.  
 
Once data was collected for this study, the authors assessed the scale reliability for 
the measures utilised by calculating the Cronbach’s alpha of each scale. Analysis 
revealed that The Medication Adherence Rating Scale (Cronbach’s α = .79), had a 
high reliability score.   
 
Predictor Variables 
Glasgow Anti-Psychotic Side Effect Scale (GASS) 
Anti-psychotic medication can cause a wide range of adverse side effects (McCann 
et al., 2009; Coffey, 1999). Current guidelines advise regular monitoring of side ef-
fects (National Institute for Health and Care Excellence (NICE) 2012). Numerous 
attempts at developing and validating a precise tool to gage the side effects of anti-
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psychotic medication have been made. As research (McCann et al., 2009) has sug-
gested that sexual dysfunction can have an adverse impact on adherence it was 
important to use a measure that assessed this. This study chose to utilise a compre-
hensive scale which not only addressed all relevant side effects to anti-psychotic 
medication but had also been validated for use with individuals suffering from psy-
chosis. Of the scales currently utilised the Glasgow Anti-Psychotic Side Effect Scale 
(GASS) is widely considered to be most suitable for clinical use and contains ratings 
of both metabolic and neuromuscular side effects. A recent validation study reported 
high construct validity, discriminatory power and test–retest reliability (Nystazaki, 
Tsapakis, Hadjulis, & Alevizopoulos, 2014). The GASS contains 21 questions for 
males and females (including questions related to gender specific sexual dysfunc-
tion). It utilises self-explanatory questions in everyday language, takes around five 
minutes to complete, and provides an organised, methodical technique of reviewing 
side effects to anti-psychotic medication. Following data collection for this study, the 
scale reliability for the GASS scale was assessed by calculating the Cronbach’s al-
pha (Cronbach’s α = .89). 
 
Duke–UNC Functional Social Support Questionnaire (FSSQ) 
Originally developed and tested on 401 randomly selected patients, the Duke-UNC 
Functional Social Support Questionnaire (Broadhead, Gehlbach, DeGruy, & Kaplan, 
1988), is an eight-item measure that takes approximately five minutes to complete 
and is a commonly used psychometric instrument to assess the social support in 
individuals with psychosis. It is an instrument which measures the strength of social 
 82 
support networks. Responses are scored on a one to five scale. The higher the av-
erage score, the greater the perceived social support. 
 
Test-retest reliability evaluations have reported a correlation coefficient of .6. Item-
remainder correlations were used to assess internal consistency and ranged from 
.50 to .85. Construct validity and concurrent validity demonstrated significant corre-
lations (Broadhead et al., 1988). Numerous studies have examined the psychometric 
properties of the Functional Social Support Questionnaire (FSSQ) in a wide range of 
populations. A recent study validated its use amongst two hundred and forty-one 
patients with psychosis, this study included a one year follow up and highlighted the 
measures reliability, validity and excellent internal consistency, concluding that the 
FSSQ is appropriate for the assessment of perceived social support in patients with 
psychosis (Mas-Expósito et al., 2013). 
   
The Cronbach’s alpha of the scale, calculated following data collection stage in this 
study indicated a high reliability for the Functional Social Support Questionnaire 
(Cronbach’s α = .96). 
 
The Drug Abuse Screening Test (DAST -10) Questionnaire  
The Drug Abuse Screening Test (DAST-10) is a 10 item brief screening tool. The 
test is easy to administer and can be used to assess drug use within a variety of 
groups (Skinner, 1982). A comprehensive literature review of articles that addressed 
the reliability and the validity of the DAST-10 reported that it tended to have moderate 
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to high levels of test–retest, validity, sensitivity, specificity and reliabilities. The review 
covered the years from 1982 to 2005 and concluded that the DAST provided suitable 
measures of reliability and validity for use as a scientific research tool within a wide 
scale of populations including psychiatric inpatients and outpatients. (Yudko, Lozh-
kina, & Fouts 2007). It assesses illicit drug use in the past 12 months, takes approx-
imately eight minutes to complete and comprises of ten questions each requiring a 
yes or no response. For the present study, the reliability for the Drug Abuse Screen-
ing Test was high, (Cronbach’s α = .90). 
 
The Brief Illness Perception Questionnaire (Brief IPQ) 
The Illness Perception Questionnaire (IPQ; Weinman, Petrie, Moss-Morris, & Horne, 
1996) is an instrument designed to offer a quantitative assessment of the relationship 
between the five components of illness representation; identity, timeline, conse-
quences, cause and control/cure as described in Leventhal’s Self-Regulatory Model 
(Leventhal et al., 1984, 1998). It has been validated for use in studies of illness per-
ception in patients with a wide range of conditions (Moss-Morris et al., 2002). A re-
vised version of the IPQ measure expanded upon the original scale utilising addi-
tional items, subscales and incorporating an assessment of patients’ perceptions on 
how well they comprehend their illness and their emotional response to the illness 
(Moss-Morris et al., 2002). Although comprehensive, its scale is long, and in many 
clinical and research situations there was a need for a shorter version, particularly 
when patients were very ill, when there was limited time available for assessment, 
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or when patients were asked to complete numerous questionnaires. In 2006, Broad-
bent, Petrie, Main and Weinman addressed this need with the publication of The 
Brief Illness Perception Questionnaire (Brief IPQ; Broadbent et al., 2006).  
 
The Brief IPQ is a nine item self-report questionnaire. It provides a quantitative as-
sessment of illness representations as set out in Leventhal’s Self-Regulation Model, 
it consists of a scale designed to swiftly evaluate cognitive and emotional represen-
tations of illness. A validation study illustrated that The Brief IPQ demonstrated good 
test–retest reliability, validity with relevant measures and also demonstrated good 
predictive validity in patients undergoing psychological interventions. The scale takes 
approximately five minutes to complete. The validity of the Brief IPQ was further sup-
ported by its ability to distinguish between different illnesses (Broadbent et al., 2006). 
 
In this study, the scale reliability for the Brief IPQ was measured by calculating the 
Cronbach’s alpha following data collection. Analysis revealed that, the Brief Illness 
Perception Questionnaire (Cronbach’s α = .749) had high reliability.  
 
The subscales of the Brief IPQ were constructed according to the scoring instructions 
(Broadbent et al., 2006). This allowed the focus to remain on the assessments of the 
components of illness representation described by Leventhal’s Self-regulation model 
(Leventhal et al., 1984, 1998) within a population of patients prescribed anti-psychot-
ics. 
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Demographic Questionnaire 
The demographic questionnaire was a self-developed, six-item tool that recorded 
age, gender and ethnicity as well as relationship, education and employment status. 
 
8.7 Procedure. 
The experimenter attended recruitment venues for a period of twenty-four weeks in 
total. Participants were given a detailed information sheet before they consented to 
take part in the study. All participants were asked to read and sign a consent form 
and informed that participation in the study was entirely voluntary. Furthermore, upon 
providing the questionnaires, participants were made aware that they were entitled 
to withdraw at any time for any reason (in which case the data provided would be 
discarded). It was made apparent that any personal information supplied, together 
with the data resulting from their participation, would remain confidential, be recorded 
in an anonymous form, and be held in a secure place. If participants chose, they 
were accompanied by their key worker or other appropriate adults. Participants were 
asked if they had fully understood what had been said and if they would like to con-
tinue participation. Upon agreeing, participants moved to a quiet office area, were 
asked to sign the consent form and provided with the Demographic Questionnaire, 
the Medication Adherence Rating Scale, The Glasgow Anti-Psychotic Side Effects 
Scale, The Drug Abuse Screening Test-10 and the Brief Illness Perception Ques-
tionnaire.  
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In order to avoid confounding effects, the order in which the questionnaires were 
handed out was randomised. Participants were asked to take their time filling out the 
questions and to ask the experimenter if they had any queries (i.e. meaning of a 
word). Upon full completion of the questionnaires, participants were debriefed and a 
‘debrief form’ was provided which informed participants of the nature and aim of the 
study. This was to ensure that participants fully understood the instructions and the 
conditions of the study. As the study involved questions about illegal recreational 
drugs, the debrief sheet emphasised that illegal drugs tend to be harmful and partic-
ipants were provided information about drug effects and made aware that if partici-
pation caused any emotional distress or concern, or they required further information 
a list of organisations that they could contact was provided. Arrangements were 
made to repeat the procedure in six months’ time at which point they were contacted 
directly by the researcher and those willing, who remained eligible were asked to 
complete the same process again. 
 
8.8 Data Analysis. 
Statistical Analysis was carried out using the Statistical Package for Social Science, 
version 24 (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 
24.0. Armonk, NY: IBM Corp). Demographic information was gathered and descrip-
tive statistics assessed. T-tests were conducted to explore how results varied be-
tween baseline scores and six month follow up scores. Relationships between differ-
ent factors were investigated utilising Pearson’s Correlations and Analysis of vari-
ance. Because this study was exploratory a standard multiple regression analysis 
was utilised with independent (predictor) variables entered simultaneously, as no 
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previous research or theoretical model could guide the choice of variables in each 
step. Therefore, Simultaneous Multiple Regression Analysis was used to explore the 
determinants of anti-psychotic medication adherence. Eleven independent variables 
were incorporated; drug use, social support, side effects, demographic factors and 
the eight components of illness perceptions (namely; consequences, timeline, per-
sonal control, treatment control, identity, concern, understanding and emotional rep-
resentations), with adherence at Baseline (T1) and Six-month follow up (T2) as the 
dependent variable. As multiple correlations were undertaken and to avoid type 2 
error, only findings at p<0.01 were considered significant. Similarly, as the analysis 
looks to determine if there is a relationship between variables in either direction, two-
tailed tests are utilised and therefore the hypothesis is non-directional. 
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CHAPTER 9. Results. 
Research Question and Hypothesis 
The objectives of the present study are based on Leventhal’s Self-Regulation Model. 
The Self-Regulation Model suggests that individual’s beliefs about the causes, dura-
tion, consequences of the illness, their identity  and whether or not they have some 
control over the illness, influences the way the person adjusts and copes with that 
illness (Leventhal, 1985).  
 
This study aims to explore factors associated with adherence in individuals with psy-
chosis. Two main questions were explored: 
 
1. Are demographic characteristics, perceived levels of social support, illness 
perceptions, drug use and side effects at baseline associated with adherence 
both at baseline and 6-month follow-up. 
2. Which of the baseline factors examined (demographic characteristics, per-
ceived levels of social support, illness perceptions, drug use and side effects) 
are the most significant determinants of adherence both at base line and 6-
month follow-up? 
Specifically, it was hypothesised that: 
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a. Demographic characteristics such as age, employment status, marital status 
and educational status at baseline will be associated with adherence to anti-
psychotic medication both at baseline and at 6-month follow-up.  
b. Perceived levels of social support at baseline will be associated with adher-
ence to anti-psychotic medication both at baseline and at 6-month follow-up. 
c. Illness perceptions (Consequences, Illness Timeline, Personal Control, Treat-
ment Control, Identity, Concern, Understanding and Emotional) at baseline 
will be associated with adherence to anti-psychotic medication both at base-
line and at 6-month follow-up.  
d. Drug use at baseline will be associated with adherence to anti-psychotic med-
ication both at baseline and at 6-month follow-up. 
e. Side effects of antipsychotic medication at baseline will be associated with 
adherence to anti-psychotic medication both at baseline and at 6-month fol-
low-up. 
 
A total of one hundred and ten participants were eventually included in the baseline 
stage of data collection, while eighty-five individuals took part in stage two of data 
collection at six-month follow up.  
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9.1 Demographic characteristics (baseline) and Dropout 
Participant characteristics. 
 
Outliers and distribution of data.  
Once the data was coded and checked preliminary analyses were carried out to en-
sure that the assumptions of normality, linearity, homoscedasticity and multicolline-
arity were not violated. No univariate or multivariate outliers were removed as all 
scores fell within the normal range. Histograms were generated for continuous data 
in order to assess for normal distribution. It was noted that the DAST scores were 
negatively skewed. Upon further analysis, it became clear that the DAST scores ap-
peared skewed as they had not been re-categorised as per the instructions accom-
panying the questionnaire and this was rectified by re-categorising scores according 
to the instructions. To establish homoscedasticity, Levene’s test was utilised. There 
was no homogeneity of variance between any measures which indicated that vari-
ances were not significantly different for any of the variables.  
 
Missing data. 
The same procedures and questionnaires were used to assess the same participants 
with a six-month gap. To check for systematic patterns in missing data, Little’s test 
of Missing Completely at Random (Little, 1988) was conducted and found not to be 
significant (Chi-square=1074.89, DF= 1053, p=.313), suggesting that the amount of 
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missing data was minor and appeared random in nature. Missing values were re-
placed with the mean scores of the remaining items when less than 20% of a sub-
scale was omitted.  
 
Demographic characteristics. 
Of the one hundred and ten individuals who took part in the baseline stage of the 
study, seventy-three were male (66.4%) and only thirty-seven were female (33.6%). 
This varies from the diagnosis demographics for the condition, which tend to be mod-
erately higher for males (McGrath et al., 2004). The majority of participants were 
aged between twenty-six and forty-five (45.4%). Twenty-five individuals (22.7%) 
were aged between twenty-six and thirty-five and twenty-five individuals (22.7%) 
were aged between thirty-six and forty-five. Conversely, only seven individuals 
(6.4%) were aged over sixty-five and only fourteen (12.75) aged under twenty-five. 
The ethnic background of individuals included 42 (38%) participants who described 
their ethnicity as “White” and thirty-six (32.7%) Black African and Black Caribbean 
participants. Participants also included four individuals (3.6%) of Bangladeshi eth-
nicity and two (1.8%) each of Indian, Pakistani and Chinese ethnicity. Twenty partic-
ipants (20.1%) marked their ethnicity as “other” which included two Afghans (1.8%), 
two Sri Lankans (1.8%), two Turks (1.8%), two individuals who described their eth-
nicity as mixed (1.8%) and one participant (0.9%) each of Arab, Greek, Libyan and 
Mauritian ethnicity.  
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The employment status of participants was diverse, with 47 individuals (42.7%) not 
in paid employment, and only nine individuals (8.2%) employed full time.  
 
Educational status was also varied with thirty-three individuals classing themselves 
as having no qualifications (30%) and only one individual (0.9%) classing themselves 
as postgraduate. 
 
The descriptive characteristics for the predictor and outcome variables were as-
sessed. Reports of social support were high with a mean score of 3.45 (SD = 1.16), 
in a scale ranging between 1-5. The mean score for side effects was high (M=42.36, 
SD=11.80) at baseline and remain high at 6-month follow-up. The mean score for 
drug use was low (M=2.16, SD=1.38) at baseline and increased slightly at 6-month 
follow-up (M=2.97.14, SD= 1.73). According to the DAST 10 scoring instructions 
scores of 1-2 are considered “low” with scores of 3-5 considered “intermediate”. 
 
A brief illustration of some of the demographic characteristics of the study’s partici-
pants is provided in table 1. While the descriptive statistics for the factors assessed 
are outlined in table 2. 
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Table 1. Summary of demographic data 
 Frequencies Percentage 
Age   
18-25 
14 12.7 
26-35 25 22.7 
36-45 25 22.7 
46-55 20 18.2 
56-65 19 17.3 
over 65 7 6.4 
Gender   
Male 73 66.4 
Female 37 33.6 
Employment   
FT 9 8.2 
PT 14 12.7 
Self-employed 6 5.5 
Not in paid employment 47 42.7 
Student 8 7.3 
Student and working 2 1.8 
Retired 9 8.2 
Other 13 11.8 
Ethnicity   
White 42 38.2 
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Black Caribbean 21 19.1 
Black African 15 13.6 
Indian 2 1.8 
Pakistani 2 1.8 
Bangladeshi 4 3.6 
Chinese 2 1.8 
Other 22 20.1 
Marital status   
Single 71 64.5 
In a relationship 21 19.1 
Married 17 15.5 
Other 1 0.9 
Education   
No qualification 33 30.0 
Vocational 18 16.4 
GCSE's 22 20.0 
A-Level 20 18.2 
Undergrad 8 7.3 
Post grad 1 0.9 
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Table 2. Summary of descriptive statistics 
 
               
Mean                    Std. Deviation                 N 
Social Support T1 3.45 1.16 110 
Social Support T2 3.51 1.02 85 
Side EffectsT1 42.36 11.81 109 
Side EffectsT2 44.20 10.90 85 
Drug use T1 2.16 1.38 110 
Drug UseT2 2.97 1.73 110 
Consequences T1 5.94 3.05 109 
Timeline T1 6.84 3.04 109 
Personal Control T1 5.06 2.80 108 
Treatment Control T1 5.72 2.82 109 
Identity T1 5.88 2.69 108 
Concern T1 6.61 2.92 109 
Understanding T1 6.00 2.73 109 
Emotional Representations T1 6.26 2.99 109 
Consequences T2 5.96 2.35 85 
Timeline T2 6.46 2.59 85 
Personal Control T2 6.06 1.99 85 
Treatment Control T2 6.19 2.20 85 
Identity T2 6.32 2.04 85 
Concern T2 6.40 2.19 85 
Understanding T2 6.73 2.00 85 
Emotional Representations T2 6.69 1.98 85 
Adherence T1 2.00 .85 110 
Adherence T2 2.24 .83 85 
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Descriptive statistics of dropout participants. 
Further analysis was conducted to compare the descriptive statistics of individuals 
who completed both stages of data collection (n=85) with those who did not complete 
the second stage (n= 25). Eighty-five individuals (77.28%) completed both stages, 
whereas 25 individuals (22.72%) dropped out after the first stage. The age of indi-
viduals taking part was evenly spread through different age groups.  
 
56 males (65.88%) and 29 females (34.12%) completed both stages whereas 17 
males (68%) and 8 (32%) females dropped out from the second stage. This indicates 
that the dropout rate was largely consistent between genders. 
  
Analysis revealed that of the group that completed both stages, only 6 individuals 
(7%) described their employment as “other”. However, 7 individuals (28%) who went 
on to drop out from the second stage described their employment status as “other”. 
 
35 Individuals (41%) who took part in both stages described their ethnic origin as 
white, while only 7 individuals (28%) who dropped out described their ethnic origin 
as white, suggesting that participants who described their ethnicity as white were 
less likely to drop out from the second stage of data collection. No other major trends 
were identified in the ethnic origin of individuals who dropped out of the second stage 
of data collection. 
 
21 Individuals (84%) who described their relationship status as “single” dropped out 
from the study whereas no individuals whose relationship status was reported as 
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“married” dropped out. Conversely 34 (40%) individuals who described themselves 
as either married or in a relationship completed both stages.  
 
Furthermore, of the individuals who completed both stages of data collection, 20 
(23%) had reported their educational status as “A-Levels” whereas no one of the “A-
Level” educational status dropped out from the study. 
 
Two-time point comparisons between potential determinants and outcome 
variable. 
A paired sample T-Test was conducted in order to evaluate changes in participant’s 
scores over the six-month period. Baseline and six-month follow up scores for all 
independent and dependent variables were compared to assess if there had been 
any significant changes over time. The results of paired samples T-tests revealed no 
significant change of scores for the dependent variable (Adherence) at baseline and 
six-month follow up. There were also no significant changes in scores for the inde-
pendent variables with the exception of drug use, which displayed a significant in-
crease over time (M=-.81, SE=1.63, t=-5.21, df=109, p<0.001). The descriptive sta-
tistics for changes to each independent and dependent variable over time can be 
found in table 3. 
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Table 3. Summary of changes in baseline and six-month follow-up scores for all variables. 
 
Mean 
Differ-
ence 
Std. Devi-
ation 
Std. Error 
Mean 
 
       t            Df                 Sig. 
 Adherence  -.11 .82 .09 -1.19 84 .235 
 Drug Use -.81 1.63 .16 -5.21 109 <0.001 
 Social Support  .09 .89 .09 1.06 84 .313 
 Side Effects -1.65 10.54 1.14 -1.44 84 .153 
 Consequences  -.14 2.14 .23 -.61 84 .544 
 Timeline  .42 2.11 .23 1.85 84 .067 
 Personal Control  -.89 2.27 .25 -3.64 84 <0.001 
 Treatment Control  -.24 1.78 .19 -1.22 84 .227 
 Identity  -.18 1.90 .21 -.86 83 .394 
  Concern  .27 2.15 .23 1.16 84 .248 
 Understanding  -.48 2.21 .24 -2.02 84 .047 
 Emotional Represen-
tations  
-.39 2.27 .25 -1.57 84 .119 
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9.2 Research Question 1:  
 
Are demographic characteristics, perceived levels of social support, illness 
perceptions, drug use and side effects at baseline associated with adherence 
both at baseline and six-month follow-up.  
 
One-way between-groups analyses of variance were conducted for the effects on 
adherence at baseline and six-month follow-up time points by demographic inde-
pendent variables (to explore the impact of employment, ethnicity, marital status, 
age, gender and education on adherence).  
 
As depicted in table 4 there was no statistically significant difference in adherence at 
baseline between groupings on the six demographic factors. 
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Table 4. Associations between demographic factors at baseline and adherence at baseline. 
 
 F df1 2f2 Sig. 
Age .115 2 107 .891 
Gender .291 2 107 .748 
Employment .650 2 105 .524 
Ethnic Background 
 
.695 
 
2 
 
107 .501 
 
Education 5.492 2 99 .005 
Marital status 0.120 2 107 0.887 
 
There was no statistically significant differences between levels of adherence at 
baseline, based on age (F(2,107)=.115, p=.891), employment (F(2,105)=.65, 
p=.524), ethnic background (F(2,107)=.695, p=.501), marital status (F(2,107)=.120, 
p=.887) and gender (F(2,107)=.291, p=.748)  at baseline. There was also no statis-
tically significant difference between adherence at baseline and education at base-
line, (F(2,99) = 5.492, p=.005). 
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Similarly, the same process was repeated for the six-month follow up stage, as de-
picted in table 5. Results at T2 showed no statistically significant differences between 
demographic groups: age (F(2,82)=2.14, p=.124), employment (F(2,82)=1.67, 
p=.194), ethnic background (F(2,82)=1.01, p=.369), marital status (F(2,82)=.293 
p=.747) and gender (F(2,82)=3.74, p=.028) on adherence at six-month follow-up. 
There was also no statistically significant difference on levels of adherence at six-
month follow-up and education at six-month follow-up, (F(2,78) = 3.82, p=.026).  
 
Table 5.  Associations between demographic factors at six-month follow-up and adherence at six-
month follow-up. 
 
 F Df Df2 Sig. 
Age 2.14 2 82 .124 
Gender 3.74 2 82 .28 
Employment 1.67 2 82 .194 
Ethnic Background 
 
1.01 
 
2 
 
82 .369 
 
Education 3.82 2 82 .026 
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Pearson’s’ correlations were conducted between predictor variables (social support, 
illness perceptions, drug use and side effects) at baseline and six-month follow-up 
and adherence at baseline and six-month follow-up.  
 
As illustrated in Table 6, correlation analysis revealed that social support displayed 
a longitudinal relationship with adherence as it was associated with adherence at 
baseline (r=.418, p<.01). While social support at six-month follow-up was associated 
with adherence at six-month follow-up (r=.574, p<.01). 
 
Baseline adherence were associated with both baseline personal control (r=.272, 
p<.01) and treatment control (r=.456, p<.01) as well as six-month follow-up personal 
control (r=.304, p<.01) and treatment control (r=.319, p<.01). Furthermore, adher-
ence at six-month follow-up was associated with six-month follow-up scores for un-
derstanding (r=.284, p<.01). 
 
Thus, in relation to research question 1, the results suggest that social support, per-
sonal control and treatment control were significantly associated with adherence 
both at baseline and at six-month follow-up, while understanding and emotional rep-
resentations are significantly associated with adherence but only at six-month follow-
up. 
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Table 6. Correlations between potential predictor factors and adherence at baseline and six-month 
follow-up.  
 Adherence T1 Adherence T2 
Social Support   
T1 .418** .246* 
T2 .292** .574** 
Side Effects   
T1 -.046 -.114 
T2 -.069 .091 
Drug Use   
T1 .061 -.049 
T2 -.180 -.043 
Consequences   
T1 .061 -.017 
T2 .083 .201 
Timeline   
T1 .090 .045 
T2 .051 .205 
Personal Control   
T1 .272** .155 
T2 .304** .361** 
Treatment Control   
T1 .456** .277* 
T2 .319** .362** 
Identity   
T1 -.008 -.097 
T2 -.025 .139 
Concern   
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Note: * p<.05, **p<.01 
 
 
 
 
  
T1 .060 .066 
T2 .031 .250* 
Understanding   
T1 .232* .088 
T2 .175 .284** 
Emotional representations   
T1 .007 -.051 
T2 .062 .284** 
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9.3 Research question 2:  
Which of the baseline factors examined (demographic characteristics, per-
ceived levels of social support, illness perceptions, drug use and side effects) 
are the strongest predictor of adherence, both at baseline and six-month fol-
low-up?  
The baseline variables that were significantly correlated with adherence at baseline 
and six-month follow-up were entered in a multiple linear regression model. Given 
multiple correlations were undertaken and to avoid type 2 error, only findings signif-
icant at p<0.01 were added in the regression model. As this study was exploratory a 
standard multiple regression analysis was utilised with independent (predictor) vari-
ables entered simultaneously as no previous research or theoretical model could 
guide the choice of variables in each step. The predictors included in the regression 
were based on significance. There were no demographic characteristics controlled 
for in the regression model, since there was none significantly (p<0.01) associated 
with adherence. At baseline, Social Support, Treatment Control, and Personal Con-
trol were all significantly associated with adherence at p<0.01 level and thus all in-
cluded in the regression. As shown in Table 7, this model suggests that at baseline, 
the independent variables explained 29.8% of the variance in adherence. Further-
more, baseline Treatment Control was the strongest determinant of baseline adher-
ence (β=.407 [.405-.095], p=.000) followed by Social Support (β=.282 [.682-.214], 
p=.002). Conversely Personal Control (β=-.012 [-.012-.095], p=.901) was not a sig-
nificant determinant as illustrated in Table 7.  
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Table 7. Regression model of Baseline Independent Variables with Baseline Adherence as dependent 
variable. 
 
 
b SE b β 
 (Constant) 
11.17 .761  
 
Social Support  .682 .214 .282* 
 
Personal Control -.012 .095 -.012 
 
Treatment control .405 .095 .407** 
 
R-squared 
Adjusted R-squared 
SE of regression 
 
.317 
.298 
  2.35 
 
Prob (F-statis-
tic) 
 
<0.001 
 
 
Note: * p<.05, **p<.01 
 
There were no baseline predictor variables that were significantly (p<0.01) associ-
ated with adherence at six-month follow-up. Therefore, no further regression model 
was explored.  
Thus, in relation to Research question 2, the results suggest that baseline independ-
ent variables potentially determined 29.8% of the variance in baseline adherence 
with treatment control and social support the strongest potential determinants. 
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SECTION 3.  
DISCUSSION 
This study looked at the associations between adherence to anti-psychotic medica-
tion and purported predictive factors; social support, illness perceptions, illicit sub-
stance use and side effects. Demographic factors and characteristics were also re-
viewed. The results suggested that social support, treatment control and personal 
control were significantly associated with adherence and that treatment control and 
social support were potential determinants of adherence. Each of these factors en-
compasses a broad range of features. Given the unique nature of anti-psychotic 
medication and the vagaries of psychosis, these findings should be interpreted in 
light of a number of confounding factors. In order to fully address these stipulations, 
it is imperative to discuss the societal and methodological caveats involved.  
 
The results of this study found that social support was significantly associated with 
adherence both at baseline and at follow-up and that social support at baseline was 
a potential determinant of adherence to anti-psychotic medication. This adds to the 
accumulative body of Health Psychology research, which suggests that social sup-
port improves outcomes across a range of health conditions (Jolley et al., 2014). 
However, research has suggested that the concept of social support is ill-defined 
and requires careful specification (Brugha 1995). Regrettably, many individuals with 
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psychosis often suffer from social dysfunction and their social relationships and net-
works are reportedly reduced (Macdonald, Hayes, Baglionii Jr, 2000). Nevertheless, 
although the size of the network is reduced, that may not necessarily reflect upon 
the level of support. In research, social support is largely represented by the size of 
the network with some evidence suggesting that reduced networks equate with a 
deficiency of close relationships (Norman, Malla, Manchanda, Harricharan, Takhar 
& Northcott, 2005). The terms social support and social networks are subjective and 
multidimensional and thus difficult to quantify and measure. Research into the phe-
nomenon has utilised a variety of measures in an attempt to explore these concepts 
in mental health populations and investigating these methods to ensure they are ro-
bust may offer additional insight. 
 
As this study utilised a quantitative approach the Duke-UNC Functional Social Sup-
port Questionnaire (Broadhead et al., 1988) was used. This is an eight-item measure 
involving the perceived functional elements of social supports (Broadhead et al., 
1988). It has been widely used in various settings and numerous studies have high-
lighted its average test–retest reliability, construct and concurrent validity and inter-
nal consistency (Broadhead et al., 1988; Isaacs, 2011; Mas-Expósito et al., 2013). 
The measure incorporates a five‐item ‘Confidant’ support scale which comprises the 
practical aspects of social support including the opportunity to talk to someone re-
garding employment, financial or domestic concerns, to be provided with advice and 
social invitations and a three‐item ‘Affective’ support measure pertaining to love and 
affection, individuals who care when ill (Castle, Slade, Barranco‐Wadlow & Rogers, 
2008). The overall total combines both of these sub‐scores. Historically, a wide vari-
ety of measures have been utilised to measure social support, ranging from simply 
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counting the number of friends to more refined comprehensive measures. This re-
flects the wide range of concepts that are put forward to encapsulate a definition of 
social support. An in-depth review by Gayer-Anderson & Morgan in 2013 investi-
gated all studies exploring social support and support networks amongst individuals 
with first episode psychosis, psychotic experiences or schizotypal traits. The authors 
reported that previous research had largely concentrated on any one of three cate-
gories of support. This included the “perception of support”, relating to whether the 
individual believed that they had others to help them and were valued in relation-
ships, “provisional support” including emotional, financial and practical assistance 
and the “structure of support networks” outlining the number and frequency of con-
tacts. Overall it was presumed that the more contacts the greater the level of support 
(Gayer-Anderson & Morgan, 2013). However, some people may feel more comfort-
able with having a small number of social contacts and may view robust support 
provided by one person as adequate. The individuals own satisfaction with the sup-
port provided may be more relevant. 
 
Social support is reportedly reduced amongst people with psychosis, with the major-
ity of support derived from caregivers and family members, thus placing particular 
research interest in these relationships (Jolley et al., 2014). Findings from this study 
suggest that enhanced social support has the potential to act as a determinant of 
adherence to anti-psychotic medication. However, the exact way in which social sup-
port affects health and the dynamics that arbitrate this relationship are not fully clear 
(Gayer-Anderson & Morgan, 2013). Health outcomes may be affected by elevated 
social support acting as a shield against stress; it can influence affective states, or 
help alter behaviour. This could occur directly through hormonal and neuroendocrine 
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impact on the immune system, or indirectly by influencing lifestyle, health behaviours 
or other features of social and psychological functioning (DiMatteo, 2004). However, 
previous studies have primarily focused on the impact of social support amongst the 
general population or those diagnosed with a physical health condition. The unique 
nature of psychosis requires focus on the specific ways that social support mediates 
the link to adherence to treatment for people with mental illness. This paper will at-
tempt to discuss some of the factors that may have influenced its findings.  
  
This study utilised the FSSQ, a sophisticated measure which has been validated to 
measure social support in a wide range of settings. However, social support is a 
capacious multidimensional concept which may differ for different individuals. Other 
ways of measuring social support include looking at distinct dimensions of social 
support and research utilising this approach have found similar results to the present 
study (DiMatteo, 2004). Empirical work has tended to confirm the existence of dis-
tinct dimensions of social support, for individuals suffering from psychosis.  New-
comb & Chon (1989) employed data gathered from 793 individuals and derived three 
main forms of support. The first refers to support type, denoting the amount of sup-
port received and satisfaction with it. Self-completion questionnaires may generally 
be appropriate in measuring this dimension. However, in a therapeutic situation more 
detail would be required in order to identify sources of dissatisfaction (Brugha, 1995). 
The second form was accounted for by sources of support, such as family, friends 
and organisations. Social support network measures would appear suitable for 
measuring this (Brugha 1995). The third form was that of support functions, which 
incorporated both affectively important functions such as psychological and emo-
tional distress and intimate relationships (emotional support), and more contributory 
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functions such as finances, health, work (tangible support). Thus, a measure of sup-
portive networks may be insufficient for this population as the quality of tangible and 
emotional support should also be explored. An alternative measure would be to use 
an interview based approach which would have allowed participants to discuss con-
cepts and sources of support in greater detail.  
 
Future research such focus on various forms of social support and its impact upon 
mental health. Practical issues such as financial support can often be overlooked 
although this may have a substantial impact and is an important form of support. 
Recent times have seen substantial changes in the standards and delivery of psy-
chiatric care. In line with the introduction of anti-psychotic medication there has also 
been increasing awareness of the importance and impact of adequate social support. 
The association between social support and health outcomes has received a sub-
stantial amount of devotion in health psychology and behavioural medicine research. 
Social support is reported to guide and enhance the capacity to adjust to and live 
with illness and it is believed that the relationship between social support and health 
may be facilitated by adherence (Dunbar-Jacob & Schlenk, 2001). Backing and as-
sistance from a support network of friends and family has been associated with en-
hancing patient adherence by heightening optimism and self-esteem, cushioning the 
stresses of being ill, reducing depression, improving health related behaviour and 
providing practical assistance (DiMatteo, 2004).   
 
Our findings reveal that Social Support impacts upon adherence to anti-psychotic 
medication. Social Support is acknowledged to impact upon mental health and has 
 112 
a role in both mental illness prevention and recovery. Research has stressed that it 
is a key influence upon the perceived severity of symptoms, adaptations and health 
outcomes amongst patients diagnosed with schizophrenia (Hamideh, Al-Magaireh, 
Abu-Farsakh & Al-Omari, 2014). It is considered a determinant in advancing recov-
ery, can positively affect both physical and mental health and perhaps most signifi-
cantly, high levels of social support is purported to act as a defensive shield that can 
positively enhance the quality of life of people with psychosis while decreasing the 
severity of their symptoms (Mas-Exposito, Amador-Campos, Gomez-Benito & Lalu-
cat-Jo, 2012). 
 
Our results also revealed that treatment control as conceptualised by Leventhal’s 
Self-Regulation Model was the strongest determinant of adherence to anti-psychotic 
medication as compared to the other variables considered. Poor insight into one’s 
treatment can, therefore, be considered a primary risk factor as adherence is essen-
tial in both recovery and relapse prevention for individuals with psychosis. These 
findings have important implications for interventions and further research into ad-
herence. It suggests that Leventhal’s Self-Regulation Model provides an innovative 
way to comprehend perceptions and responses in individuals with psychosis.  
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CHAPTER 10. Insight and treatment control. 
The results of this study highlight that the controllability that individuals perceive to 
have on their treatment will affect their adherence to treatment and this impact re-
mains extant over time. Within mental health settings the term “lacking in insight” is 
often erroneously used to outline a commonly held view that individuals who do not 
accept their illness will not adhere to their treatment (Coffey, 1999). Our findings 
therefore have significant clinical implications. People’s perceptions of their illness, 
influence their adherence to medication. According to the Self-Regulation Model, 
treatment control denotes perceptions of controllability/curability, which refers to the 
extent to which individuals believe they will be able to recover from or control the 
illness through treatment (Leventhal et al., 1998, 2001). 
Individuals diagnosed with mental illness often have little or no insight into their con-
dition. They often do not consent to treatment. This results in a lack of engagement 
and trust towards health care professionals (Andreasen & Black, 2014). Thus, de-
veloping an effective therapeutic relationship is vital. Research suggests that the 
term “lacking in insight” can be incorrectly used in clinical settings to refer to the belief 
that patients who do not accept their diagnosis and will not adhere to treatment 
(Coffey, 1999). Use of the term ‘insight’ into one’s illness’ can also be contentious 
within mental health settings, as classifying a psychological problem as an illness 
can in itself be seen as a form of coping. The nature of mental health conditions can 
influence the ability to reflect upon one’s own experiences and thus to construct an 
illness perception (Fortune et al., 2004). 
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With psychological conditions, the distinction between being considered ill or healthy 
is at least partially a subjective consideration (Witteman, Bolks & Hutschemaekers, 
2011). Individuals diagnosed with a mental health condition often do not believe 
themselves to be ill, even if they recognise that they have an affliction. 
 
The potential relevance of the Self-Regulation Model’s representations of illness in-
sight can help explore how people experience their mental health problems in rela-
tion to treatment outcome is recognised. Illness perceptions have been studied in a 
few disorder-specific client groups, including schizophrenia (Lobban et al., 2004, 
2005), depression (Fortune et al., 2004; Manber et al., 2003) and eating disorders 
(Stockford et al., 2007). A recent study (Witteman, Bolks & Hutschemaekers, 2011), 
investigated the appropriateness of using the IPQ in the mental health domain and 
suggested that the self-regulation model does seem applicable to clients with mental 
health conditions. 
 
Research suggests that poor insight is a common characteristic in psychosis, partic-
ularly amongst individuals suffering from schizophrenia with prevalence rates of poor 
insight reportedly as high as 98% (Novick et al., 2015). A crucial element to consider 
when deliberating on the nature of treatment control in psychosis, is the nature of 
recovery from a psychotic episode. Individuals experiencing severe psychotic symp-
toms are very rarely aware of this and they may therefore not be fully aware of how 
their symptoms manifest. Because of the time it takes for anti-psychotic medication 
to take effect, people may not be able to distinguish symptoms with side effects from 
anti-psychotic medication or associated treatment with improvements in their mental 
health (Kemp & David 1996). Furthermore, according to research illness perceptions 
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effected the duration of untreated psychosis which in turn has an impact on severity 
of symptoms (Drake et al., 2000). Suggesting that these issues may be multifactorial 
and interrelated. This is backed by the findings from this study which highlighted that 
scores on the BIPQ were also associated with social support, side effects and drug 
use.  
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CHAPTER 11. Use of the Self-Regulation 
Model and measures of illness perceptions. 
Our results support the suitability of using the Self-Regulation Model due to its multi-
dimensional approach in making sense of illness and this has wide implications for 
use within mental health settings. Psychosis has biopsychosocial causes and is con-
textualized within a cultural setting. To fully comprehend the impact of causal attrib-
utions, the influence of psychosocial factors and cultural views toward psychotic con-
ditions should be considered in addition to investigating the effects of biological 
causes on perception of controllability (Mak et al., 2014).  Furthermore, it is beneficial 
to consider the broader perception of psychosis, in addition to the attributions of con-
trollability and stability. Therefore, the Self-Regulation Model can be used in an at-
tempt to understand how the public’s multidimensional illness perceptions of psycho-
sis are associated with their adherence to anti-psychotic medication.  
 
To date the Self-Regulation Model has been productively utilised in attempts to fur-
ther understandings of health outcomes in various conditions including chronic fa-
tigue syndrome, chronic pain, cardiovascular disease, ﬁbromyalgia, cancer, trau-
matic brain injury and numerous other conditions (Wearden & Peters, 2008; Snell et 
al., 2013; Sivell et al., 2011). There has been increasing exploration of illness per-
ceptions in mental health utilising the Self-Regulation model. A comprehensive 2013 
review by Baines & Wittkowski examined 13 studies utilising the Self-Regulation 
model in mental health and concluded that while mental illnesses were often viewed 
as cyclical and chronic, use of the Self-Regulation model was largely supported. The 
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most common instrument utilised to provide a quantitative assessment of the rela-
tionship between the five components of illness representation; identity, timeline, 
consequences, cause and control/cure as described in Leventhal’s Self-Regulatory 
Model (Leventhal et al., 1984, 1997) is the Illness Perception Questionnaire (IPQ; 
Weinman et al., 1996).  It has been used in studies of illness perceptions in patients 
with a wide range of conditions. Subsequently, a revised version of the IPQ measure 
referred to as the IPQ-R (Moss-Morris et al., 2002), expanded upon the original scale 
utilising additional items, subscales and incorporating an assessment of patients’ 
perceptions on how well they comprehend their illness and their emotional response 
to the illness.  
 
The length of both scales resulted in a need for a shorter version which was ad-
dressed with the publication of The Brief Illness Perception Questionnaire (Brief IPQ; 
Broadbent et al., 2006). During the patient involvement group that took place prior to 
data collection, participants commented on the ease of filling in the measure, with all 
items offered in the form of a ten-point Likert scale. The BIPQ measured various 
aspects of illness perception; cognitive representations (which involve the extent of 
individual control over the disorder, views on the gravity, length and impact of the 
condition and effectiveness of a cure), comprehensibility (of the condition) and emo-
tional representations (negative feelings regarding the condition). Previous studies 
have highlighted its reliability and validity and it had been appositely applied in stud-
ies involving individuals with psychosis (Broadbent et al., 2008).  
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The use of the BIPQ allowed us to investigate how illness perceptions evolved over 
time, considering the purported cyclical nature of human self-regulation. Our findings 
support the view that interventions to enhance adherence to anti-psychotic medica-
tion would benefit from a focus on treatment related attitudes. The results provide 
sustenance to contemporary research which has advocated therapeutic techniques 
for interventions based upon Leventhal’s Self-Regulation Model (Wearden & Peters, 
2008). 
 
  
 119 
CHAPTER 12. Importance of therapeutic rela-
tionships upon treatment control in psycho-
sis. 
The crucial importance for mental health practitioners to develop therapeutic rela-
tionships may have impacted the concepts of treatment control experienced by their 
patients. The findings from this study and others indicate that the relationship be-
tween side effects, illness perceptions and adherence is complex and multifaceted. 
Illness perceptions relating to treatment control can be used to elucidate how indi-
viduals construct a personal representation of their disorder so that they can better 
understand and counteract their circumstances (Gómez-de-Regil et al., 2014).  
The present study expanded upon previous research into illness perceptions, high-
lighting the relationship between treatment control and adherence to anti-psychotic 
medication. The findings from this study can help inform the focus of future interven-
tions. Future research may focus on enhancing treatment control and whether im-
provements result in enhanced adherence to treatment. The long-term impact of 
treatment control emphasised by the results of this study suggests that including 
patients in treatment choices, in addition to understanding and accounting for their 
beliefs about treatment within clinical mental health settings, is vital to their adher-
ence to treatment.  
 
The unique nature of mental illness may also help explain the heightened impact of 
treatment control as a potential determinant of adherence and why personal control 
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was univariately significant but did not prove to be a multivariate determinant of ad-
herence. The engagement levels of patients within mental health services plays a 
key role in treatment and is considered dependent upon the development of a ther-
apeutic relationship based on trust, empathy and mutual understanding. Individuals 
diagnosed with mental illness often have little or no insight into their condition. They 
often do not consent to treatment. This can result in a lack of engagement and trust 
towards health care professionals (Andreasen & Black, 2014). Thus, treatment con-
trol may have a crucial impact. The necessity for mental health practitioners to de-
velop an effective therapeutic relationship may impact the concept of treatment con-
trol experienced by their patients. Developing an effective therapeutic relationship is 
vital. The engagement levels of patients with mental health services plays a key role 
in treatment and is considered dependent upon the development of a therapeutic 
relationship based on trust, empathy and mutual understanding. Research into the 
impact of illness insight upon therapeutic relationships has enhanced awareness of 
its influence However, relatively little research has focused on the impact of thera-
peutic relationships upon treatment control amongst individuals diagnosed with psy-
chosis. It can be argued that one of the main findings of this research is that it is not 
necessarily the amount of insight into treatment that a patient has which has the 
biggest impact on adherence but rather the amount of perceived “control” over their 
treatment. 
 
Hitherto, relatively little research has explored strategies to increase insight in pa-
tients suffering from psychosis (Novick et al., 2015). The Self-Regulation Model may 
provide a useful framework for understanding how a patient’s representation of their 
illness inﬂuences their adherence to anti-psychotic medication as specified by the 
 121 
results of this study. This could potentially have a profound impact upon treatment 
regimens within mental health, as illness insight has been shown to have a significant 
impact on therapeutic relationship for inpatients suffering from schizophrenia and 
schizoaffective disorder and an effective therapeutic relationship is often considered 
a cornerstone to effective treatment (Lehrer & Lorenz, 2014).  
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CHAPTER 13. Demographic Findings  
 
The results of this study indicated that demographic characteristics did not have a 
significant impact upon adherence. However, the demographic characteristics of the 
present study show interesting trends. Only 15.5% of those taking part were married. 
Other findings revealed that at the first stage of data collection only 33% of partici-
pants were female. This contrasts with previously reported rates indicating that 
males are only moderately more likely to be diagnosed with the condition (McGrath 
et al, 2004). This study also found that participant’s gender revealed significant cor-
relations with employment status, ethnic background, marital status, drug use, social 
support and illness perception. These findings are revealing and there are a number 
of possible explanations. Overall, it is reported that mental health issues affect males 
and females equally, with no consistent gender differences in prevalence rates re-
ported. However, certain mental health issues are more common in females than 
males and vice versa. When investigating the role of gender in mental health it is 
important to be aware of the division between the relatively low-prevalence of severe 
mental health disorders such as schizophrenia and bipolar disorder, where preva-
lence rates have no significant gender differences have been consistently conveyed, 
and the high-prevalence disorders of anxiety and depression where large gender 
differences in rates have been consistently reported. Depression accounts for 41.9% 
of overall psychiatric disorders in females, and just 29.3% in males (Murray & Lopez 
1996).  
 
Numerous investigations have recognised clear gender differences in social support 
which appear constant across the life cycle, with females consistently reporting to 
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receive more support than males (Matud, Ibañez, Bethencourt, Marrero, & Carbal-
leira, 2003; Laireiter & Baumann, 1992; McFarlane et al., 1981). Findings indicate 
that although males often tend to socialise in groups, from childhood females report 
a larger number of more intimate personal friendships and relationships and larger 
supportive networks than males (Laireiter & Baumann, 1992; McFarlane, Neale, Nor-
man, Roy, & Streiner, 1981). Research has suggested that females are more inclined 
to seek out a support network to provide sustenance during traumatic events and 
times of stress, whereas males attempt to try to manage on their own (Taylor, 2002). 
Good social support networks have been viewed as a shield against stress and a 
variety of illnesses. The supportive social relationships that are more prevalent in 
females may provide greater protection for females with psychosis than males. 
These differences could potentially have substantial implications upon health promo-
tion, seeking support in times of need and subsequently adherence. 
 
Gender disparities in mental health are an extremely significant topic which appears 
to endure a paucity of research. Although gender differences in rates of overall men-
tal disorders, including disorders such as schizophrenia, are negligible, there are 
significant gender differences in rates for somatic complaints including depression 
and anxiety with females almost twice as likely to be diagnosed with anxiety disor-
ders. (McManus, Bebbington, Jenkins & Brugha 2016). Females appear to face in-
creased burden due to the gender discrimination which is existent in society. Studies 
have indicated that females are affected by additional pressures such as multiple 
roles, poverty, malnutrition, overwork, domestic violence and sexual abuse to a 
larger extent than males (Martin-Merino, Ruigomez, Wallander, Johansson & Garci-
aRodriguez, 2009). Traumatic life events are a predictor of depression (Bromley et 
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al. (2014). A greater understanding of gender inequalities is essential in order to 
promote the formulation and implementation of health policies that address female's 
needs and concerns should be recognised in order to develop a gender sensitive 
framework that can be adopted to improve adherence to anti-psychotic medication 
in mental health care practice and research. 
 
Furthermore, less than 14% of participants described themselves as full-time or self-
employed, with employment status showing significant correlations with both age 
and gender. The results also highlighted the fact that participants who self-reported 
higher educational status were less likely to drop out from the second stage of data 
collection. 61.8% of participants in this study belonged to ethnic minority subgroups. 
Members of ethnic minority groups were also more likely to drop out from the second 
stage of data collection. However, there was no significant association between eth-
nicity and adherence.  
 
The overrepresentation of ethnic minorities in mental health statistics has been the 
subject of significant debate and research (Tsang, Fung & Corrigan, 2008). There is 
a theoretical underpinning as to why there may be ethnic differences in adherence 
to medication regimes. Differences in communication styles may result in increased 
difficulties in conveying symptoms, side effects and concerns. Certain cultures may 
also display increased lack of acceptance of psychosis and anti-psychotic medica-
tion may be seen as irrelevant to the problem (Tsang, Fung & Corrigan, 2008). In 
order to improve the cultural sensitivity of mental health services, matching patients 
with professionals of the same ethnic origin is commonly endorsed, with patients 
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reportedly preferring treatment from professionals who shared their ethnic back-
ground (Pinikahana, 2005).  
 
The National Institute for Health and Clinical Excellence guidelines on adult mental 
health (NICE clinical guidance 136) recommends that healthcare professionals work-
ing with people with psychosis should confirm competency in working with people 
from diverse ethnic and cultural backgrounds in order to explain the psychosis and 
treatment options, while addressing cultural and ethnic differences in treatment ex-
pectations and adherence, for people from diverse ethnic and cultural backgrounds 
(NICE 2002). Studies have reported that ethnic minority patients suffering from psy-
chosis are more likely to remain in treatment when working with a counsellor of the 
same ethnic background or language group (Ziguras et al., 2001). Removing cultural 
barriers and communication issues may impact upon adherence and thus have a 
significant impact upon outcomes.  
 
Previous research has proposed that socio-demographic factors correlate with ad-
herence to anti-psychotic medication (Pinikahana, 2005). However, the results of 
correlations carried out by these studies have been inconclusive (Tsang, Fung & 
Corrigan, 2008). Further research in this area is required and mental health practi-
tioners should work to ensure that culturally appropriate treatment is delivered to 
people from various ethnic and cultural backgrounds. 
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CHAPER 14. Patient perspectives in identify-
ing side effects and the impact of profession-
als.  
Our findings did not reveal the severity of side effects to be a significant determinant 
of adherence to anti-psychotic medication. A number of factors may have mediated 
these findings. Professional literature suggests that atypical anti-psychotics will be 
more appealing to patients because of the lower risk of side effects. However, there 
appears to be very little clear research evidence to support this commonly held view 
of many mental healthcare professionals (Coffey, 1999). Crucially, relatively little re-
search has focused on the patient’s own experience of their side effects. The majority 
of previous studies focused on professional views rather than the view of patients. 
This is a common issue in mental health settings where patients may often be per-
ceived as lacking insight into their condition and do not always consent to treatment. 
Despite reductions in the severity of side effects since the introduction of newer atyp-
ical anti-psychotic medications, there has been no significant change in the rates of 
adherence compared to traditional typical anti-psychotics (Acosta et al., 2009). Cli-
nician’s views regarding side effects suggest that they feel extrapyramidal effects are 
the most troubling for patients but there is little evidence to suggest that patient them-
selves share this view (Coffey, 1999). The fact that this study attempted to address 
patient rather than professional views of side effects may offer an explanation as to 
why findings from this study differ from previous associations between side effects 
and adherence. 
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Other mediating factors which may have impacted upon results include the individ-
ual experience of the patient, professional input and the way that this can go on to 
impact upon illness perceptions. It can be very difficult for some patients to deter-
mine side effects from the symptoms of psychosis particularly during the early 
stages of treatment (McCann et al., 2009). All of these factors can further compli-
cate identifying side effects for patients. While anti-psychotic medication may re-
duce symptoms, patients may be reliant on professionals to help them identify side 
effects and raise illness perceptions. Conscientious and sensitive treatment by cli-
nicians to explore the patients’ experiences of side effects is essential and it is vital 
that these views are not dismissed as irrelevant. However, a survey of psychiatrists 
has suggested that that the majority believed that fully informing patients of possi-
ble side effects would lead to adherence problems, while community mental health 
nurses were reportedly ineffective at identifying several of the traditional side ef-
fects of anti-psychotic medication and many clinicians underestimate the extent of 
suffering caused by side effects (Coffey, 1999).  
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CHAPTER 15. Measures of side effects.   
The results of this paper suggest that the severity of side effects is not a significant 
determinant of adherence to anti-psychotic medication. Ethicists recommend that the 
autonomy of the patient should always be respected and this needs to be encour-
aged during inpatient admissions under the Mental Health Act (1983) or acute epi-
sodes when anti-psychotic medication is prescribed (Coffey, 1999). A collaborative, 
sensitive non-judgmental approach adopted by mental health care professionals 
which addresses patients’ concerns regarding side effects may expand the patient’s 
confidence in treatment. Choosing an appropriate measure of side effects that as-
sessed patient’s views and addressed the issue of sexual side effects raised in the 
patient involvement groups during this study was therefore considered imperative.  
 
Previous findings have suggested that 74% of patients who discontinued long term 
use of anti-psychotics did so due to sexual side effects (Lambert et al., 2004). This 
study attempted to utilise a measure which inspected side effects to anti-psychotics 
and specifically addressed sexual dysfunction, as both the focus group prior to data 
collection and previous research (McCann et al., 2009; Lambert et al., 2004), has 
highlighted the distressing impact of sexual side effects upon patients.  
A number of measures focus primarily on Extra Pyramidal Symptoms and were 
therefore not used in this study. More recent measures provide scales which can be 
self or physician completed and address a wide range of side effects related to both 
typical and atypical anti-psychotics. Of the self-completion scales The Glasgow Anti-
Psychotic Side Effect Scale (GASS) is often considered the most popular in the 
United Kingdom and widely used in clinical settings. The GASS rates metabolic and 
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neuromuscular side effects as well as sexual dysfunctions (Nystazaki et al., 2014). 
It was therefore considered germane to all relevant issues and chosen for use in this 
paper. The fact that the GASS measure elucidates patients rather than professional 
views while addressing sexual dysfunction, addressed the concerns raised in the 
patient involvement groups and provides additional credence to the findings of this 
study. 
 
The National Institute for Clinical Excellence guidelines on adult mental health (NICE 
clinical guidance 136), recommends that the selection of anti-psychotic medication 
should be made by the patient and healthcare professional collaboratively, incorpo-
rating the views of carers if the patient agrees. Clinicians should offer information 
and discuss the likely benefits and potential side effects of medication, including ex-
trapyramidal, metabolic, cardiovascular, hormonal, sexual and social sequelae.  
 
Research suggests that the term “lacking in insight” can be incorrectly used in clinical 
settings to refer to the belief that patients who do not accept their diagnosis and will 
not adhere to treatment (Coffey, 1999). The findings from this study and others indi-
cate that the relationship between side effects, illness perceptions and adherence is 
complex and multifaceted.  
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CHAPTER 16. Drug Use and Adherence. 
The results of this paper suggest that drug use is not a significant determinant of 
adherence to anti-psychotic medication. An ample body of research has suggested 
that illicit substance use is common amongst individuals suffering from schizophrenia 
(Asher & Gask, 2010; Bahorik et al., 2014; Margolese et al., 2004; Fowler et al., 
1998). Increased drug use amongst patients has been linked to numerous adverse 
outcomes including earlier onset of the disorder, increased rates of relapse, rehospi-
talisation, suicide and non-adherence to medication (Asher & Gask, 2010; Akvardar 
et al., 2004). These previous studies have used the Drug Abuse Inventory (Skinner, 
1982) to assess substance use. The present study used The Drug Abuse Screening 
Test (DAST-10) to assess drug use, as the DAST has been viewed as an improve-
ment upon other widely used measures such as the DAI (Skinner, 1982) and offers 
moderate to high levels of test–retest, validity, sensitivity, specificity within a wide 
scale of populations including psychiatric inpatients and outpatients. (Yudko et al., 
2007). The use of different measures may explain the discrepancies in the results of 
the present studies to previous studies in the area. 
 
The results also revealed a significant change of scores for drug use at baseline and 
six-month follow-up, suggesting that drug use significantly increased over time 
(M=2.16, SE=.13, t=-.52, p<.05). These findings promote discourse of a number of 
factors. Drug use is illegal and many users may have a vested interest to conceal 
usage (Van Dorn et al., 2012). Reviews into drug use amongst patients with psycho-
sis have suggested that measures reliant upon patient disclosure may significantly 
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underreport actual usage rates, particularly during periods of acute breakdown (Ba-
horik et al., 2013). This may explain why the results of this study indicated that scores 
on drug use measures increased at the second stage of data collection. As partici-
pants became more familiar with the purpose of the study and less concerned by 
legal ramifications, they may have been more accurate in disclosure.  Recent studies 
have explored the accuracy of reported substance use amongst adults with schizo-
phrenia and have incorporated tests such as urinary drug screens and hair analysis 
as part of a comprehensive assessment of inpatients (Van Dorn et al., 2012). Bio-
logical measures may offer increased accuracy over self-report measures in the de-
tection of illicit substances, but they also face increased impugns regarding their use. 
Urine drug screening only has a small timeframe for accurate screening depending 
upon the substance used, with certain substances only detectable within 24 hours of 
use. Hair analysis offers an increased timescale to detect drug use and is reportedly 
less susceptible to countermeasures when compared to urine analysis (Van Dorn et 
al., 2012).  However, both forms of laboratory testing have been accused of being 
over intrusive, impacting upon patient rights and have faced challenges as to whether 
they are statistically more accurate than self-report measures.  
 
Research has suggested that self-report measures are actually more accurate in 
detecting alcohol and drug use disorders than urine and blood tests (Wolford et al., 
1999). The majority of previous research utilising biological/laboratory drug testing 
have taken place within in-patent settings, and it may be difficult to replicate these 
findings in the community because of the intrusive nature of testing. Participants that 
were willing to take part in these tests may not necessarily be representative of the 
overall population of individuals suffering from psychosis. Although the majority of 
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previous research has focused on Europe and North America, findings from around 
the world have considerable variance in illicit substance use (Margolese et al., 2004), 
highlighting the need for representative local analyses to explore the nature and 
magnitude of drug use amongst local populations. Due to the legal, ethical and moral 
implications surrounding drug use, exploration of all mediating factors can be con-
troversial. 
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SECTION 4. Clinical Implications, Fu-
ture Research, Limitations and Con-
clusions 
 
CHAPTER 17. Clinical Implications 
Health Psychology has provided numerous theories and models to explain, describe 
and predict health behaviour and Health Psychologists are increasingly involved in 
both the design and delivery of interventions (Michie & Abraham, 2004). A strong 
understanding of the processes involved is required to effectively assess the thera-
peutic techniques utilised in interventions and how the intervention relates to theory 
(Michie & Abraham, 2004). This paper will attempt to identify interventions based 
upon the findings from this study, so that the practicality of different therapeutic tech-
niques can be evaluated.  
 
Although Health Psychologists are involved in the design and delivery of interven-
tions (Michie et al., 2005), relatively few Health Psychologists work directly with pa-
tients within mental health settings and it is not standard practice for Health Psy-
chologists to be employed within mental health wards. This may have resulted in 
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inadequate development of therapeutic interventions based upon the science and 
evidence base of Health Psychology within this setting.  
The symptoms of psychosis manifest in a unique way and it is extremely rare for two 
individuals to suffer from identical symptoms. In order to develop, design and deliver 
individualised interventions, Health Psychologists would need to be experienced in 
working with people with psychosis, familiar with the unique nature of working within 
mental health settings and comfortable in providing long-term patient contact. 
Whereas, in order to effectively develop and properly evaluate therapeutic tech-
niques utilised in such individualised interventions, a clear understanding of the pro-
cesses involved, a comprehensive knowledge of how the intervention relates to the-
ory and thus an experienced background in Health Psychology would appear ideal 
(Michie & Abraham, 2004).  
 
The findings of this study have highlighted that treatment control, personal control 
and social support are all associated with adherence, while treatment control and 
social support were found to be determinants of adherence to anti-psychotic medi-
cation. The aim of this author is to provide an overview of illustrative examples of 
interventions that may be utilised based on the findings. Future research could po-
tentially evaluate the usefulness of different therapeutic techniques which may help 
identify and develop more detailed interventions.  
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17.1 Potential use of Leventhal’s Self-Regulation model in 
mental health Interventions. 
The results of this study have indicated that personal control and treatment control 
are significantly associated with adherence with treatment control an effective deter-
minant of adherence to anti-psychotic medication. This has underlined the prospect 
for therapeutic techniques based on Leventhal’s self-regulation model within mental 
health settings. This offers an expedient method by which to comprehend the role of 
cognitive and perceptual factors in the management of mental health conditions such 
as psychosis and has the potential to kindle further research into the application of 
Leventhal’s model within mental health settings. It also encourages the development 
of techniques to enhance treatment control and insight as a route to improve adher-
ence to anti-psychotic medication.  
 
The link between treatment control and adherence highlighted in this study advances 
a compelling argument for further research into this area. The implications of these 
findings could potentially serve as an important factor to be considered in clinical 
interventions designed to improve adherence to anti-psychotic medication. In-
creased awareness of how illness perceptions amongst individuals with psychosis 
affect emotions and treatment outcomes would enhance our understanding and aid 
the development of approaches to facilitate effective treatment. Therapeutic inter-
ventions which address treatment control may enhance adherence to treatment, 
therapeutic relationships, engagement levels, community treatment and family and 
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marital relationships while reducing repeated relapse, costly long-term service use 
and the duration of untreated psychosis (Gómez-de-Regil et al., 2014).   
  
The core elements of the Self-Regulation Model could potentially be utilised in the 
formulation of patient-centred interventions for adherence for patients suffering from 
psychosis. Illness representations are theorised to develop from concrete experi-
ences, and abstract information, such as awareness of the illness obtained from var-
ious sources (Leventhal et al., 1984). Interventions should emphasize the role of both 
cognitive and behavioural interventions to reﬂect the bidirectional nature of the as-
sociations between concepts as outlined by the Self-Regulation Model. Interventions 
to improve adherence could be conceptualised in techniques facilitating people to 
achieve conscious control over automatic processes (Wearden & Peters, 2008). As 
a parallel-processing model, the Self-Regulation Model also distinguishes the 
inﬂuence of cognitions on emotions and it postulates the methods to regulate emo-
tion utilising behavioural techniques, thus the emotion regulation aspect of the model 
could also be utilised to develop interventions. Previous research has assessed in-
terventions grounded in Leventhal’s Self-Regulation Model and recommend that in 
order to maximise usefulness, future interventions should comprise components to 
encourage threat-focused and emotion-focused regulation procedures, the authors 
went on to appeal for additional research on the interaction between cognitive rep-
resentations and the process by which emotion regulation strategies are selected 
(Cameron, Petrie, Ellis, Buick, & Weinman, 2005). 
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17.2 Potential interventions pertaining to treatment con-
trol.  
Previous findings have reported that adherence and insight are associated with atti-
tudes towards treatment and clinical variables (Kemp & David, 1996). The impact of 
developing effective therapeutic relationships and the significance of staff communi-
cation are crucial factors to be considered in mental health settings. There is increas-
ing scope for mental health nurses in the provision of providing support and infor-
mation to improve illness insight, raise illness perceptions and enhance treatment 
control. This would enable patients to make informed decisions and provide a way 
of taking an element of control over their treatment (Coffey, 1999). However, increas-
ing information and broader educational programmes appears insufficient in improv-
ing adherence to anti-psychotic medication, as providing education and information 
does not equate to understanding and conceptualising the education in the manner 
of those providing it (Hughes, Hill, & Budd, 1997). A study exploring the impact of 
providing psycho-educational training to individuals with schizophrenia on medica-
tion management found it had no impact upon levels of adherence, although it did 
improve confidence in the consultant and medication while decreasing the fear of 
side effects (Hornung, Klingberg, Feldmann, Schonauer, & Schulze Monking, 1998). 
Thus, education may improve attitudes towards medication but not necessarily im-
pact adherence (Coffey, 1999). It is therefore imperative that procedures are put in 
place to enhance one’s treatment control. 
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Previous research utilising the Self Determination Theory as a practice model for the 
promotion of control, indicated that perceptions of autonomy and competence were 
increased by perceived autonomy support, and that alteration in autonomous moti-
vation and in perceived competence were found to predict improvement (Williams, 
McGregor, Zeldman, Freedman, & Deci, 2004). This demonstrates that the principles 
of the Self Determination Theory provide a framework with which to explore the mo-
tivational characteristics in individuals. Adversarial approaches are unlikely to be ef-
fective in enhancing treatment control amongst individuals with psychosis, as evi-
dence suggests that client centred approaches are more effective in the facilitation 
of behaviour change, with patients reportedly preferring a client centred approach in 
developing effective therapeutic relationships (Rubak, Sandbæk, Lauritzen, & Chris-
tensen, 2005). 
 
The autonomy of the patient should always be respected and encouraged while ex-
ploring methods to augment treatment control. A collaborative, sensitive, non-judge-
mental approach is essential when dealing with behaviour change. An increasingly 
popular approach in working with the issue of behavioural change is Motivational 
Interviewing, due to its recognition of ambivalence and emphasis on working with 
individuals’ readiness to change.  
 
Motivational Interviewing could be adopted as a technique to develop interventions 
to enhance treatment control and ultimately augment adherence to anti-psychotic 
medication levels. This technique appears to have unique potential as mental health 
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patients do not always enter therapeutic sessions in a willingness to change dispo-
sition which often leads to confrontational, antagonistic and adversarial dynamics 
within mental health settings (Coffey, 1999). Repeatedly advising a patient regarding 
adherence may result in the patient taking a defensive position. Motivational Inter-
viewing circumvents these setbacks through its “spirit” of encouraging patients to 
identify the positive and negative elements of a course of action, thereby fostering a 
collaborative therapeutic relationship.  
 
Interventions utilising Motivational Interviewing would encourage empathetic under-
standing from practitioners who should be provided with training to raise awareness 
and understanding of the range of motivational techniques utilised within this ap-
proach. Knowledge of other behaviour change theories, such as the Stages of 
Change Model which supports the principles for readiness to change, and the Self 
Determination Theory which suggests that individuals are more likely to adopt 
healthy behaviours when their basic psychological needs for autonomy, competence 
and relatedness are supported would also be an advantage. Exploration into the uti-
lisation of Motivational Interviewing interventions within mental health settings would 
appear to be an expedient area for future research.  
 
17.3 Potential interventions to enhance social support. 
The potential predictive capacity of social support upon adherence to anti-psychotic 
medication as highlighted in this study, can be employed in an attempt to develop 
interventions designed to increase adherence. In order to maximise the success of 
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these interventions they would need to be culturally sensitive and take into account 
gender differences in social support. Current National Institute for Clinical Excellence 
guidelines on adult mental health (NICE clinical guidance 136) recommends the use 
of peer support for people with psychosis to enhance service user experience and 
quality of life. Providing and enhancing support networks for individuals with psycho-
sis should be viewed as a key part in community based treatment programmes. One 
potential way in which this could be encouraged is through the development of group 
exercise sessions. Exercise is often considered a neglected intervention in mental 
health care with scant consideration of exercise as a treatment option.  
 
To date there has been relatively little research into the influence of group physical 
activity on mental health. However, some findings have suggested that group phys-
ical activity can be an effective supplementary treatment for psychosis (Faulkner & 
Biddle, 1999), yet the vast majority of previous research has mainly focused upon 
the role of exercise in assuaging the symptoms of anxiety or depression amongst 
non-psychiatric populations. Conversely, evidence suggests that higher rates of ex-
ercise coincide with higher rates of self-esteem, social standing and body satisfaction 
(Doğan et al., 2004). In light of the findings of this study, which highlighted the impact 
of social support on adherence to anti-psychotic medication, this has important clin-
ical implications. The role of group exercise as a method to enhance social networks 
has the potential to influence outcomes and is worthy of careful deliberation, partic-
ularly when the financial connotations are considered. Hospital treatment tends to 
be costly and long-term in mental health disorders (Allison et al., 2009), whereas the 
effect of non-adherence to anti-psychotic medication is associated with detrimental 
treatment outcomes such as increased risk of relapse, rehospitalisation, increased 
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use of emergency psychiatric services, reduced psychosocial functioning, poorer 
prognoses, detrimental mental functioning and increased risk of suicide (Weiden et 
al., 2004; Beck, et al., 2011).  Additionally, research suggests that a lack of 
knowledge of the positive aspects of exercise programmes is prevalent on many 
mental health wards, resulting in a lack of exercise (Acil, Dogan, & Dogan, 2008). 
Weight gain is a common side effect of anti-psychotic medication and in addition to 
the impact upon physical health can also influence self-esteem, personal relation-
ships, destabilise wellbeing, affect morbidity and mortality and necessitate the re-
quirement of regular medical supervision (Wolters et al., 2009).  
 
Group physical exercise programmes are a potentially cost-effective, easily applica-
ble and readily available addition to current mental health interventions. It could be 
used as an alternative to existing treatments or to supplement existing therapy aimed 
at raising self-esteem and overall quality of life of patients, both in a clinical environ-
ment and also for individuals residing in the community (Acil et al., 2008). Group 
exercise classes can be utilised as a means to develop socialisation skills and de-
velop a supportive social network with shared goals. A recent study highlighted the 
associations between social support and group exercise participation (Rackow, 
Scholz, & Hornung, 2015). The authors found links between social support and ex-
ercising via constructs of self-regulation, such as self-efficacy. The study examined 
the effects of different kinds of social support (emotional and instrumental) on exer-
cising by means of self-efficacy but also self-monitoring and action planning. The 
study involved participants procuring and then exercising regularly with a new exer-
cise companion. The results indicated that emotional social support predicted self-
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efficacy, self-monitoring, and action planning in participants undertaking group exer-
cise, with emotional social support indirectly connected with exercise via the exam-
ined mediators. The effect from received emotional social support via self-efficacy 
contributed to the total effect. The authors suggested that actively engaging with a 
new exercise companion and exercising together promoted enriched emotional and 
instrumental social support and that support in turn promotes exercise by enabling 
better self-regulation (Rackow et al., 2015).  
 
Modifying health behaviour entails maintaining the individual’s motivation and inter-
est over a protracted period of time. Health Psychology can play an important role in 
raising awareness for effective exercise programmes amongst mental health practi-
tioners, encouraging in-patients to practice exercise activity, adapting programmes 
of peer-led group exercise for those residing in the community and developing inter-
ventions in relation to augmenting the exercise habits of patients while helping to 
improve self-esteem, social networks and overall well-being (Callaghan, 2004). 
Awareness could also be raised amongst GP’s, psychiatric nurses, social workers 
and community CPN’s to help implement exercise interventions during patient con-
tact and possibly incorporating lifestyle assessments encouraging group exercise 
activity into mental health assessments. 
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CHAPTER 18. Future research. 
Potential for future research would involve exploring the concepts of adherence to 
anti-psychotic medication over a longer time-scale to assess whether the trends 
evinced in this study persist. A theoretical possibility for future research would be to 
narrow the scope of the research area to focus on a particular condition or medica-
tion.  Although a great deal of Health Psychology research has explored the concept 
of adherence, data and research into these concepts within mental health popula-
tions are rare (Dunbar-Jacob & Schlenk, 2001). The findings of this study serve as 
an important preliminary exploration of the association of treatment control, personal 
control and social support on adherence to anti-psychotic medication.  
 
Health Psychology has provided substantial empirical evidence for the impact of the 
self-regulation model in exploring concepts of adherence. The findings from this 
study suggest that future research could focus on the concepts of treatment and 
personal control within mental health settings. Similarly, while Health Psychology has 
provided substantial empirical evidence for the association of social support with ad-
herence in other conditions, the findings of this study emphasise the impact of social 
support upon adherence to anti-psychotic medication. Mental health care profession-
als should pay heed to the potential impact of treatment control and social support 
on patients. Future research should focus on the relationship between treatment 
control, social support and adherence. Health Psychologists should cogitate the po-
tential of utilising interventions based around these factors to potentially augment 
adherence to anti-psychotic medication.  
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Future research should focus on the variations in social support, as it is a multi-
dimensional, culturally sensitive concept. Additional investigation into these concepts 
and increased knowledge of how individuals with psychosis experience social sup-
port and its impact upon adherence is fundamental in developing culturally compe-
tent interventions relating to anti-psychotic medication. Although the positive impact 
of social support is well documented, there is a dearth of research exploring how 
social support varies across different cultures for individuals suffering from psycho-
sis. The results of this study would suggest that such enquiry plays a fundamental 
role in the development of culturally appropriate care.  
 
Our findings have suggested social support, personal control and treatment control 
to be significantly associated with adherence. In line with previous research, these 
relationships may be interlinked and multifactorial (Drake, Haley, Akhtar, & Lewis, 
2000). National Institute for Clinical Excellence guidelines on adult mental health 
(NICE clinical guidance 136) recommends that mental healthcare professionals 
should regularly monitor for other coexisting conditions, including substance misuse. 
Research from this paper and others has emphasised the significance of social sup-
port on adherence to anti-psychotic medication, larger social groups amongst pa-
tients with dual diagnosis may be a mediating factor for adherence in this subgroup. 
Due to legal, ethical and moral implications surrounding drug use, exploration of all 
mediating factors can be controversial.  
 
The onus is placed on future research to conduct thorough exploration of all mediat-
ing factors in a robust methodical manner. The associations with adherence to anti-
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psychotic medication as highlighted in this study could potentially have important 
implications for mental health professionals. Future research should take the per-
ceived treatment control and social support of patients into account and attempt to 
incorporate these concepts when designing interventions aimed at optimising adher-
ence. 
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CHAPTER 19. Limitations and challenges.  
Given the relatively small sample size of this study it is recognised that the sample 
may not necessarily be representative of the adult population prescribed anti-psy-
chotic medication. The majority of participants were individuals residing in group liv-
ing environments in the North, North East and West London areas and the sample 
subsequently snowballed via word of mouth. Strengths of this method of sampling 
include that it enabled the recruitment of participants who were self-administering 
their medication and not dependent on others to administer their medication, as is 
the case during in-patient settings. However, while the sample was made up of a 
range of ages, ethnic & cultural backgrounds it is conceivable that a sample com-
prised of individuals living in similar locations and circumstances could retain simi-
larities in terms of economic and social backgrounds. Other noteworthy demographic 
findings were also observed. At the first stage of data collection only 33% of partici-
pants were female. This contrasts with previously reported rates, which indicated 
that males are only moderately more likely to be diagnosed with the condition 
(McGrath et al., 2004). This points to specific subgroups within samples which may 
be misrepresented in research findings. The majority of research in psychosis takes 
place amongst in-patient wards which are often divided into male or female only 
wards. However, these wards may specialise in different forms of psychotic illness. 
Future research should ensure that the samples included are representative of psy-
chosis in general. A greater understanding of gender inequalities is essential in order 
to promote the formulation and implementation of health policies that address both 
female and male needs, and concerns should be recognised in order to develop a 
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gender-sensitive framework that can be adopted to improve adherence to anti-psy-
chotic medication in mental health care practice and research. 
 
Furthermore, 61.8% of participants in this study belonged to ethnic minority sub-
groups. The overrepresentation of ethnic minorities in mental health statistics has 
been the subject of significant debate and research (Fenton et al., 1997; 
Fleischhacker et al., 2003; Pinikahana, 2005). There is a theoretical underpinning as 
to why there may be ethnic differences in adherence to medication regimes. Differ-
ences in communication styles may result in increased difficulties in conveying symp-
toms, side effects and concerns. Certain cultures may also display increased lack of 
acceptance of psychosis and anti-psychotic medication may be seen as irrelevant to 
the problem (Tsang et al., 2009). In order to improve the cultural sensitivity of mental 
health services, matching patients with professionals of the same ethnic origin is 
endorsed, as patients reportedly prefer treatment from professionals who shared 
their ethnic background (Ziguras et al., 2001).  
 
Assessments and measures used may also have impacted findings. This study uti-
lised the Duke-UNC Functional Social Support Questionnaire (Broadhead et al., 
1988). The FSSQ is a sophisticated measure which has been validated to measure 
social support in a wide range of settings. However, social support is a capacious 
multidimensional concept which may differ for different individuals. Future research 
should focus on various forms of social support and its impact upon mental health. 
Practical issues such as financial support can often be overlooked although this may 
have a substantial impact and is an important form of support. Financial support may 
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have additional significance in the current economic climate, particularly in light of 
the recent changes to Disability Living Allowance and Personal Independence Pay-
ments which may affect individuals with psychosis (Duffy, 2013).  
 
There is no “gold standard” evaluation method to monitor and assess adherence in 
research and clinical settings. In research, the choice of method has a significant 
impact on results. The most frequent methods utilised are based on indirect or sub-
jective measures. Whereby either the patient, family members or clinicians are asked 
to rate the adherence levels. However, subjective measures of adherence are re-
ported to have poor validity, with subjective self-report measures relying upon the 
accuracy of the individual completing the questionnaire. Clinicians are often reported 
to underestimate non-adherence (Haddad et al., 2014). This has led to an increase 
in the use of objective measures of adherence, such as the use of biological markers. 
The increased employment of anti-psychotic clozapine medication and the associ-
ated safeguards and guidelines involving regular white blood cell checks have coin-
cided with the use of plasma drug levels to assess adherence (Coffey, 1999). Current 
findings suggest that plasma levels can vary depending on metabolism, tobacco use 
and other medications. Plasma levels only provide information of adherence of the 
days immediately prior to the test (Haddad et al., 2014). These issues make the 
assessment of adherence through plasma drug levels substantially polemic.  
This study utilised the Medication Adherence Rating Scale (Thompson et al., 2000) 
as it addressed deficiencies of widely used measures, expanding upon previously 
used tools such as the Drug attitude inventory (DAI) and the Medication Adherence 
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Questionnaire (MAQ). The adherence measure utilised in this study provided a reli-
able measure as highlighted in the patient led groups prior to data collection. Future 
research should ensure that adherence is considered from a patient rather than clin-
ical perspective and could potentially utilise several measures at the same time in 
order to evaluate which measure performs better in a population of individuals pre-
scribed anti-psychotics. 
 
 19.1 Choice of theory. 
This study utilised the Self-Regulation Model while exploring concepts surrounding 
adherence to anti-psychotic medication. While there is a growing body of research 
suggesting that the Self-Regulation Model’s illness dimensions are appropriate for 
use in psychosis (Baines & Wittkowski, 2013), there are also other health psychology 
theories that could potentially have been useful in helping us understand the high 
rates of non-adherence in psychosis due to the unique nature of anti-psychotic treat-
ment. Psychosis is not the only condition in which the side effects of treatment is 
considered to influence upon adherence. The impact of an individual’s treatment-
related beliefs on their adherence to the prescribed treatment programme are out-
lined in the Necessity-Concerns Framework (Horne & Weinman, 1999). The Neces-
sity-Concerns Framework, is an increasingly influential multidimensional theory that 
emphasises the relationships between patients’ necessity beliefs and concerns re-
garding medication, helps predict outcomes of medication adherence. According to 
the Necessity-Concerns Framework adherence is swayed by implicit judgments of 
one’s personal need for the treatment (necessity beliefs) and their concerns regard-
ing the possible unfavourable consequences of taking it. The Necessity-Concerns 
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Framework posits that individuals implicitly evaluate the costs and benefits of taking 
medication when deciding whether to adhere to it. Medication adherence will be en-
hanced if the individual’s beliefs in the necessity of adhering to the medication ex-
ceed their concerns (Horne et al., 2013). Recent studies have attempted to utilise 
the Necessity-Concerns Framework across numerous illness domains, including 
asthma, HIV, cystic fibrosis, haemophilia, renal disease, hypertension, depression, 
diabetes, cardiac illnesses, cancer, and stroke survivors (Phillips, Diefenbach, Kron-
ish, Negron, & Horowitz, 2014). A meta-analytic review of the Necessity-Concerns 
Framework, exploring 93 studies involving 24,864 patients in 18 countries, covering 
23 different long-term conditions, has provided support for its use in exploring adher-
ence (Horne et al., 2013). It was argued that treatment-related beliefs predict adher-
ence more strongly than socio-demographic variables, clinical variables, and other 
beliefs (Phillips et al., 2014). However, it remains to be seen if the predictive capacity 
of the Necessity-Concerns Framework can be successfully applied to adherence in 
psychosis where cognitive functioning is often impaired. Due to the unique nature of 
the condition and the often debilitating consequent side-effects of many anti-psy-
chotic medications, it is also imperative that the measures used in such exploration 
be validated and apt for use amongst individuals diagnosed with psychosis. Never-
theless, the development of this framework has provided an important operational 
method for addressing non-adherence, highlighting adherence to treatment as a pri-
ority for research and practice.  
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Chapter 20. Conclusion. 
The findings from this study serve to further the understanding of adherence to anti-
psychotic medication and can help inform the focus of future interventions. Adher-
ence to medication is a complex multi-factorial phenomenon, influenced by a number 
of parameters. Adherence to anti-psychotic medication presents with a unique set of 
challenges. Ultimately it is crucial to remember that adherence is the individual’s 
choice. Involving patients in decisions about their treatment is critical to the success 
of their treatment. However, within clinical mental health settings professionals are 
often more authoritarian, occasionally opting to view patients as non-compliant which 
can cause distress, impede recovery and potentially breach human rights unless pri-
oritising patients’ best interests (Rethink Mental Illness, 2010).  
 
Adherence to a medication programme is a behaviour and like all behaviours can be 
subject to change if the individual is willing. The role of the health care professional 
should be to work collaboratively with the patient to promote and encourage positive 
change. Numerous approaches have been proposed in an attempt to explain behav-
iour change and provide a framework for the development of interventions.  
 
Encouraging adherence to prescribed medication can be challenging in numerous 
illnesses. However, individuals suffering from psychosis face a particular set of chal-
lenges to adherence that are unique to the condition. It is largely accepted that anti-
psychotic treatment is effective in enhancing positive outcomes and the prevention 
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of relapse while reducing the severity of symptoms. Adherence to anti-psychotic 
medication has therefore been the subject of increasing research (Kao & Liu, 2010). 
The results of this study indicate that social support, and treatment control are deter-
minants of adherence to anti-psychotic medication.  
 
Unlike many physical health conditions, the symptoms of psychosis display consid-
erable capriciousness between individuals. Conversely, the efficacy of anti-psychotic 
medication in the treatment of acute psychosis is well-established (Haddad et al., 
2014). Non-adherence occurs in numerous chronic medical disorders, investigations 
into non-adherence amongst individuals suffering from psychosis is particularly chal-
lenging due to issues surrounding social isolation, lack of insight, co-morbid sub-
stance misuse and the severe side effects associated with anti-psychotics.  
 
The potential consequences of non-adherence with medication for those suffering 
from psychosis are well documented, and include lower quality of life and increased 
risk of relapse, self-harm and rehospitalisation. This in turn is associated with longer 
in-patient treatments and associated costs. At a time when NHS budgets are facing 
increasing uncertainty and potential cuts, mental health services have borne the 
brunt of recent cuts in budget.  This makes identifying the risk factors associated with 
non-adherence and attempting to eradicate or diminish these risks imperative as 
modifiable risk factors could be targeted by interventions (Velligan et al., 2009). The 
results of this study identify social support, treatment control and personal control as 
factors linked with adherence, with treatment control and personal control considered 
to be a determinant of adherence to anti-psychotic medication. As identified in the 
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discussion, there are a number of factors, which may have affected these findings. 
However, what is clear is that the potential for Health Psychology theories, frame-
works and principles to not only scrutinise adherence within mental health settings 
but also develop behaviour change interventions to target identified risks is pertinent, 
and it is the hope of the author that this study will stimulate further research in this 
area and enhance the practice of Health Psychology within mental health settings.   
    
Considering the overwhelming consequences of non-adherence, future research uti-
lising Health Psychology theories should conduct further longitudinal studies explor-
ing causes of non-adherence, concentrating on identifying risk factors, while devel-
oping interventions, approaches, strategies and planning to promote greater aware-
ness of this phenomenon.  
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Departmental Administrator  Chair  
Email:    Email:
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B: PPI Measures  
1. The Illness Perception Questionnaire (IPQ). 
 
2. The Social Support Questionnaire (SSQ). 
 
3. The Systematic Monitoring of Adverse events Related to Treatments 
(SMARTS). 
 
4.  The Medication Adherence Questionnaire (MAQ). 
 
5. The Drug Attitude Inventory (DAI).  
 
6. The Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS). 
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YOUR VIEWS ABOUT YOUR ILLNESS 
Listed below are a number of symptoms that you may or may not have experienced 
since your illness. Please indicate by circling Yes or No, whether you have experi-
enced any of these symptoms since your illness, and whether you believe that these 
symptoms are related to your illness. 
 
I have experienced this symptom since my illness 
This symptom is 
related to my illness 
 
Pain Yes No Yes No 
Nausea Yes No Yes No 
Breathlessness Yes No Yes No 
Weight Loss Yes No Yes No 
Fatigue Yes No Yes No 
Stiff Joints Yes No Yes No 
Sore Eyes Yes No Yes No 
Headaches Yes No Yes No 
Upset Stomach Yes No Yes No 
Sleep Difficulties Yes No Yes No 
Dizziness Yes No Yes No 
Loss of Strength Yes No Yes No 
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We are interested in your own personal views of how you now see your current illness. 
 
Please indicate how much you agree or disagree with the following statements 
about your illness by ticking the appropriate box. 
 
  
VIEWS ABOUT YOUR ILLNESS 
 
STRONG
LY DISA-
GREE 
 
DISA-
GREE 
NEI-
THER 
AGR
EE 
NOR 
DISA-
GREE 
 
AGREE 
 
STRONL
GY 
AGREE 
IP1 My illness will last a short time      
IP2 My illness is likely to be permanent rather 
than temporary 
     
IP3 My illness will last for a long time      
IP4* This illness will pass quickly      
IP5 I expect to have this illness for the rest of 
my life 
     
IP6 My illness is a serious condition      
IP7 My illness has major consequences on my 
life 
     
IP8 My illness is easy to live with      
IP10 My illness strongly affects the way others 
see me 
     
IP11 My illness has serious financial conse-
quences 
     
IP13
* My illness causes difficulties for those who are close to me 
     
IP17 There is a lot which I can do to control my 
symptoms 
     
IP18 What I do can determine whether my ill-
ness 
gets better or worse 
     
IP20
* The course of my illness depends on me      
IP21
* Nothing I do will affect my illness      
IP22
* I have the power to influence my illness      
IP23
* My actions will have no affect on the out-come of my illness 
     
IP26 My illness will improve in time      
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IP27 There is very little that can be done to im-
prove my illness 
     
IP28
* My treatment will be effective in curing my illness 
     
IP29
* Negative effects of my illness can be pre-vented (avoided) by my treatment 
     
IP30
* My treatment can control my illness      
IP31
* There is nothing which can help my condi-tion 
     
IP32 The symptoms of my condition are puz-
zling to me 
     
 
  
VIEWS ABOUT YOUR ILLNESS 
 
STRONG
LY DISA-
GREE 
 
DISA-
GREE 
NEI-
THER 
AGR
EE 
NOR 
DISA-
GREE 
 
AGREE 
 
STRONL
GY 
AGREE 
IP33 My illness is a mystery to me      
IP34
* I don't understand my illness      
IP35
* My illness doesn't make any sense to me      
IP36
* I have a clear picture or understanding of my 
condition 
     
IP37 The symptoms of my illness change a great 
deal from day to day 
     
IP38
* My symptoms come and go in cycles      
IP39
* My illness is very unpredictable      
IP41
* I go through cycles in which my illness gets better and worse. 
     
IP44 I get depressed when I think about my ill-
ness 
     
IP45
* When I think about my illness I get upset      
IP46
* My illness makes me feel angry      
IP47
* My illness does not worry me      
IP48
* Having this illness makes me feel anxious      
IP50
* My illness makes me feel afraid      
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CAUSES OF MY ILLNESS 
We are interested in what you consider may have been the cause of your illness. As 
people are very different, there is no correct answer for this question. We are most in-
terested in your 
own views about the factors that caused your illness rather than what others including 
doctors or family may have suggested to you. Below is a list of possible causes for 
your illness. Please indicate how much you agree or disagree that they were causes 
for you by ticking the appropriate box. 
 
  
POSSIBLE CAUSES 
 
STRONG
LY DISA-
GREE 
 
DISA-
GREE 
NEI-
THER 
AGRE
E NOR 
DISA-
GREE 
 
AGREE 
 
STRONL
GY 
AGREE 
C1 Stress or worry      
C2 Hereditary - it runs in my family      
C3 A Germ or virus      
C4 Diet or eating habits      
C5 Chance or bad luck      
C6 Poor medical care in my past      
C7 Pollution in the environment      
C8 My own behaviour      
C9 My mental attitude e.g. thinking about life 
negatively 
     
C10 Family problems or worries      
C11* Overwork      
C12* My emotional state e.g. feeling down, 
lonely, anxious, empty 
     
C13* Ageing      
C16* Accident or injury      
C17* My personality      
C18* Altered immunity      
 
 
 
In the table below, please list in rank-order the three most important factors that 
you now believe caused YOUR ILLNESS. You may use any of the items from the 
box above, or you may have additional ideas of your own. 
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The most important causes for me: 
1. 
 
2. 
3. 
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2. SARASON SOCIAL SUPPORT QUESTIONNAIRE (Short Form) 
SSQSR 
 
INSTRUCTIONS: 
The following questions ask about people in your life who provide you with help or support. 
Each question has two parts. For the first part, list all the people you know, excluding yourself, 
who you can count on for help or support in the manner described. Write the person’s initials 
and their relation to you (see example). Do not list more than one person next to each of the 
numbers beneath the question. 
 
For the second part, circle how satisfied you are with the overall support you have. 
 
If you have no support for a question, circle the words “No one,” but still rate your level of sat-
isfaction. Do not list more than nine people per question. 
 
Please answer all the questions the best you can. All your responses will be kept confidential. 
Example: 
Who do you know who you can trust with information that can get you into trouble? 
No one 1.)T.N. (brother) 4.) D.N. (father) 7.) 
2.) L.M. (friend) 5.) W.T. (employer) 8.) 
3.) R.S. (friend) 6.) 9.) 
 
How satisfied? 
 
6 – very 5 - fairly 4 - a little 3 - a little 2 - fairly 1- very satisfied satis-
fied satisfied dissatisfied dissatisfied dissatisfied 
1. Who can you really count on to be dependable when you need help? 
 
No 
one 
1.) 4
.
) 
7.) 
 2.) 5
.
) 
8.) 
 3.) 6
.
) 
9.) 
 
 
2. How satisfied? 
 
6 - very 5 - fairly 4 - a little 3 - a little 2 - fairly 1- 
very 
Satisfied satisfied satisfied dissatisfied dissatis-
fied 
dissat-
isfied 
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3. Who can you really count on to help you feel more relaxed when you are 
under pressure or tense? 
 
No one 1.) 4
.
) 
7.) 
 2.) 5
.
) 
8.) 
 3.) 6
.
) 
9.) 
 
 
 
4. How satisfied? 
 
6 - very 5 - fairly 4 - a little 3 - a little 2 - fairly 1- 
very 
Satisfied satisfied satisfied dissatisfied dissatis-
fied 
dissat-
isfied 
 
 
 
5. Who accepts you totally, including both your worst and best points? 
 
No one 1.) 4
.
) 
7.) 
 2.) 5
.
) 
8.) 
 3.) 6
.
) 
9.) 
 
 
 
6. How satisfied? 
 
6 - very 5 - fairly 4 - a little 3 - a little 2 - fairly 1- 
very 
Satisfied satisfied satisfied dissatisfied dissatis-
fied 
dissat-
isfied 
 
 
 
7. Who can you really count on to care about you, regardless of what is happening to 
you? 
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No one 1.) 4
.
) 
7.) 
 2.) 5
.
) 
8.) 
 3.) 6
.
) 
9.) 
 
 
 
8. How satisfied? 
 
6 - very 5 - fairly 4 - a little 3 - a little 2 - fairly 1- 
very 
Satisfied satisfied satisfied dissatisfied dissatis-
fied 
dissat-
isfied 
 
 
 
9. Who can you really count on to help you feel better when you are feeling down-in-
the- dumps? 
 
No one 1.) 4
.
) 
7.) 
 2.) 5
.
) 
8.) 
 3.) 6
.
) 
9.) 
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10. How satisfied? 
6 - very 5 - fairly 4 - a little 3 - a little 2 - fairly 1- 
very 
Satisfied satisfied satisfied dissatisfied dissatis-
fied 
dissat-
isfied 
 
11. Who can you count on to console you when you are very upset? 
 
No 
one 
1.) 4
.
) 
7.) 
 2.) 5
.
) 
8.) 
 3.) 6
.
) 
9.) 
 
 
 
6. How satisfied? 
 
6 - very 5 - fairly 4 - a little 3 - a little 2 - fairly 1- 
very 
Satisfied satisfied satisfied dissatisfied dissatis-
fied 
dissat-
isfied 
 
 
TO SCORE SSQSR: 
 
1. Count the total number of people for each of the odd-num-
bered items. Add the total together (Max = 54). Divide by 
6 per item SSQ Number Score, or SSQN. 
 
2. Add the total satisfaction scores for the 6 even-numbered 
items (Max = 36). Divide by 6 per item SSQ Satisfaction 
Score or SSQS. 
 
3. You can also compute a Family score and a Non-Family 
score by using the method in #1 for all people describes as 
family members, or not described as family members re-
spectively.   
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3.SMARTS 
Systematic Monitoring of Adverse events Related to TreatmentS 
Instructions:  We want to be sure that you are receiving the best treatment, and would like to check whether you have any problems which may result from taking your medications. Please circle any of the following items that trouble you, so that your doctor or nurse can discuss them with you. 
Are you troubled by:  1. Difficulties in your movement such as shaking, stiffness or muscle aches? 2. Changes in your weight or appetite? 3. Problems with your sex life? 4. Changes in your periods or changes in your breasts? 5. Dizziness or light-headedness? 6. Tiredness or sleepiness? 7. Restlessness or feeling fidgety? 8. Constipation, diarrhoea, nausea, stomach problems or dry mouth? 9. Difficulty passing water or passing water very frequently? 10. Problems with your concentration or memory? 11. Feeling anxious or depressed? 12. Any other problems which you think may be related to your medication? Please state________________________________________________________________________________________________________________________________________________________________________________________________________ 
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4. Medication Adherence Questionnaire (MAQ) 
 
 
  
 194 
5. DAI-10 questionnaire 
 Q
u
e
s
t
i
o
n 
Answer 
(True/Fals
e) * 
1 For me, the good things about medication outweigh the bad T 
/ 
F 
2 I feel strange, "doped up", on medication T 
/ 
F 
3 I take medications of my own free choice T 
/ 
F 
4 Medications make me feel more relaxed T 
/ 
F 
5 Medication makes me feel tired and sluggish T 
/ 
F 
6 I take medication only when I feel ill T 
/ 
F 
7 I feel more normal on medication T 
/ 
F 
8 It is unnatural for my mind and body to be controlled by medications T 
/ 
F 
9 My thoughts are clearer on medication T 
/ 
F 
1
0 
Taking medication will prevent me from having a breakdown T 
/ 
F 
If you have any further comments about medication or this questionnaire, please write 
them below 
T = True, F = False 
*Answers shown in bold are scored +1; answers in normal font are scored -1 
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C- Measures Used in Research 
 
 
 
1. Medication Adherence Rating Scale (MARS).  
2. Drug Abuse Screening Test (DAST-10). 
3. Glasgow Anti-Psychotic Side Effect Scale (GASS). 
4. Duke Functional Social Support Scale (FSSQ). 
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MARS questionnaire 
 
Question Answer 
1. Do you ever forget to take your medication? Yes / No 
2.  Are you careless at times about taking your medication? Yes / No 
3.  When you feel better, do you sometimes stop taking your medication? Yes / No 
4. Sometimes if you feel worse when you take the medication, do you stop taking 
it? Yes / No 
5. I take my medication only when I am sick Yes / No 
6. It is unnatural for my mind and body to be controlled by medication Yes / No 
7. My thoughts are clearer on medication Yes / No 
8. By staying on medication, I can prevent getting sick. Yes / No 
9. I feel weird, like a ‘zombie’ on medication Yes / No 
10. Medication makes me feel tired and sluggish Yes / No 
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Drug Use Questionnaire (DAST-10) 
   
Participant No:  
  
___________________________________  
Test Date:    
  
___________________________________  
Score:  ___________________________________  
  
  
 Preliminary Comments  
Adapted from language provided by Dr. Harvey Skinner (January 5, 2009)  
  
  The following questions concern your potential involvement with drugs other than alcohol.  When 
you answer the questions, remember that the term “drug abuse” does not include alcohol.  Instead, it refers to 
your use of prescribed or over the counter drugs in excess of the recommended dosage.  For example, if you 
were given a prescription for pain killers, but took more than you were supposed to, that would be included.  
The phrase “drug abuse” also includes any non-medical drug use, including illegal drugs.  This includes sub-
stances like marijuana, valium, cocaine, amphetamines, LSD, and heroin.  Remember that the term “drug 
abuse” does not include alcohol.  If you have difficulty with a statement, then choose the response that is 
mostly right.  
  
  Do you understand?  
  
Questions  
  
These questions refer to the past 12 months.          Circle the   
                    Response  
  
1. Have you used drugs other than those required for medical reasons?    Yes  No  
  
2. Do you abuse more than one drug at a time?          Yes  No  
  
3. Are you always able to stop using drugs when you want to?      Yes  No  
  
4. Have you had “blackouts” or flashbacks” as a result of drug use?      Yes  No  
  
5. Do you ever feel bad or guilty about your drug use?        Yes  No  
  
6. Does your spouse (or parents) ever complain about your involvement with drugs?   Yes       No 
  
7. Have you neglected your family because of your use of drugs?      Yes  No  
  
8. Have you engaged in illegal activities in order to obtain drugs?      Yes  No  
  
9. Have you ever experienced withdrawal symptoms (felt sick) when   you stopped taking drugs?  
 
           Yes  No 
  
10. Have you had medical problems as a result of your drug use      Yes  No  
(e.g. memory loss, hepatitis, convulsions, bleeding, etc.)?  
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Duke–UNC Functional Social Support Questionnaire (FSSQ) 
Here is a list of some things that other people do for us or give us that may be helpful or 
supportive.  Please read each statement carefully and place an ‘X’ in the column that is 
closest to your situation.  Give only 1 answer per row. 
 5 4 3 2 1 
  As much as I 
would like 
Almost as much 
as I would like 
Some, but 
would like more 
Less than I 
would like 
Much less than I 
would like 
1. I have people who care 
what happens to me. 
     
2. I get love and affection.      
3. I get chances to talk to 
someone about prob-
lems at work or with 
my housework. 
     
4. I get chances to talk to 
someone I trust about 
my personal or family 
problems. 
     
5. I get chances to talk 
about money matters. 
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6. I get invitations to go 
out and do things 
with other people. 
     
7. I get useful advice about 
important things in life. 
     
8. I get help when I am 
sick in bed. 
     
Source:  adultmeducation.com 
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Department of Psychology 
City University London 
 PARTICIPANTS NEEDED FOR 
RESEARCH IN HEALTH PSYCHOLOGY 
 We are looking for volunteers to take part in a study investigating determinants of adherence to 
anti-psychotic medication. 
What is the purpose of this research? 
People prescribed anti-psychotic medication commonly report non-adherence to their medi-
cation.  The purpose of this study is to test the principles of Health Psychology in determin-
ing adherence to anti-psychotic medication.   
Why have I been chosen? 
You are invited to participate in this study if you are aged 18 or above, take anti-psychotic 
medication and reside in the community. Participants are being recruited from a range of 
locations including online forums, social media and local resources. We will be aiming to 
recruit 100 people in total. 
Do I have to take part? 
 No, participation in this research is completely voluntary. If you decide to take part, then 
you are still free to withdraw from the study, without giving a reason and without any nega-
tive consequences.  
For more information about this study, or to take part,  
please contact: 
 
Faisal Satti / Dr Angeliki Bogosian 
Psychology Department 
at 
 
 
 
 
 
What happens if I decide to take part? 
You would be asked to complete 5 anonymous  
questionnaires and then the same five questionnaires again in one years’ time.  
Your participation would involve 2 sessions, each of which is approximately 30 minutes. 
What are the possible benefits of taking part? 
 
If found to be helpful, the results of the study materials will be developed further and used 
in future trials to understand the factors that help people adhere to anti-psychotic medica-
tion.  
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Will participation be kept confidential? 
 
Yes, the data you provide will be accepted in complete confidence and will not be dis-
closed beyond the researchers involved. All data will be reported anonymously in any fu-
ture publication of the results. 
This study has been reviewed by, and received ethics clearance  
through the Psychology Research Ethics Committee, City University London 
[PSYCH (P/F) 14/15 155].  If you would like to complain about any aspect of the study, please contact the Secre-tary to the University’s Senate Research Ethics Committee on   
 
 
Thank you very much for taking the time to read through this information 
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An investigation into determinants of adherence to anti-psychotic medication. 
We would like to invite you to take part in a research study. Before you decide whether you 
would like to take part it is important that you understand why the research is being done 
and what it would involve for you. Please take time to read the following information carefully 
and discuss it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. 
 
What is the purpose of the study?  
You are being invited to take part in a study on anti-psychotic treatment. The research is 
done to better understand issues around taking anti-psychotic medication. If you decide to 
take part I would be very grateful if you could take some time out to fill the attached ques-
tionnaires that will take approximately 30 minutes to complete.  
 
Why have I been invited? 
Adults who are living in the community, have been diagnosed with schizophrenia, and are 
currently self-medicating are invited to take part. 
 
Do I have to take part?  
Participation in the project is voluntary, and you can choose not to participate in part or the 
entire project. You can withdraw at any stage of the project without being penalised or dis-
advantaged in any way. It is up to you to decide whether or not to take part. If you do decide 
to take part you will be asked to sign a consent form. If you decide to take part you are still 
free to withdraw at any time and without giving a reason.  
 
What will happen if I take part? 
You would be asked to complete 3 anonymous questionnaires and then the same three 
questionnaires again in one years’ time. Your participation would involve 2 sessions, each 
of which will take approximately 30 minutes. The questionnaires can be completed in a time 
and place convenient to yourself. 
 
What do I have to do?  
Attached is a consent form, three questionnaires and a debrief sheet, please read through 
and sign the consent form as a formal agreement in taking part in this study prior to filling 
out the questionnaires. Moreover, if you need/want more information regarding the study 
please do not hesitate to ask. 
  
What are the possible disadvantages and risks of taking part?  
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This study will involve questions about illegal recreational drugs. This is to explore whether 
illicit substance use is a predictor to adherence to anti-psychotic medication. Your responses 
will be anonymised and your details will remain confidential, so we would encourage you to 
answer truthfully. Neither City University, nor the researchers undertaking this study, con-
done the use of illicit drugs. Taking part in this study should therefore not be seen as provid-
ing any support or encouragement for the use of illegal drugs.  
 
If the participation caused any emotional discomfort or if you would like to talk to someone 
or find out information about where you can receive help for any health related problems 
you will be provided with details of registered agencies that may be useful to you. 
 
 
 
What are the possible benefits of taking part? 
We cannot guarantee that you will benefit from taking part in this study. But the results of 
this study will help us better understand issues around taking medication and what makes it 
easier or more difficult.  
 
What will happen when the research study stops?  
All data collected from the participants will be anonymized and securely stored with only the 
researchers having access to it. If the project is stopped all collected data will be destroyed 
 
Will my taking part in the study be kept confidential?  
All data is kept strictly confidential, only the researcher will have access to your personal 
information which will immediately be anonymised. However, the researcher may have to 
breach confidentiality if concerned that someone could be at risk of harm. Confidentiality 
may be broken in the following circumstances:  If a participant tells the researcher something 
that causes significant concern, for example that they plan to hurt themselves or others. 
 
What will happen to the results of the research study? 
The results will be written up as part of a professional doctorate in health psychology. The 
results may also be result in possible future publications. If this occurs complete anonymity 
of all participants will be maintained.  
 
What will happen if I don’t want to carry on with the study?  
You are free to stop and withdraw yourself from the study within two weeks after completing 
the questionnaires and any data collected will be destroyed.  
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What if there is a problem? 
If you have any problems, concerns or questions about this study, you should ask to speak 
to a member of the research team. If you remain unhappy and wish to complain formally, 
you can do this through the University complaints procedure. To complain about the study, 
you need to phone . You can then ask to speak to the Secretary to Senate 
Research Ethics Committee and inform them that the name of the project is: Exploring pre-
dictors of adherence to anti-psychotic medication. 
 
You could also write to the Secretary at:  
Anna Ramberg 
Secretary to Senate Research Ethics Committee  
Research Office, E214 
City University London 
Northampton Square 
London, EC1V 0HB                                      
 
 
City University London holds insurance policies which apply to this study. If you feel you 
have been harmed or injured by taking part in this study you may be eligible to claim com-
pensation. This does not affect your legal rights to seek compensation. If you are harmed 
due to someone’s negligence, then you may have grounds for legal action. 
 
Who has reviewed the study? 
This study has been approved by City University London Psychology Research Ethics Com-
mittee, [insert ethics approval code here]. 
 
Further information and contact details: If you would like any further information any in-
quiries about the research can be made to; 
Faisal Satti / Dr Angeliki Bogosian Psychology Department at  or Email:
 
Thank you for taking the time to read this information sheet.    
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Title of Study: Investigating determinants of adherence to anti-psychotic medication.   
Ethics approval code: [PSYCH (P/F) 14/15 155] 
Please initial box 
1. I agree to take part in the above City University London research pro-
ject. I have had the project explained to me, and I have read the par-
ticipant information sheet, which I may keep for my records.  
 
I understand this will involve: 
  completing questionnaires asking me about adherence to 
medication. 
  making myself available to complete the same question-
naires again in one years’ time. 
 
2. This information will be held and processed for the following pur-
pose(s):  
 
  to compare questionnaires measuring adherence 
  to explore issues surrounding adherence from Health Psy-
chology perspective 
 
3.  
I understand that any information I provide is confidential, and that no 
information that could lead to the identification of any individual will 
be disclosed in any reports on the project, or to any other party. No 
identifiable personal data will be published. The identifiable data will 
not be shared with any other organisation.  
 
4. I understand that my participation is voluntary, that I can choose not 
to participate in part or all of the project, and that I can withdraw at 
any stage of the project without being penalized or disadvantaged in 
any way. 
 
5. I agree to City University London recording and processing this infor-
mation about me. I understand that this information will be used only 
for the purpose(s) set out in this statement and my consent is condi-
tional on the University complying with its duties and obligations un-
der the Data Protection Act 1998. 
 
6. I agree to take part in the above study.  
 
 
____________________ ____________________________ _____________ 
Name of Participant  Signature    Date 
 
 
____________________ ____________________________ _____________ 
Name of Researcher  Signature    Date 
 
When completed, 1 copy for participant; 1 copy for researcher file. 
 
Note to researcher: to ensure anonymity, consent forms should NOT include participant numbers and should be stored 
separately from data. 
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Investigating determinants of adherence to anti-psychotic medication. 
 
DEBRIEF INFORMATION 
 
Thank you for taking part in this study and completing the questionnaires. Now that 
it’s finished we’d like to explain the rationale behind the work.  
We are going to look into the issue of taking prescribed anti-psychotic medication by 
adults living in the community. Your participation will be valuable in raising aware-
ness of a significant topic that may improve further understandings of this area. 
 
I would like to remind you that all of your data will be kept strictly confidential and will 
be anonymised. If for any reason you would like to withdraw your data you can do 
so within two weeks of completing the questionnaires. If you have any queries, then 
contact myself, or the academic supervisor Dr Angeliki Bogosian (contact details at 
the bottom of the page). 
 
The study has been conducted under supervision of City University London and will 
contribute towards the researchers Doctorate in Health Psychology. It has been con-
ducted according to the Code of Conduct, Ethical Principles & Guidelines of The 
British Psychological Society. 
 
If the participation caused any emotional discomfort or if you would like to talk to 
someone or find out information about where you can receive help for any health 
related problems the following registered agencies may be useful to you:   
 
The Independent Mental Capacity Advocate Service 
The statutory advocacy service under the Mental Capacity Act:  
24 hour confidential emotional support, tel. 0845 3302900, e-mail: customer ser-
vices@publicguardian.gsi.gov.uk; web: www.publicguardian.gov.uk 
 
NHS Direct:  
The NHS 24 hour helpline, tel. 0845 4647, web: www.nhsdirect.nhs.uk 
 
Samaritans: 
The 24 hour confidential emotional support, tel. 08457 90 90 90, web: www.samar-
itans.org 
 
 
Talk to Frank: 
This study involved questions about illegal recreational drugs. All illegal drugs tend 
to be harmful, and some can be very damaging. We advise all drug uses to quit using 
drugs, or at least to limit their consumption. 
 
Further valuable information about drug effects:  tel. 0800 776 600, web: 
www.talktofrank.com 
 
The image part with relationship ID rId42 was not found in the file.
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Or if the research has raised any concerns you might find it useful to contact your 
GP, Key Worker or an appropriate mental health professional e.g. your social worker 
or care coordinator. 
 
We hope you found the study interesting. If you have any other questions please do 
not hesitate to contact us at the following:  
 
Researcher: Faisal Satti, e-mail:  
 
Supervisor: Dr Angeliki Bogosian, e-mail:  
 
 
We will be happy to answer any questions or receive any feedback. 
 
Ethics approval code: [PSYCH (P/F) 14/15 155.]   
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SECTION C 
 
 
PROFESSIONAL 
PRACTICE 
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CORE UNIT 1 
DHP 061 
 
 
GENERIC PROFESSIONAL COMPETENCE 
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Unit 1.1 Implement and maintain systems for legal, 
ethical and professional standards in applied psy-
chology. 
During my time as a trainee Health Psychologist, I was employed in a community-
based mental health setting. I will outline and reflect upon my professional practice 
within my post as the manager of a community project for forensic mental health 
patients. I will reflect upon my professional development as an applied Health Psy-
chologist and the application of psychological principles throughout my professional 
practice. I will also provide an account of how I have enhanced a range of skills, 
including; conducting research and systematic reviews, developing consultancies, 
implementing behaviour change, teaching and training, providing feedback, psycho-
logical advice and guidance to others in addition to maintaining systems for legal 
ethical and professional practices in applied psychology.   
 
1.1a Establish, maintain and review systems for the secu-
rity and control of information. 
Prior to commencing the training, I sought advice from various professionals includ-
ing the course leader of a professional doctorate in Health Psychology programme. 
I wanted to have a clear understanding of the requirements and practicalities of un-
dertaking the process. My main concern was whether it was practical to attempt 
combining the training, with my role as a manager specialising in forensic mental 
health patients. I felt passionately that incorporating Health Psychology principles 
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with a client group where little focus was placed upon physical health, would poten-
tially be of immense practical benefit. The advice that I received made it apparent 
that the amount of client contact, coupled with the scope and autonomy that I had 
within my role, would be a considerable advantage with regard to the ease of directly 
applying theory within my professional practice. Although I was not supervised by an 
applied Health Psychologist within my professional setting, the Health Psychology 
supervision that I would receive as part of the professional doctorate, would be of 
immense practical benefit. The fact that establishing, maintaining and reviewing 
systems for the security and control of information was already a large part of my 
role, provided me with an understanding of the protocols required to ensure legal, 
ethical and professional standards.  
 
Throughout my employment, I have been required to establish, maintain and review 
systems for the security and control of information. Maintaining confidentiality across 
organisations is a key factor. I initially work with service users while they remain in-
patients within secure forensic wards and help them transition post discharge. Ulti-
mately, facilitating their reintegration into society. I have ensured that the storage, 
access and transfer of all patient information was in accordance with the Data Pro-
tection Act 1988. Overall, the aims of my professional practice included providing a 
safe environment in which the patient has as much control over their lives as possi-
ble. Enabling them to achieve the maximum degree of independence while retaining 
their dignity. Providing each individual with an opportunity to build new skills for life 
and adapt old ones. I looked to develop a therapeutic programme under the care 
programme approach, relevant to individual needs, while facilitating each to function 
at their potential.  
 217 
I was registered with The Care Quality Commission (CQC) who regulate all 
registered activities that I managed. This process involves in-depth unannounced 
inspections. During the professional practice that makes up this portfolio, I received 
an unannounced inspection by a team of four CQC inspectors on the 18th of October 
2016. By this point, I had been practising as a trainee Health Psychologist for two 
years. The resulting inspection report provides an in-depth account of my profes-
sional practice (please refer to Practice Log). While completing the research thesis 
and behaviour change intervention, I ensured that all BPS and HCPC ethical guide-
lines regarding participant data protection were met. All information was securely 
stored on an encrypted USB and in locked filing cabinets. Participants were re-
minded that participation was voluntary, would not have any bearing on any other 
treatment and reminded that they could withdraw at any stage if they choose to do 
so.  
 
1.1b Ensure compliance with legal, ethical and profes-
sional practices for self and others. 
In my role as the Registered Manager, I specialised in providing support to forensic 
clients who were subject to various Ministry of Justice ascribed conditions. As the 
registered individual with CQC, I am charged with overall responsibility for the legal, 
ethical and professional running of the unit. The CQC has in-depth regulatory guide-
lines for how this should take place as outlined in CQC (Registration) Regulations 
2009 (as amended March 2015). These guidelines are informed by the Health and 
Social Care Act 2008 (Regulated Activities) Regulations 2014.   
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Within my role, I was required to develop and implement all policies and procedures 
ensuring that they meet legal, ethical and professional standards not just of the CQC 
but also of the local authority and relevant NHS organisations. Many of the principles 
that underpin these standards are similar to BPS ethical guidelines. Thus, I have had 
ample opportunity to meet these requirements throughout my professional practice. 
I have also had the responsibility of supervising staff to ensure that these standards 
are met by others.  
 
I ensured that compliance with legal, ethical and professional practices for both my-
self and others by working within CQC Regulations. Furthermore, as a member of 
both the British Psychological Society (BPS) and the Division of Health Psychology 
(DHP), I made certain to adhere to the Society’s Code of Ethics and Conduct (2006). 
Throughout my professional practice and in the supervision of others, I endeavoured 
to meet the values that underpin the ethical principles of respect, responsibility, com-
petency and integrity which form the code. The policies and procedures that I have 
developed to ensure compliance reflect this. Furthermore, the process of success-
fully obtaining ethical approval ensured that my research conformed to the Univer-
sity’s ethical committee guidelines. 
 
1.1c Establish, implement and evaluate procedures to en-
sure competence in psychological practice and research. 
 219 
Before commencing the training, I had taken the time to evaluate how I would at-
tempt to establish, implement, meet and subsequently evaluate the various compe-
tencies and I developed a time-scale for achieving this. It became apparent that the 
nature of my professional role would be of enormous benefit due to the existing level 
of psychological practice and direct patient contact. In my discussions with profes-
sionals who had completed the training, I was keen to ascertain what was felt to be 
a reasonable timescale to achieve competence. I was consistently informed that sta-
bility within the trainee’s work setting was a key factor to consider regarding duration 
for the overall process. I, therefore, became extremely apprehensive when a month 
after commencing the training I became aware that my organisation was the subject 
of a change of ownership. However, the subsequent changes in structure culminated 
with an increased level of professional autonomy within my role, affording me the 
scope to establish, implement and evaluate procedures in accordance with the train-
ing that I was receiving as part of the programme. I was able to design and implement 
competencies in line with this training and the support and guidance that I received 
from both my Professional and Academic Supervisors. This ensured that the com-
petence of my psychological practice was robustly evaluated and reflected upon. 
With changes and alterations made where necessary. A prime example of this is 
provided by the behaviour change competency which was chronologically the first 
competence that I undertook. As I had extensive experience of designing and imple-
menting behaviour change interventions within mental health settings, I felt comfort-
able when setting up the competence. However, when evaluating procedures as part 
of my professional practice as a trainee Health Psychologist, I realised that I needed 
to structure and design sessions in a very different way to ensure that in-depth for-
mulations, assessments and Health Psychology evaluations were conducted in a 
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way which is unique to the profession of an applied Health Psychologist. Through 
reflection and the guidance of my supervisors, I was able to achieve this.   
 
Further opportunities to establish, implement and evaluate procedures to ensure 
competence, were provided by the research practice conducted as part of the train-
ing. My research thesis and systematic review provide evidence that my work was 
conducted in a robust, planned manner. I developed a protocol to establish proce-
dures for the systematic review. To develop effective appraisal of the quality and 
validity of studies reviewed, a scoring system was initially devised. However, this 
was reviewed during supervision and a joint decision on how to conduct quality as-
sessment was made. Progression was regularly reviewed with my supervisor to en-
sure the quality of the systematic review process. 
 
The research and systematic review have been adapted and are currently being 
peer–reviewed for publication. I believe that the process of peer-review will add an 
additional evaluation of the research and provides an excellent opportunity for the 
dissemination of findings.  
 
Unit 1.2 Contribute to the continuing development 
of self as a professional applied psychologist. 
Upon commencing the programme, I strived to maximise every opportunity of self-
development. Initially, I felt that my previous professional experience and first-hand 
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practical knowledge had provided me with an understanding of direct client contact 
and behaviour, which was useful in my academic endeavours. However, the longer 
I spent on the course furthering my development, the more I subsequently found the 
reverse to be true. Ultimately, I increasingly discovered that my training altered my 
professional practice when working with clients, as I progressively incorporated more 
advanced techniques and methods. Reflecting on my practice, through practice logs 
and discussions with supervisors and peers, also helped me recognise areas where 
I could improve. This enabled me to reflect on whether the work I was conducting for 
the Health Psychology competencies had the effect I was looking for and elements 
that I could improve. 
 
1.2a Establish, evaluate and implement processes to de-
velop oneself professionally. 
The stage two training at City, University of London has provided numerous oppor-
tunities to establish, evaluate and implement processes for professional develop-
ment. Competency-based workshops helped supplement training, and the applica-
tion of psychological models within the competencies provided a framework to con-
textualise theoretical perspectives in an applied setting. I attended all of the Health 
Psychology doctorate workshops including ethics, consultancies, teaching and train-
ing, research methods, CBT, Motivational Interviewing and Systematic reviews. All 
of which helped enhance my professional development.  I took advantage of numer-
ous other forms of development including being awarded a bursary for a compre-
hensive training programme provided by SCCH Health Psychology Consulting LLP- 
 222 
“Health Psychology Interventions in Practice” (Please refer to Practice Log). This 
training programme was of immense benefit as it was conducted by experienced 
Applied Health Psychologists who were able to provide numerous examples from 
their professional backgrounds and the focus was on the practical application of the 
discipline. The Training provided by the SCCH afforded an invaluable insight into the 
development and implementation of Health Psychology interventions. It bestowed a 
core understanding of implementing the science and evidence base of Health Psy-
chology and Health Behaviour Change into the world of person-centred healthcare. 
I also attended conferences and completed several work-based training pro-
grammes to broaden my skills (Please refer to Practice Log).  
 
Throughout the training, I have become increasingly involved in both the design and 
delivery of interventions. However, it became apparent that many Health Psycholo-
gists work exclusively in academia or research. Others have found employment in 
roles where they are not primarily delivering Health Psychology interventions.  Rel-
atively few Health Psychologists' primary role involves directly delivering person-
centred interventions to patients within clinical settings. As a trainee working with 
forensic mental health patients, I feel it is important to distinguish between the ways 
that clinical and Health Psychologists go about this. I found the Health Psychology 
training of immense benefit in helping me develop professionally, as it provided first-
hand accounts and examples of putting Health Psychology theory into practice. As 
a professional working within mental health, the training was of additional value as it 
outlined the challenges of applied professional practice. It explored the issues and 
complications that can arise in practical applications and outlined how to address 
and overcome these issues. Overall, the doctorate training was a valuable exercise 
 223 
in helping to further my understanding of implementing the science and evidence 
base of Health Psychology and Health Behaviour Change in person-centred 
healthcare and helped inform my professional development.  
 
1.2b Elicit, monitor and evaluate knowledge and feedback 
to inform practice. 
During the training, I actively sought to regularly obtain feedback from a variety of 
sources. Initially, I would seek advice from my supervisor on aspects where I was 
unclear. However, as the training progressed, I augmented confidence in my ability 
to seek feedback from others. After jointly agreeing upon a supervision plan with my 
academic supervisor, we would meet regularly, and I would monitor, evaluate and 
reflect upon the feedback provided. Initial supervision focused on exploring ap-
proaches, concepts and ideas in relation to conducting competencies. I became 
adept at applying constructive feedback to enhance my skills and incorporate best 
practice.  
 
As I began implementing the competencies, I was afforded with greater opportunities 
to elicit, monitor and evaluate knowledge and feedback to inform practice. Some of 
this feedback has been included as part of this portfolio. For example, during each 
training session I carried out, I designed and handed out feedback forms for all par-
ticipants. I would evaluate these forms and altered subsequent training sessions ac-
cordingly. Similarly, after evaluating the feedback following the first lecture that I car-
ried out at the University (refer to practice log), I adapted my approach for 
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subsequent lectures. It is a source of pride that the feedback that I received during 
the training was largely positive and appeared to improve as the training developed.  
 
1.2c Organise, clarify and utilise access to competent 
consultation and advice. 
I used and accessed competent consultation and advice from various sources. This 
included both my academic and professional supervisors, my line manager, work 
colleagues, professionals and specialists from various disciplines such as clinical 
psychology and psychiatry as well as other trainees on the course.  
 
A few months after commencing the training I was appointed the course representa-
tive of the “student staff liaison committee”. I felt it was important to organise pro-
cesses of competent advice that would benefit all trainees on the program. During 
the first meeting, I advocated the use of regular “peer supervision” meetings. I felt 
that as trainees worked in such a diverse range of fields, we could all benefit from 
shared experiences and support. Peer supervision commenced at the start of the 
second year and proved a useful way to help organise, clarify and access relevant 
consultation and advice. For my leadership and guidance skills in my role as a course 
representative I have been awarded a programme representative of the year award 
(refer to practice log). 
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Rather than working in isolation, I continually sought the consultation and advice of 
experts during all aspects of this portfolio and I believe that it has benefitted from 
these collaborations. Things were often reviewed or discussed with the relevant ex-
perts or team. Examples of this are provided by the behaviour change competency, 
during which I shadowed a team of health trainers before commencing work with 
clients and with the planning of my research, during which I conducted a “Patient 
Involvement” group prior to conducting data collection.  
 
1.2d Develop and enhance oneself as a professional ap-
plied psychologist. 
I was aware of the importance of continuously developing and enhancing myself as 
a professional psychologist and feel that this occurred organically throughout the 
training. I joined the Division of Health Psychology and kept abreast of developments 
in Health Psychology to ensure that I applied the most up to date and relevant find-
ings in my practice. I also became a member of the University’s Research Focus 
Group, to enhance and develop my writing skills and seek opportunities and collab-
orations for potential publications. I have regularly attended relevant Health Psychol-
ogy conferences and have presented the findings from my research at conferences, 
augmenting my professional skill set. I continually sourced and utilised various 
sources to further advance and enrich my practice such as: Applying Psychology to 
Health (Banyard, 1996), The Health Psychology Reader (Marks, 2002), The 
development of professional Health Psychology: European Federation of 
Professional Psychologists’ Association (EFPPA) (Marks et al.,1998) and Michie and 
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Abraham's (2004) Health Psychology in Practice. As well as Susan Michie’s Theo-
retical Domain Framework, which helped inform which model and theory to use for 
particular interventions, and their most effective method of implementation (Michie 
et al., 2005).  
 
I set the behaviour change competency within a mental health setting to highlight the 
overbearing need and potential benefit of implementing Health Psychology with this 
client group. However, for subsequent competencies I strived to find exciting and 
challenging opportunities which were often far removed from my area of expertise to 
ensure that I continually developed and enhanced my professional skills.  
 
1.2e Incorporate best practice into one's own work. 
The in-depth CQC Inspection report highlights my attempts to incorporate best prac-
tice into my work setting, not just myself but also by supervising others. Although 
aspects such as smoking cessation do not form part of my role, I was aware of the 
potential dangers of smoking in patients who were prescribed clozapine as well as 
their long-term reluctance to attend stop smoking clinics. I, therefore, worked with 
clients having attained full National Centre for Smoking Cessation and Training 
(NCSCT) certification as a smoking cessation practitioner. I also completed addi-
tional NCSCT qualifications in Face to Face Behavioural Support and the NCSCT 
Mental Health Specialty module, to support clients that I had already established a 
therapeutic relationship with, thereby enhancing their well-being and the efficacy of 
their treatment.  
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The more I developed and progressed as a trainee Health Psychologist, the more I 
was able to incorporate more advanced techniques and methods. During my profes-
sional development, I was increasingly able to utilise these skills to ensure best prac-
tice. I was also able to disseminate the knowledge that I had gained while supervis-
ing others to ensure that best practice was maintained throughout my work place. 
Evidence of this is provided in the CQC inspection report (please refer to practice 
log). 
 
Unit 1.3 Provide psychological advice and 
guidance to others. 
 
1.3a Assess the opportunities, need and context for giving 
psychological advice. 
I have had numerous opportunities to provide psychological advice and guidance to 
others. The organisation that I worked at is a provider of specialist residential and 
supported accommodation in London. There are several forms of resources, all of 
which are are specifically designed for adults with complex mental health needs. The 
organisation offers 24-hour support provided from a large pool of multi-disciplined 
staff including Mental Health Nurses, General Nurses, Psychologists, Social Work-
ers, and Health and Social Care trained staff. Back up is provided from the Local 
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Community Mental Health Teams (CMHTs), working closely with Forensic Consult-
ant Psychiatrists, Community Psychiatric Nurses and Forensic Social Workers.  
 
The resources can admit patients who may be subject to conditions of section 37/41 
of the Mental Health Act 1983 or individuals who are subject to conditions by the 
Ministry of Justice. Working within this role provided continuous opportunities need 
and context for providing psychological advice to others both in multi-disciplinary 
team meetings and during one-to-one sessions with clients. 
 
1.3b Provide psychological advice. 
Throughout my professional practice, I remained dedicated to developing a thera-
peutic relationship with patients based on trust, empathy and understanding as a 
precursor to providing psychological advice. I regularly undertook literature reviews 
on relevant areas to ensure that the advice provided was up-to-date and evidence 
based. A few months after commencing the training I was appointed the Student 
representative on the course, and within this capacity, I frequently provided advice 
to peers. I was asked to conduct talks on two induction sessions to prepare trainees 
for the rigours of the course while providing tips and input. As I progressed through 
the training, I was increasingly contacted by peers and new trainees to provide ad-
vice and input on their work. 
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1.3c Evaluate advice given. 
I utilised a number of methods to evaluate my performance and adapt the content of 
my advice accordingly. This included feedback forms from the various competencies 
and advice and input provided from clients, tutors, programme directors, colleagues, 
trainers, peers and most relevantly, both my academic and workplace supervisors. I 
believe that I developed a good rapport with all the professionals that I worked with 
and particularly with my academic supervisor. I was able to work collaboratively, but 
also responded well to feedback and constructive criticism in a reflective manner.  
 
In my role as Programme Representative I was awarded two accolades a “Lead 
Student Representative of the Year” award and the Department of Arts and Social 
Sciences overall “Programme Representative of the Year” award (Please refer to 
Practice Log).   
 
Unit 1.4 Provide feedback to clients. 
1.4a Evaluate feedback needs of clients. 
Throughout the training, I had unique opportunities to evaluate the feedback needs 
of a diverse range of clients. In my professional practice, I provided feedback to a 
range of individuals including service users, their key workers and family members 
as well as all the professionals involved in their case such psychiatrists, social 
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workers and Community Psychiatric Nurses as well as the board of directors of my 
organisation in monthly meetings. I evaluated and tailored the feedback according 
to the requirements and needs of each specific group of clients, and thus the feed-
back provided to clients can take a variety of forms. This can include verbal one to 
one sessions, group presentations, or specifically tailored reports. An example of 
this is provided by the referral feedback that I provide for clients following a referral 
assessment. The detailed referral feedback report that I provided to the referring 
agency (Refer to Practice Log) is very different to the funding report that I provide 
the local authority’s funding panel. It also varies considerably from the verbal feed-
back that I would provide to the client to inform them if their placement request had 
been accepted, and from the verbal feedback that I would provide to professionals 
at service users’ ward rounds.  
 
1.4b Prepare and structure feedback. 
I had several opportunities to prepare and structure feedback throughout the train-
ing. I carried out an annual business plan for the unit which incorporates a swot 
analysis, quality assurance monitoring and a service review process. A triangulation 
of the results provided me with a systemised structure to prepare and feedback at 
the annual directors meeting. During this meeting, feedback is reviewed; directors 
ask questions, provide input and contributions are welcomed. Goals for the following 
year’s business plan are then considered. My role as the supervisor of the staff team 
was another frequent opportunity to prepare and structure feedback for various pro-
fessionals.  
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1.4c Select methods of communicating feedback. 
Woking with individuals with severe and enduring conditions which have effected 
their cognitive functioning to varying degrees ensured that I remained mindful of 
selecting the most effective method of communicating feedback depending on the 
particular circumstances and client. I have also presented my thesis at the doctoral 
conference at City, University of London and findings from the research thesis were 
presented at the BPS Division of Health Psychology conference in September 2017.   
 
1.4d Present feedback to clients. 
During the training, I became increasingly comfortable with presenting feedback to 
clients in various formats and circumstances. Feedback for staff supervisions and 
appraisals included both verbal face-to-face feedback and a written report. Feedback 
for other professionals would involve a verbal assessment during a ward round or 
professionals meeting and a written report, whereas feedback for directors involved 
PowerPoint presentations accompanied by a detailed business plan for the following 
year. I frequently assessed and evaluated my feedback and was able to expand 
upon my communication skills, reflective listening and Socratic questioning. I looked 
to ensure concordance with the aims, requirements and needs of the client. While 
completing the Consultancy competence, clients were asked to carry out a variety 
of feedback forms. I also designed a pre and post programme questionnaire to eval-
uate the Consultancy. I subsequently presented this feedback during the final eval-
uation session with the primary client, which proved to be a useful method of high-
lighting the success of the programme. 
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Conclusion. 
The training has afforded me with the skills to develop and enhance myself as a 
professional applied psychologist. I felt that there was an element of uncertainty re-
garding the use of Health Psychology within a mental health project. Throughout my 
training, I have developed a clear expertise in applying Health Psychology in mental 
health settings, but I have also developed my skills further by working with other 
populations. For example, designing and delivering interventions to the general pub-
lic who wanted to quit smoking, delivering teaching and training to MSc Health Psy-
chology students and conducting training to other healthcare professionals. This has 
ensured that although there has been a main focus in my training, there has also 
been considerable variety. The training has highlighted the scope of Health Psychol-
ogy to be applied within a diverse range of settings. I feel extremely passionately 
about the numerous benefits of its real-world applications, expanding the boundaries 
of its implementation and the positive role that Health Psychology can play within 
mental health populations.   
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Introduction 
This case study will provide an account of the experience ensuing from being ap-
pointed as an external consultant by the London Hypnotherapy Studio, to deliver the 
particular task of providing Smoking Cessation support to their clients. It will chroni-
cle the request, negotiation, development, review, monitoring and evaluation of the 
consultancy contract utilising the relevant theoretical frameworks.   
Background 
The London Hypnotherapy Studio is a well-established, professional hypnotherapy 
service, which provides successful and safe treatment for a wide range of pur-
poses. These include: 
 
· Anxiety 
· Assertiveness 
· Chronic pain 
· Confidence 
· Depression 
· Phobias 
· Procrastination 
· Public speaking 
· Relationships 
· Self-esteem and maximising achievement & potential 
· Sleep problems 
· Side effects of medical treatments 
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· Stopping smoking 
· Stress 
· Unwanted habits 
· Weight loss 
Recent research suggests that hypnotherapy is becoming an increasingly popular 
therapy, used for a variety of purposes such as smoking cessation. Some of the 
reasons for this increase in popularity include, the absence of side effects and the 
enhancement of the feeling of self-control by simultaneously utilising many motiva-
tional dimensions specific to an individual (Bonshtein, Shaar, & Golan, 2005).  
 
Hypnotherapy is well-established as a therapeutic tool, utilised by medical profes-
sional groupings in a variety of countries for many years. Research suggests that it 
is an effective and powerful tool for changing patterns of behaviour when utilised as 
an adjunct to other therapies, including Cognitive Behavioural Therapy (CBT) (Kirsch 
& Lynn, 1995).  
 
3.1 Assessment of the request for consultancy.  
Identification of the client. 
In December 2014, it was brought to my attention by the founder of the London Hyp-
notherapy Studio (LHS), that the organization was facing adversity in meeting client 
demand for smoking cessation appointments. The organisation anticipated that it 
would struggle to meet the expected increase in new customers that traditionally 
followed the New Year Period, while maintaining sessions with regular long-term 
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clients. The organisation was, therefore, looking to employ an external consultant to 
help meet these challenges.  
 
Identify, prioritise and agree to expectations, needs and require-
ments of the client. 
I was invited to attend an initial meeting to provide input and discuss these concepts 
further. This constituted the first exploratory meeting of the consultancy. It is recom-
mended that this meeting is attended by the person who possesses the problem and 
requires help (Schein, 1999).  During this initial contact, I decided to adopt a multi-
dimensional approach to the consulting process, incorporating elements of the Pro-
cess consultation model, the Expert Model of Consultancy and the Doctor-Patient 
Model (Cope, 2010). At the meeting, the founder of the organisation explained that 
the organisation was featured on several promotional websites such as “Groupon” 
and “Wowcher” following which, there would be an anticipated spike in demand in 
hypnotherapy sessions. Traditionally, there was also increased demand for smoking 
cessation therapy just after the New Year. However, although the introductory rates 
would often prove extremely popular and attracted many new clients, it could poten-
tially lead to dissatisfaction amongst existing customers, who would have to pay con-
siderably more for their hypnotherapy sessions. The founder anecdotally explained 
that many existing clients would often seek to give up smoking as part of their New 
Year resolutions, and would thus pursue additional sessions for this, further to their 
regular hypnotherapy sessions. This would potentially result in twice as many ap-
pointment requests from many existing clients as well as the forecasted large in-
crease in new clients. We discussed how, although additional Hypnotherapists had 
been contracted to deal with the heightened demand, this did not address the fact 
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that new clients would be able to purchase up to three sessions at a lower rate than 
existing clients. 
 
Due to the agreement with the promotional websites, the advertised reduce rates 
could not be offered to existing clients for legal purposes. Therefore, LHS had de-
cided to contract a qualified smoking cessation consultant, so that existing clients 
could be offered smoking cessation sessions. As I am fully qualified with the National 
Centre for Smoking Cessation and Training (NCSCT), and experienced in smoking 
cessation, I was therefore requested during this meeting to fulfil this consultancy 
capacity within my role as a trainee Health Psychologist. 
 
The requirements of the organisation were:  
1) To work collaboratively to meet the demand for appointments during the first 
quarter of the year.  
2) To provide existing clients who agreed to take part in the programme with a 
tailored smoking cessation programme.  
Several follow-up meetings and telephone conversation took place, in order to gain 
a more in-depth understanding of the expectations regarding my involvement, to as-
sess whether I could help with the problem and to further explore the needs of the 
organisation. 
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Review psychological literature and other information sources.  
Prior to this initial meeting, I had spent time scrutinising the consulting process itself. 
Research has suggested that a clear conceptual and operational visualisation of 
consultation is required to identify the best suited operational models to facilitate the 
particular consultation process (Kurpius, Fuqua, & Rozecki, 1993). 
 
“Consultancy” has been defined as the process of consulting, with the objective of 
delivering sustainable value within a diverse range of client situations (Cope, 2010). 
Consultants are utilised to find solutions that improve the performance of the organ-
isation. Consultancy involves the process of creating value for organisations by im-
proving performance. This is achieved by providing objective advice and implement-
ing solutions. Literature reviews had revealed that the most significant predictor of 
an effective consultation outcome was to have an accurate problem description that 
both the consultant and consultee agree on (Bergan & Tombari, 1976; Fuqua & Gib-
son, 1980; Kratochwill & Bergan, 1990). I adopted a multi-dimensional approach to 
the consulting process incorporating elements of the Process consultation model, 
the Expert Model of Consultancy and the Doctor-Patient Model (Cope, 2010). Schein 
has suggested that the consultant should always start in process consultation mode. 
This was utilised during the initial assessment period, which had reflected a spirit of 
inquiry (Schein, 1990). After the opening stage, the model of the consultancy was 
very much in line with the Doctor-Patient model. The client was aware of the prob-
lems but was unsure of the best way for this to be addressed (Schein, 1999). Fol-
lowing the pre-entry stage this had expanded into the Expert Model. The client was 
able to communicate the problem accurately, had outlined their objectives, aims and 
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requirements. Therefore, as consultant, I had to ensure that I had the knowledge, 
skills and competencies to solve the problems and meet the client’s needs (Schein, 
1999; Cope, 2010). 
 
Assess the feasibility of the proposed consultancy. 
A planning and contracting meeting was scheduled in early January. In line with the 
multi-dimensional approach to the consulting process, this was arranged to clarify 
consultee needs and expectations (Kurpius et al., 1993). It was decided that the main 
challenges that the organisation faced were twofold; Firstly, its lack of capacity to 
meet the increased demand for appointments from clients during the first three 
months of the year and secondly, its inability to match the reduced rate for hypno-
therapy sessions that was on offer for new clients, to existing clients. 
 
Once the problem was defined, the next important step was to reach agreement on 
the ownership of the problem (Kurpius et al., 1993). It was agreed that an external 
consultant providing a course of smoking cessation based on traditional methods 
would allow the company to offer the sessions at a reduced rate. This was because 
it would not be hypnotherapy that would be provided. Therefore, to appease existing 
clients the organisation would offer the service free of charge as a gesture of thank-
ing them for their continued valued custom. Furthermore, it would allow the company 
to focus its resources on new clients during the first quarter of the year, while still 
retaining existing clients. It was agreed that the course of smoking cessation would 
be offered to a maximum of 8 clients and only those that chose to take part would 
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undergo the sessions. It was agreed that the clients would have to undertake the 
sessions between the months of January to March 2015. Finally, it was also estab-
lished that from an organisational viewpoint the company did not view the overall 
success of the consultancy in terms of the smoking cessation success rates, but 
rather in terms of the clients completing the smoking cessation programme. Follow-
ing these initial discussions, I considered the consultancy as feasible and set about 
developing a contract for the process (refer to Appendix).  
 
3.2 Plan Consultancy 
Determine aims, objectives, criteria, theoretical frameworks and 
scopes of interventions. 
During the initial meetings with the organisation regarding the feasibility of the con-
sultancy, the aims and objectives had already been well-established as previously 
outlined. At the pre-entry stage I utilised the Expert Model. The client was able to 
communicate the problem accurately, had outlined their objectives, aims and re-
quirements. I utilised the knowledge, skills and competencies to solve the problems 
and meet the client’s needs (Schein, 1999; Cope, 2010). 
 
It was agreed that the client required specific knowledge in the area of smoking ces-
sation. I would be able to provide this in my role as a trainee Health Psychologist, 
through my qualifications in smoking cessation (Full NCSCT Certification as a Smok-
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ing Cessation Practitioner) and my experience of conducting smoking cessation ses-
sions with a varied client group (NCSCT Mental Health Specialist). Therefore, the 
consultancy model that I ultimately utilised, was the purchase of information or expert 
model. This provided the theoretical framework for the consultancy, in which I took 
the role of the expert providing a service to the client (Schein, 1990). This model 
posits that the client accurately knows what the problem is, the client has accurately 
communicated the real problem, ensured that the consultant knows what is required 
and that the client is responsible for any consequences associated with the consul-
tancy. 
 
Produce implementation plans for the consultancy. 
Prior to finalising the contract for the consultancy, the consultancy plan and timetable 
were discussed with the organisation. At this stage it was unclear how many clients 
would take up the offer of sessions. Thus, it was agreed that it would be difficult to 
have precise timescale, but rather to develop a timeframe that could be regularly 
reviewed. A consultancy contract was then drawn up and signed by both parties 
(refer to Appendix) 
 
3.3 Establish, develop and maintain working relationship 
with clients. 
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This consultancy involved planned change through the delivering of an intervention. 
Experts in the field of consultation have stated that the intervention is to enter into 
an ongoing system of relationships, developed between or among people, groups or 
objects, for the purpose of helping them (Argyris, 1970).  
 
I had already established a close relationship with the founder of the London Hyp-
notherapy Studio prior to commencing the consultancy. My working relationship was 
via telephone conversations and face-to-face contact in the form of professional 
meetings. I felt that this allowed for the initial stages of the consultancy to develop 
well, as communication flowed naturally and expedited the process of developing 
relationships with others involved, whom I had not worked with previously. 
 
During the consultancy, I developed and maintained a close working relationship 
with office staff at the two locations where sessions took place. Namely West Hill 
consulting rooms in Highgate and Earls Court Health & Wellbeing Centre.  
 
Ultimately, the key relationship was with the LHS clients that engaged in the smoking 
cessation sessions. I attempted to develop a therapeutic relationship based on trust 
empathy and mutual understanding. I felt that this was a vital part of the therapeutic 
process and strived to continually monitor and evaluate this relationship, which was 
in due course measured through feedback forms. 
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3.4 Conduct Consultancy. 
Upon delivering the consultancy proposal, a final meeting was scheduled with the 
organisation (Refer to Appendix). I was informed that five of the eight clients con-
tacted had decided to take up the offer and had been encouraged to make contact 
to schedule sessions.  
 
There were numerous criteria taken into consideration while I searched for the inter-
vention that best suited the client group. A fundamental set of principles established 
for classifying interventions prior to their selection is to determine if the focus is on 
primary, secondary or tertiary helping (Kurpius et al., 1993). These have been re-
ferred to as the stages of prevention. Primary interventions are utilised to decrease 
the likelihood of the problem reoccurring in the future. Secondary interventions are 
employed to treat pre-existing problems and shorten their duration. Whereas when 
problem resolution is unlikely, tertiary interventions are utilised to prevent relapse or 
to comfort clients (Caplan, 1970).  
 
I opted to utilise the Standard treatment programme for one-to-one smoking cessa-
tion support as prescribed by the NHS Centre for Smoking Cessation and Training 
(NCSCT 2014). Knowledge skills and competencies from NCSCT training were also 
incorporated while carrying out the treatment programme that is considered the 
benchmark of quality smoking cessation support (NCSCT 2014). 
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Sessions took place between January the 12th and March the 27th 2015. The pro-
gramme consisted of two half hour and four one-hour sessions for each participant. 
The first session was referred to as the “pre-quit assessment”, during which the client 
was informed about the treatment programme and various assessments regarding 
readiness and ability to quit were carried out and a quit date set. The second session 
was arranged for as close to the quit date as possible. This session mainly involved 
confirming the readiness and ability to quit, discussing withdrawal symptoms, crav-
ing and urges and advice on changing routines. I attempted to arrange sections 3, 4 
and 5 at approximately weekly intervals. These sessions were very similar in content 
whereby I would check on the participant’s progress, discuss difficult situations ex-
perienced, as well addressing any potential high-risk situations in the coming week 
and coping methods. I did this by utilising Motivational Interviewing techniques. Mo-
tivational Interviewing has been described as a collaborative, goal-orientated style 
of communication, with particular attention to the language of change (Miller & 
Rollnick, 2013). It is geared towards the strengthening of personal motivation for and 
the commitment to a particular goal. This technique allows the practitioner to elicit 
and explore the individual’s reasons for change within an atmosphere of acceptance 
and compassion.  
 
During sessions, I attempted to utilise the four processes of Motivational Interviewing 
namely engaging, focusing, evoking and planning (Miller & Rollnick, 1991). I ensured 
that I used counselling skills such as open questioning, affirming, reflective listening 
and summarising in line with Motivational Interviewing procedures (Stott, Rollnick, 
Rees, & Pill, 1995). The final session took the form of a four-week follow-up appoint-
ment. However, the content of an individual face-to-face session varied greatly as 
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research has highlighted the importance of interaction with smokers being client led 
(NCSCT 2015). Therefore, I attempted to ensure the interaction was as client led as 
possible. Thus, some elements of the sessions were individualised based on the 
particular client. 
 
3.5 Monitor the Implementation of Consultancy. 
As outlined in the consultancy contract, it was established that monitoring of the 
consultancy would take the form of working party meetings. These meetings were 
arranged in advance and took place separate to the sessions. Regular meetings with 
the LHS took place throughout the duration of the treatment programme. I ensured 
that I reported the progress of the programme and kept the organisation informed of 
developments. Throughout the implementation of the consultancy I ensured that I 
adhered to The British Psychological Society & HPCP ethical requirements to uphold 
the highest standards of professionalism, promoting ethical behaviour, attitudes and 
judgements (BPS Code of ethics and Conduct, 2009). I ensured that I did not dis-
close what was discussed in sessions with the organisation, but rather reported over-
all progress of the programme. I endeavoured to adhere to HCPC Standards of con-
duct performance and ethics (2007) to make sure that I worked within ethical guide-
lines. I took the lead in keeping the LHS informed of scheduling issues and missed 
appointments. When issues arose, I reported this to the organisation to seek resolu-
tion. The delivery of the programme was relatively straightforward and issue free. 
The main challenge I faced involved scheduling issues and required a great deal of 
flexibility and time management on my part.  
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A further issue that arose was in relation the venues for the sessions. Participants 
were offered sessions in Highgate and Earls Court. Although I was aware that there 
was a charge to arrange sessions at each venue, I was not aware that one of the 
venues could provide consulting rooms on a half-hour basis whereas the other al-
ways charged an hourly rate. I did not factor this in when arranging the first half hour 
sessions but rectified this during the second round of half hour appointments. I also 
underestimated the travel time between different venues but factored this into sub-
sequent appointments. 
 
In line with good practice guidelines, additional measures were put in place to mon-
itor the process and outcomes of the consultancy. The client (LHS), was asked to 
complete an assessment at the end of the programme providing feedback on the 
whole consultancy process. The response of the feedback was largely positive (Re-
fer to Practice Log). Research has suggested that if a client feels confident it is an 
indication of the success of the consultancy (Earll & Bath, 2004).  
 
3.6 Evaluate the Impact of the consultancy. 
In accordance with the organisations policy, all participants were asked to complete 
out a variety of feedback forms provided by the LHS, following sessions. I also de-
signed a pre and post programme questionnaire to evaluate the Consultancy. Over-
all, all clients who took up the offer of smoking cessation completed the programme 
attending all scheduled appointments. The results of the programme indicated that 
at the four-week follow-up, four of the five clients had continued to remain abstinent 
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from cigarettes. Feedback from consumers who undertook the programme had been 
positive with some indicating that they had felt empowered by the process. Client 
empowerment has been highlighted as a useful method of evaluating the success of 
consultancy work (Bath et al., 2004). 
Outcomes of the aims and objectives of the consultancy process were monitored in 
various ways. As outlined the aims of the consultancy were as follows: 
1) To work collaboratively to reduce the demand for appointments during the 
first quarter of the year. 
2) To provide existing clients who agreed to take part with a tailored smoking 
cessation programme.  
The assessment that the primary client (LHS), was asked to complete at the end of 
the process was designed to assess client satisfaction, feedback from the secondary 
client group (participants), and whether the consultancy met with the aims and ob-
jectives (Cope, 2010). The LHS was asked to comment on both the positive and 
negative aspects of the consultancy, my conduct during the consultancy, what could 
have been handled differently etc. This monitored the processes and outcome from 
the client’s point of view. The feedback was predominantly positive (refer to Practice 
Log). The organisation has indicated that they would like to repeat the consultancy 
with me the following year, which is an indication of the projects success.  
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CONSULTING AGREEMENT 
THIS CONSULTING AGREEMENT (the "Agreement") dated this 5th day of Janu-
ary, 2015 
 
BETWEEN: 
 
London Hypnotherapy Studio of 2 Hogarth Road, Earls Court, England SW5 0PT 
 
 
(the "Client")  
- AND - 
 
Faisal Satti of City University London, Northampton Square, London, England EC1V 
0HB  
 
 
(the "Contractor").  
BACKGROUND: 
A. The Client is of the opinion that the Contractor has the necessary qualifications, ex-
perience and abilities to provide services to the Client. 
B. The Contractor is agreeable to providing such services to the Client on the terms 
and conditions set out in this Agreement. 
IN CONSIDERATION OF the matters described above and of the mutual benefits and 
obligations set forth in this Agreement, the receipt and sufficiency of which consideration 
is hereby acknowledged, the Client and the Contractor (individually the "Party" and col-
lectively the "Parties" to this Agreement) agree as follows:  
Services Provided  
1. The Client hereby agrees to engage the Contractor to provide the Client with ser-
vices (the "Services") consisting of:  
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o provide smoking cessation support. 
2. The Services will also include any other tasks which the Parties may agree on. The 
Contractor hereby agrees to provide such Services to the Client. 
Term of Agreement 
3. The term of this Agreement (the "Term") will begin on the date of this Agreement 
and will remain in full force and effect until the completion of the Services, subject 
to earlier termination as provided in this Agreement. The Term of this Agreement 
may be extended with the written consent of the Parties. 
4. In the event that either Party wishes to terminate this Agreement prior to the com-
pletion of the Services, that Party will be required to provide 10 days written notice 
to the other Party. 
Performance 
5. The Parties agree to do everything necessary to ensure that the terms of this Agree-
ment take effect. 
Currency 
6. Except as otherwise provided in this Agreement, all monetary amounts referred to 
in this Agreement are in GBP. 
Compensation 
7. For the services rendered by the Contractor as required by this Agreement, the Cli-
ent will provide compensation (the "Compensation") to the Contractor of a fixed 
amount of £0.00. 
8. The client will be invoiced after the work is complete. 
9. Invoices submitted by the Contractor to the Client are due within 30 days of re-
ceipt. 
10. The Compensation as stated in this Agreement does not include Value Added Tax. 
Any Value Added Tax required will be charged to the Client in addition to the 
Compensation. 
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11. The Contractor will be responsible for all income tax liabilities and National Insur-
ance or similar contributions relating to the Compensation and the Contractor will 
indemnify the Client in respect of any such payments required to be made by the 
Client. 
Reimbursement of Expenses 
12. The Contractor will be reimbursed from time to time for reasonable and necessary 
expenses incurred by the Contractor in connection with providing the Services un-
der this Agreement.  
13. All expenses must be pre-approved by the Client. 
Confidentiality 
14. Confidential information (the "Confidential Information") refers to any data or in-
formation relating to the business of the Client which would reasonably be consid-
ered to be proprietary to the Client including, but not limited to, accounting rec-
ords, business processes, and client records and that is not generally known in the 
industry of the Client and where the release of that Confidential Information could 
reasonably be expected to cause harm to the Client. 
15. The Contractor agrees that they will not disclose, divulge, reveal, report or use, for 
any purpose, any Confidential Information which the Contractor has obtained, ex-
cept as authorized by the Client or as required by law. The obligations of confiden-
tiality will apply during the term of this Agreement and will survive indefinitely 
upon termination of this Agreement. 
16. All written and oral information and material disclosed or provided by the Client to 
the Contractor under this Agreement is Confidential Information regardless of 
whether it was provided before or after the date of this Agreement or how it was 
provided to the Contractor. 
Ownership of Intellectual Property 
17. All intellectual property and related material (the "Intellectual Property") that is de-
veloped or produced under this Agreement, will be the property of the Contractor. 
The Client is granted a non-exclusive limited-use license of this Intellectual Prop-
erty.  
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18. Title, copyright, intellectual property rights and distribution rights of the Intellec-
tual Property remain exclusively with the Contractor.  
Return of Property 
19. Upon the expiry or termination of this Agreement, the Contractor will return to the 
Client any property, documentation, records, or Confidential Information which is 
the property of the Client. 
Capacity/Independent Contractor 
20. In providing the Services under this Agreement it is expressly agreed that the Con-
tractor is acting as an independent contractor and not as an employee. The Contrac-
tor and the Client acknowledge that this Agreement does not create a partnership or 
joint venture between them, and is exclusively a contract for service. 
Notice 
21. All notices, requests, demands or other communications required or permitted by 
the terms of this Agreement will be given in writing and delivered to the Parties of 
this Agreement as follows:  
a. London Hypnotherapy Studio 
2 Hogarth Road 
Earls Court, England, SW5 0PT 
b. Faisal Satti 
City University London, Northampton Square  
London, England, EC1V 0HB  
or to such other address as any Party may from time to time notify the other.  
Indemnification 
22. Except to the extent paid in settlement from any applicable insurance policies, and 
to the extent permitted by applicable law, each Party agrees to indemnify and hold 
harmless the other Party, and its respective directors, stockholders, affiliates, offic-
ers, agents, employees, and permitted successors and assigns against any and all 
claims, losses, damages, liabilities, penalties, punitive damages, expenses, reasona-
ble legal fees and costs of any kind or amount whatsoever, which result from or 
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arise out of any act or omission of the indemnifying party, its respective directors, 
stockholders, affiliates, officers, agents, employees, and permitted successors and 
assigns that occurs in connection with this Agreement. This indemnification will 
survive the termination of this Agreement. 
Additional Clauses 
23. Mr Satti has declared that the consultancy will count towards units of accreditation 
for a professional doctorate in Health Psychology and a corresponding account will 
be included in his portfolio.  
24. All individual clients details anonymised.  
Dispute Resolution 
25. In the event a dispute arises out of or in connection with this Agreement, the Par-
ties will attempt to resolve the dispute through friendly consultation. 
26. If the dispute is not resolved within a reasonable period then any or all outstanding 
issues may be submitted to mediation in accordance with any statutory rules of me-
diation. If mediation is unavailable or is not successful in resolving the entire dis-
pute, any outstanding issues will be submitted to final and binding arbitration in ac-
cordance with the laws of the Country of England. The arbitrator's award will be 
final, and judgment may be entered upon it by any court having jurisdiction within 
the Country of England. 
Modification of Agreement 
27. Any amendment or modification of this Agreement or additional obligation as-
sumed by either Party in connection with this Agreement will only be binding if 
evidenced in writing signed by each Party or an authorized representative of each 
Party. 
Time of the Essence 
28. Time is of the essence in this Agreement. No extension or variation of this Agree-
ment will operate as a waiver of this provision. 
Assignment 
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29. The Contractor will not voluntarily or by operation of law assign or otherwise 
transfer its obligations under this Agreement without the prior written consent of 
the Client. 
Entire Agreement 
30. It is agreed that there is no representation, warranty, collateral agreement or condi-
tion affecting this Agreement except as expressly provided in this Agreement. 
Enurement 
31. This Agreement will ensure to the benefit of and be binding on the Parties and their 
respective heirs, executors, administrators and permitted successors and assigns. 
Titles/Headings 
32. Headings are inserted for the convenience of the Parties only and are not to be con-
sidered when interpreting this Agreement. 
Gender 
33. Words in the singular mean and include the plural and vice versa. Words in the 
masculine mean and include the feminine and vice versa. 
Governing Law 
34. It is the intention of the Parties to this Agreement that this Agreement and the per-
formance under this Agreement, and all suits and special proceedings under this 
Agreement, be construed in accordance with and governed, to the exclusion of the 
law of any other forum, by the laws of the Country of England, without regard to 
the jurisdiction in which any action or special proceeding may be instituted. 
Severability 
35. In the event that any of the provisions of this Agreement are held to be invalid or 
unenforceable in whole or in part, all other provisions will nevertheless continue to 
be valid and enforceable with the invalid or unenforceable parts severed from the 
remainder of this Agreement. 
Waiver 
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36. The waiver by either Party of a breach, default, delay or omission of any of the 
provisions of this Agreement by the other Party will not be construed as a waiver 
of any subsequent breach of the same or other provisions. 
IN WITNESS WHEREOF the Parties have duly affixed their signatures under hand and 
seal on this 5th day of January, 2015.   
         
      London Hypnotherapy Studio (Client)  
         
      
Per:_________________________ 
(SEAL)  
         
 
 
   
         
      _____________________________  
      Faisal Satti (Contractor)  
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CORE UNIT 4 (DHP 065) 
 
TEACHING & TRAINING COMPETENCE 
 
CASE STUDY A 
 
Behaviour Change, Communication skills and 
Healthy Eating Workshops in mental health care 
settings  
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Introduction 
This case study will provide an account of my experience of designing and running, 
a series of workshops designed for mental health care professionals. The training 
workshops took place at a variety of registered mental health wards and residential 
services operating under the umbrella of the Prudential Independent Hospitals (PIH) 
UK Ltd in the North London area. The organisation employs a multi-disciplinary staff 
team including Registered Mental Health Nurses, Social Workers, Nurses, Occupa-
tional Therapists and Consultant Psychiatrists all of whom took part in the training. 
 
4.1 Plan and design training programmes that enable stu-
dents to learn about psychological knowledge, skills & 
practices. 
In December 2014, in my role as a trainee Health Psychologist within the PIH ser-
vice, I had designed and implemented a behaviour change intervention for service 
users regarding healthy eating. I gained invaluable insight into issues surrounding 
healthy eating within mental health settings. This was disseminated within the or-
ganisation and my supervisor was eager for me to share the knowledge that I had 
gained from studying behavioural change within Health Psychology with the rest of 
the staff team.  
 
4.1 Assess training needs. 
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Hauer and Quill (2011), recommend a comprehensive needs assessment to assess 
training needs. In line with this advice, I met with my workplace supervisor - a director 
at the organisation, to conduct a needs assessment of the required training pro-
gramme. During the preparation for the behaviour change competency, it became 
apparent that a great deal of research has highlighted the link between individuals 
treated with anti-psychotic medication and raised obesity levels (Oliver, Lubman, & 
Fraser, 2007).  PIH is registered to provide support for adults with mental health 
needs, specialising in individuals with complex severe and enduring mental health 
issues. It was identified that the organisation attempts to optimise the mental health 
and physical well-being of patients. A major challenge to the physical health of ser-
vice users is excessive body weight. This is due to the fact currently the foremost 
treatment of schizophrenia is anti-psychotic medication, yet a main side effect of 
anti-psychotic medication is weight gain (Allison et al., 2009) and associated exces-
sive weight gain is purported to expose those taking anti-psychotic medication to 
serious health risks (Acil, Dogan, & Dogan, 2008). 
 
It was agreed that raising awareness of the benefits of healthy eating, focusing spe-
cifically on aiding service users within a mental health setting, would be of great use 
to staff members within the organisation. We went on to discuss learning objectives 
as recommended by Heron (1999). It was felt that equipping employees with the 
required skills, knowledge and confidence to initiate discussions and create support 
plans for service users relating to healthy eating within a mental health setting would 
be key. This correlates with the taxonomy of learning objectives (Bloom, Engelhart, 
Furst, Hill, & Krathwohl, 1956). Three realms of educational activity were identified 
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by Bloom et al. (1956). Namely; Cognitive - relating to mental skills (knowledge), 
Affective - relating to growth, emotional areas, or feelings (attitude) and Psychomo-
tor- relating to manual and physical tasks (skills). However, Bloom’s taxonomy had 
faced criticisms in that it did not contain a systematic rationale of construction and 
was therefore not a fully structured taxonomy (Morshead, 1965). This was subse-
quently addressed, and the taxonomy was revised to reflect a more active form of 
thinking (Anderson, Krathwohl & Bloom, 2001). This training would attempt to affect 
the cognitive and affective domains with trainees acquiring applied knowledge of 
healthy eating, with attitudes towards unhealthy eating being targeted.   
 
Once the needs assessment and learning objectives of the training workshops was 
established my supervisor encouraged me to design and structure the training pro-
gramme for implementation in the summer of 2015. 
 
4.1b Identify training programme structures and content. 
While tailoring the programme structure and content, I attempted to ensure that the 
teaching methods effectively met the learning outcomes (Race & Brown, 2004).  I 
designed the training based on my existing knowledge and experience of applying 
Health Psychology principles within a mental health setting and spent several weeks 
adapting the interventions developed as part of the behaviour change competency. 
While designing the training, I discussed source material with work colleagues and 
my workplace supervisor. It soon became apparent that while providing staff mem-
bers with information surrounding healthy eating was essential, another paramount 
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requirement of the training, would be illustrating how they could raise and discuss 
these issues with service users. 
 
Service users within mental health settings often have little or no insight into their 
illness. They often do not consent to treatment having been sectioned and subject 
to conditions of Section 37/41 of the 1983 Mental Health Act, resulting in a lack of 
engagement and trust towards health care professionals (Andreasen & Black, 2001). 
Thus, developing a therapeutic relationship with service users based on trust empa-
thy and mutual understanding is a key component of the of the treatment process. 
Instructing staff on how to cultivate and practice the required communication skills 
to develop therapeutic discussions is essential. In my experience, Motivational Inter-
viewing (Miller & Rollnick, 2002) had been an exceedingly useful technique in help-
ing people change health behaviour, particularly in mental health settings. I there-
fore, decided that the training should include an introduction to the principles and 
spirit of Motivational Interviewing.  
 
Motivational Interviewing is an evidenced based, client centred style of counselling. 
It aims to enhance intrinsic motivation to change, by exploring and increasing am-
bivalence (Miller & Rollnick, 2002). It is a relatively new therapy that has been utilised 
in addressing a range of behaviours and mental health problems (Miller, Rollnick, & 
Butler, 2008). Motivational interviewing evolved from the client centred counselling 
approach developed by Carl Rogers (1951). This is very much in line with the organ-
isations stated outlook and appeared to be an ideal fit for the organisations training 
programme. I therefore, structured the training programme to contain information on 
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amalgamating the themes of healthy eating, behaviour change, communication and 
motivational interviewing into one package. 
 
4.1c Select training methods and approaches. 
Further discussion with my workplace supervisor took place in relation to the specif-
ics of the training, including whether it would be voluntary or mandatory, where it 
would take place, how long it would last for, whether it would be paid or unpaid (for 
the attendants) and which staff members would take part in the training. I decided to 
develop a learner profile enabling me to focus on the most effective training methods 
and approaches for the particular trainee group (Verderber, Jiang, Hughes, & Xiao, 
2014). Initially, it was decided that the training would be voluntary and all members 
of the multi-disciplinary staff team could be invited to take part. However, it was an-
ticipated that the staff members most eager to take part and supplement their exist-
ing training would include the support workers, occupational therapists and keywork-
ers directly involved in behaviour change interventions with service users.  
 
Therefore, I initially decided to utilise a constructivist teaching approach (Hsiu-Mei 
Huang, 2002) as this allowed me to acknowledge staff members existing knowledge 
and experience. Specialist research has suggested that it is important to recognise 
the staff members’ knowledge as adults and professionals (Merriam, Caffarella, & 
Baumgartner, 2007). Trainees would receive further erudition in addition to their pre-
existing knowledge and skills, thus supplementing knowledge beyond its original lev-
els. This process has been described as a form of scaffolding (Wood, Bruner, & 
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Ross, 1976). My aim was to be a facilitator rather than a transmitter of knowledge 
(Kaufman, 2003).  
 
However, upon further research into learning styles I decided to use a variety of 
teaching techniques to maximise learning including the didactic and experiential 
methods of teaching. This was because evidence has suggested that individuals 
have varying learner styles (Honey & Mumford, 2001). This includes “activists” who 
learn by taking part in activity; the “reflector” who learn by taking time to reflect on 
the information provided and those who like to “engage” with what they are learning 
so that internalisation and transformation can take place (Fry, Ketteridge, & Marshall, 
1993). 
 
4.1d Produce training materials. 
Professionals who work in mental health frequently have to contend with challenging 
illnesses, events and extreme circumstances often in seditious situations and envi-
ronments. This can occasionally lead to a rather insular approach and dismissive 
stance towards other health care professionals and their input. I, therefore, had to 
ensure that the training and associated materials were produced in a way that this 
particular set of trainees would engage with and absorb. I decided to incorporate 
skill-based activities, such as role plays and work based, real-life group scenario 
exercises. This promoted learning through activities. It also provided trainees with a 
chance to reflect and discuss things within a smaller section before presenting their 
responses to the whole group. This was in line with Honey and Mumford’s (2001) 
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and Winefield’s et al. (2003) emphasis on the importance of allowing individuals time 
to reflect on their work as well as Jaques (2003) stressing the importance of group 
discussion as an important tool for developing proactive communications.   
 
4.1e Use appropriate media to deliver training materials. 
I designed the training utilising various visual aids such as a PowerPoint presenta-
tion, flip chart and handouts. I also used a pack of “food cards” designed by the 
British Heart Foundation (2013). This provided 56 cards of everyday foods, contain-
ing fat, salt and sugar content and designed to improve understanding of healthy 
eating. This was used to enhance audience engagement and visual comprehension 
(Race, 2005).  
 
4.2 Deliver such training programmes.  
Once the training programme was designed I informed my workplace supervisor to 
schedule the training. However, this process proved more polemic than anticipated. 
My supervisor requested that I plan the training on a day suited to myself and contact 
staff from several of the wards to organise participation. This expanded into an ex-
tremely time-consuming process as staff members began providing their availability 
and asking numerous questions about payments for training attendance. I, therefore, 
requested the organisation’s Events Coordinator to schedule and arrange partici-
pants for the training. I provided several dates that I could implement the training on 
and asked that a minimum of ten trainees would be required for the group exercises 
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and role-plays to be worthwhile. Once the Events Coordinator took on the task of 
scheduling and arranging attendance, it allowed me to focus purely on the imple-
mentation of the training. 
 
4.2a Implement training methods. 
To ensure that I was fully prepared and able to respond appropriately to trainees, I 
read a number of articles and books on teaching small groups. Research has sug-
gested that the physical environment, including room layout has a significant impact 
on participation, interaction and learning (Jaques, 2003).  On the day of the training 
I arrived early to ensure that all training materials, the PowerPoint presentation and 
refreshments were available, I arranged catering and set up the room so that seating 
was arranged in a semi-circular formation with the screen easily visible to encourage 
audience participation. 
 
Upon the arrival of trainees, I asked them to sign in, outlined learning outcomes and 
the agenda for the day and made them feel welcome to ensure that they were 
equipped and prepared for the day ahead (Race & Brown, 2004). To prompt and 
encourage discussion, I utilised Socratic questioning (Miller & Rollnick, 2002) to dis-
cuss staff member’s experiences and to guide the learning process. 
  
4.2b Facilitate learning. 
 274 
The first training session was attended by 16 individuals including my workplace 
supervisor and a director at the organisation. To facilitate learning, I utilised didactic, 
interactive and experiential teaching methods via the PowerPoint presentation, food 
cards and group reflection exercises respectively. However, the style that I mainly 
used to deliver the training was that of the democratic facilitator (Exley & Dennick, 
2004). This allowed me to work collaboratively with trainees in setting aims, objec-
tives and activities. I began the training by asking questions and then conducted a 
quiz utilising the food cards, moving on to small group exercises. This led to imme-
diate learning involvement (Silberman, 2004), providing trainees with an opportunity 
to voice their opinions (Killen, 2007). This resulted in staff members opening up and 
outlining their experience of behaviour change within mental health settings. I went 
on to describe reflective listening techniques (Miller & Rollnick, 2002), to illustrate 
ways to improve communication and engagement levels within mental health set-
tings. While facilitating the training, I endeavoured to check understanding, offer 
clear instructions and provide positive feedback to the audience to enhance trainee 
participation in the sessions.   
 
4.3 Plan and implement assessment procedures for such 
training programmes  
4.3a Identify assessment methods 
4.3ba Select assessment regimes 
4.3c Establish the availability of resources for assessment proce-
dures 
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4.3d Produce assessment materials 
4.3e Ensure fair appreciation of assessment methods 
4.3f Produce relevant records of progress and outcomes 
 
The organisation did not want formal assessment for the workshops as it was felt 
that this might hinder attendance. Therefore, training was not assessed. Instead, I 
designed a feedback form to evaluate participant ratings (refer to practice log). I 
gathered feedback from all participants at the end of each training session. I also 
actively encouraged participants to provide verbal feedback where appropriate and 
I received verbal feedback from my supervisor. After the initial training, I reflected on 
these assessments and decided to adapt and modify a new feedback form to take 
into account learning outcomes through confidence ratings (Winefield et al., 2003).     
 
Unit 4.4 Evaluate such training programmes. 
My workplace supervisor and a director of the organisation were both present at the 
initial training session, following which they stated their pleasure of its content and 
how relatable and pertinent it was for staff members. They felt that it provided real 
world context of the benefits of the application of Health Psychology within mental 
health settings. They requested that I continue to roll out the training and that it would 
be made mandatory for staff members. This resulted in me carrying out a total of 9 
sessions for 137 employees. 
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4.4a Evaluate training programme outcomes. 
I utilised three methods of evaluation throughout the training programme. Evaluation 
forms completed by trainees, an observers report (please refer to practice log) com-
pleted by my workplace supervisor and self-reflection following each training ses-
sion. Trainees were asked to complete a feedback questionnaire at the end of each 
session. This involved ten questions in total. Six questions where trainees were re-
quired to rate various aspects on a Likert scale and four open-ended questions 
where they were requested to provide more in-depth responses. This was because 
the original questionnaire (please refer to practice log) which was all open-ended 
had a poor response rate.  
 
At the end of each session, I would reflect on the programme and analyse the re-
sponse of the feedback form. I would take suggestions on board and adapted the 
training accordingly. This included arranging for warm beverages to be made avail-
able, including recipes from various cultural cuisines while specifying religious re-
quirements and repositioning seating in a way to minimise noise from passing trains. 
On the whole feedback was extremely positive.  
 
4.4b Identify factors contributing to training programme outcomes.  
The qualitative comments on the feedback form were instrumental in informing train-
ing programme outcomes. Questions included suggested changes and areas of im-
provement. Several of the respondents mentioned having to go through such a vast 
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amount of information in the allocated time. On reviewing these comments, I dis-
cussed how to better meet the learning outcomes with my workplace supervisor and 
as result workshop times were extended so that training delivery could be adapted.  
 
4.4c Identify improvements for the design and delivery of training 
for implementation in future programmes. 
I was in the fortunate position to constantly be able to review and adapt the training 
programme, as I had the opportunity to amend things on eight occasions. I feel that 
my skills were progressively developing and the training was greatly enhanced with 
each session, particularly in terms of time-keeping, vocal delivery and confidence. 
  
One of the ways that training could potentially have been improved may have been 
by providing a handout incorporating the whole training to each participant. As the 
training involved 142 different slides, work based practicalities prevented me from 
being able to do so. Also, responses on the feedback form suggested that the train-
ing may have benefited from being prolonged into a two-day session. Once again, 
work based issues around arranging staff cover prevented the organisation from al-
lowing me to do so.  
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School of Social Sciences  
Doctorate of Health Psychology 
 
Form DHP07 
 
WORKPLACE CONTACT REPORT 
 SECTION A: To be completed by the trainee  
Name of Trainee 
 
Faisal Satti 
Name of Workplace Contact 
 
John Kearns 
 
Nature of Work and Competence Assessed 
 
Staff Training Workshops  
(Teaching and Training competence) 
Date of the workshop: 15.06.2015 
Time of training: 9.30-16.30 (7 hours) 
Attendees: 16 Mental Healthcare Professionals.  
 
SECTION B: To be completed by the Workplace Contact 
Views on the Trainee’s Performance on above piece of work (write comments below 
or email a separate report) 
 
I attended the first training workshop that Mr Faisal Satti delivered. The workshop was attended by fifteen 
other professionals working in mental health. Mr Satti outlined the aims and objectives that he would cover 
and explained that the workshop would be divided into four sections with scheduled breaks. What immediately 
struck me was his ability to put everyone at ease ensuring all in attendance were comfortable yet attentive.  
The amount of material that Mr Satti covered was vast yet he explained things well. He would discuss theories 
but would then provide real world examples that other professionals could relate to. The session was extremely 
interactive with group work. Initially some of the attendees appeared reserved but following a cue card quiz 
early in the healthy eating section all attendees became more active in discussions.  
Mr Satti used a power point presentation but also used frequent activities such as role plays, quizzes, video 
clips and a cue card games which ensured that the session was fun and diverse.  The trainees had the oppor-
tunity to ask questions and discuss their experiences.  
 
I was extremely impressed with the standard of the training session particularly as it was the first workshop. 
The feedback I received from others was also extremely positive. Due to the high standard of this session Mr 
Satti was requested to roll out the training he had designed to all staff members employed by the company. 
He was later asked if he could incorporate Recovery Model training into the workshops which was agreed to 
do. Overall the training was extremely successful and all feedback was positive.    
Please return this form to City University by one of the following means: 
Post:  Department of Psychology. City University, Northampton Square, London EC1V 
0HB 
Email: Renata Pires, Email;  
Declaration  
I verify that the above named trainee has undertaken the above mentioned piece of work. I 
am of the opinion that it has been completed to a satisfactory professional standard. 
 
Signature: _______________________________________ Date:  
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CORE UNIT 4  
DHP 064 
 
TEACHING & TRAINING COMPETENCE 
 
CASE STUDY B 
 
MSc Lecture:  Social and Psychological Conse-
quences of Alopecia  
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Introduction 
This case study will provide an account of designing and conducting a lecture on the 
Masters programme at City, University of London. The three hour lecture took place 
on the 17th of March 2016 and was attended by fourteen MSc Health Psychology 
students.   
 
4.1 Plan and design training programmes that enable stu-
dents to learn about psychological knowledge, skills & 
practices. 
During a supervision session in November 2014, I discussed the possibility of con-
ducting a lecture on the master’s programme at City, University of London with my 
Academic Supervisor. We deliberated on the training needs of the students and my 
area of expertise. Potential topics were reviewed, and it was agreed that I would 
conduct a lecture the following academic year. On June the 22nd 2015, my Supervi-
sor contacted me to ascertain if I would prefer to conduct a lecture on the psycho-
logical impact of Alopecia (the area of my systematic review) or health behaviour 
interventions in mental health settings (the area of my work practice). As I was eager 
to maximise my lecturing experience, I requested to conduct a lecture on both topics. 
However, for the purposes of this case study I will expand upon the lecture I deliv-
ered on the psychological impact of Alopecia. 
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The first step when designing a lecture or training is to assess the students training 
needs (Hauer & Quill, 2011). I therefore, liaised with the Module coordinator to con-
duct a needs assessment of the required lecture and deliberated on the content of 
the course programme, the levels of student’s knowledge, the content of the module, 
module aims, objectives and learning outcomes. I also obtained a description of the 
module, a list of sessions and a session’s overview.  
At Masters Level (level 7), students are Stage 1 trainee Health Psychologists, taught 
to use psychological principles to promote changes in people’s behaviour and their 
associated beliefs about health and illness. According to Bloom’s updated taxonomy 
(2001), at this level students should be able to demonstrate synthesis and naturali-
sation. Furthermore, Heron (1999) recommends setting the learning objectives early 
and it was agreed that raising awareness of the social and psychological impact of 
Autoimmune Alopecia, would be of use in exploring concepts of coping with a chronic 
illness amongst the students. It was therefore decided that for the detail required at 
Masters Level, it was appropriate for the lecture to comprise of four main learning 
outcomes, as including more would be beyond the scope of a single three-hour lec-
ture. 
 
While designing the lecture, I was aware of the need for learning outcomes to be 
effectively addressed through the teaching methods (Brown & Race, 1995). I had 
conducted a great deal of research on the subject matter having recently completed 
an extensive systematic review and I had tabulated the research evidence. However, 
much of this information was written in an academic style and I wanted to ensure 
that the lecture was dynamic and informative.  
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Knowing about MSc students’ academic backgrounds and topics covered in the 
module, I was better able to choose the most effective training methods and ap-
proaches for the lecture (Verderber, Jiang, Hughes, & Xiao, 2014). Alopecia is not a 
common skin disorder. Therefore, I ruled out employing a constructivist teaching ap-
proach (Huang, 2002), as I could not assume that students would have previous 
knowledge and experience in this area. For this lecture, I aimed to cover materials 
that would supplement students’ knowledge (Kaufman, 2003), while acknowledging 
their current experience and expertise (Merriam, Caffarella, & Baumgartner, 2007).  
 
The first draft of the lecture that I designed, was largely based on the research I had 
recently conducted and contained lots of statistical data. However, my recent expe-
rience of conducting training and a lecture on the course had made me aware that 
there are various learner styles (Honey & Mumford, 2001). Upon further research 
into learning styles, I decided to utilise assorted teaching techniques to optimise 
learning. I went on to develop a visual quiz, cue games looking at celebrities and 
animals with Alopecia, video diaries of patients and various real-life case studies, to 
promote emotive discussion. This was to stimulate “activist”, “reflector” and “en-
gager” learning styles (Fry, Ketteridge, & Marshall, 1993).  
 
4.2 Deliver such training programmes.  
I arrived at the lecture room early to ensure there was sufficient time to set up and 
test material as recommended by Race and Brown (2004). This proved extremely 
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useful, as I discovered that the fonts used on the headings of the PowerPoint presen-
tation were not available on the lecture room computer. However, I had enough time 
to rectify this. Seating was arranged in a semi-circular formation, promoting an envi-
ronment for questions and answers and to encourage discussion (Jaques, 2003).  
 
To facilitate learning, I utilised didactic, interactive and experiential teaching methods 
via the PowerPoint presentation. After explaining the types of Alopecia, I carried out 
a celebrity quiz to familiarise students with the various forms of Alopecia, followed 
by a discussion on animals with Alopecia to draw parallels with humans. This pro-
moted immediate learning involvement (Silberman, 2004). I then moved on to look-
ing at data from Alopecia studies, video diaries of patients, case studies and group 
reflection exercises providing students with an opportunity to voice their opinions 
(Killen, 2007). This resulted in students opening up and outlining their thoughts and 
feelings on the psychological and social impact of chronic illness 
 
From my previous experience in delivering teaching and training, I know it is best to 
keep my slides simple and talk around them, this also makes the arguments and 
learning points flow more easily (Winefield, 2004). My slides were not overloaded 
with text and care was taken not to go below font size 20 (Farrow, 2003). 
 
4.3 Plan and implement assessment procedures for such 
training programmes.    
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As the lecture was part of a structured MSc programme, formal procedures for as-
sessment had been established prior to the lecture. Once the needs assessment 
and learning objectives of the lecture were established my supervisor encouraged 
me to design the lecture to fit in with the unit structure. As part of the lecture, students 
were arranged into “teams” and asked to take part in a visual quiz (refer to practice 
log). This was to provide students with encouragement, feedback and gave them the 
opportunity to reflect and discuss things within a smaller section, before presenting 
their responses to the whole group (Honey & Mumford, 2001). As group discussion 
is considered a key tool in developing proactive communications (Jaques, 2003).   
 
Unit 4.4 Evaluate such training programmes. 
An evaluation form (refer to practice log) was designed to assess how successful 
the lecture had been in meeting the aims and objectives. The evaluation form was 
provided to all fourteen students who attended. Five questions were made up of a 
five point Likert scale assessing improvements in knowledge and four open ended 
questions allowed students to record their views, comments and advice on the lec-
ture. 100% of students strongly agreed with the statement that the training was “well-
prepared and presented”. 71% of participants strongly agreed that “the aims and 
objectives were well set out”. 71% strongly agreed that “the various sections of the 
lecture made sense to me: I understand their purpose: 92% “felt encouraged to par-
ticipate and respond to others” and 92% felt “the instructor treated the trainees with 
respect”. I was extremely pleased with the overwhelmingly positive feedback pro-
vided by the students in the open ended questions (refer to appendix). Comments 
included “clear, good presentation and funny”, “encouraging everyone to take part 
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with various activities to keep students attention”, “funny and great speaker”. To the 
question; “What suggestions would you give to improve the instructor’s teaching” 
one student commented “Nothing, it was a lovely lecture”. However, two respondents 
suggested that my voice was low at points, while one suggested “slow done a bit on 
the more technical slides”. Although I checked that everyone could hear me at the 
start of the lecture, in the future I will endeavour to maintain the volume and tone of 
my voice consistently and talk louder if competing with external noises. I will also 
look to improve the pacing of more technical parts of lectures by double checking 
that everyone has understood things and delivering information at a slower pace. 
 
When preparing the lecture, I felt nervous about the prospect of being asked tech-
nical questions, but also excited by the opportunity of developing what I hoped would 
be an informative but fun lecture, and disseminating some of the findings and 
knowledge that I had gained during the development of my systematic review on 
Alopecia. While carrying out the lecture, I felt surprisingly relaxed and comfortable. I 
felt that I was quickly able to establish a good rapport with the students by involving 
them in a visual task and engaging in anecdotes and humorous discourse regarding 
celebrities and animals. I believe that this helped set the tone for the lecture, with 
everyone engaging well and willing to take part in the activities. I enjoyed designing, 
planning and delivery the lecture immensely, it strengthened my interest in pedagogy 
and I subsequently enrolled on a course in academic practice to gain formal qualifi-
cation as an Associate Fellow of the Higher Education Authority. If I were to deliver 
the session again, I would ensure that there was more time to discuss the final sec-
tion where students were encouraged to develop interventions for their fictional cli-
ent, as some of the suggestions put forward were excellent while others may have 
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benefitted from more detailed deliberation regarding their planned intervention. My 
Academic Supervisor also attended the lecture and provided a formal evaluation re-
port (refer to appendix).  
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Module: Behavioural Medicine, PSM407 
Title of the session: Coping with alopecia 
Date of the lecture: 17.03.2016 
Time of training: 9.00-12.00 (3 hours) 
Attendees: 14 MSc health psychology students  
Observer: Dr Angeliki Bogosian 
 
Supervisor’s feedback: 
Faisal delivered a very engaging and informative lecture on psychosocial factors associated with 
alopecia. The session was very interactive, and Faisal was assessing students’ understanding regu-
larly. In the beginning, Faisal set clear objectives of the lecture and gave definitions of different types 
of alopecia, followed by a quiz. The overview of the psychological context in alopecia was concise 
and accurate. Faisal was able to talk around his slides well, he is clearly very knowledgeable, and he 
answered students’ questions well. His arguments were based on research evidence with references 
given in the slides. He used examples that draw the attention of the students and made his points 
clear, e.g. using examples of famous people or animals with alopecia or other everyday examples 
that made his key points memorable. He was professional and friendly during the session and man-
aged to put everyone at ease. He used a mix of different teaching modalities, e.g. slides, group work, 
video clips, perspective taking to facilitate learning. Activities he had put in place (e.g. case studies, 
quizzes etc) proved to be very popular with students. Students got the chance to engage with the 
material and understand the psychological factors involved in managing alopecia. The slides were 
very well put together with lots of images that complemented the content nicely. Overall, I was very 
impressed by the high standards of this lecture. At the Student Staff Liaison Meeting at the end of 
the year, students commented on how much they liked Faisal’s lectures and they were happy to see 
him again after the lecture he delivered in the previous semester.  
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CORE UNIT 5 
DHP 065 
 
Conduct psychological interventions within 
a healthcare context to change behaviour of 
individuals or groups. 
 
CASE STUDY 
 
 
Implementing a Healthy Eating Behaviour Change 
Intervention for Individuals with Schizophrenia 
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The following case study outlines a behaviour change intervention targeting 
healthy eating within several mental health units operating under the umbrella of a 
Care Quality Commission (CQC) registered organisation. The organisation 
operates a number of registered mental health units and other residential services 
in the North London area.  
 
Background 
Antipsychotic medication is the most common form of treatment for schizophrenia, 
evidence has highlighted the efficacy of anti-psychotic medication in treating the 
symptoms of psychosis and bringing about improvements in the course and outcome 
of the condition (Zygmunt, Olfson, Boyer, & Mechanic 2002). However, anti-psy-
chotic medications have also been associated with a range of side effects, with 
around 75% of individuals prescribed anti-psychotic medication experiencing some 
form of side effects (Coffey, 1999). The nature, severity and extent of these side 
effects vary widely among individuals, but weight gain remains a frequent concern 
(Kurzthaler & Fleischhacker, 2001). Individuals gain an average of 13lbs in the first 
two months of taking antipsychotic medication and this continues over the first year. 
In fact, 29% of males and 60% of females with severe and enduring mental health 
issues are obese, compared with 17.7% of men and 28.5% of women overall (Dau-
mit et al., 2003). This has been associated with serious health risks, as when com-
pared to the general population, individuals diagnosed with schizophrenia are twice 
as likely to develop diabetes (Bailey, Thorpe & Smith, 2013), three times more likely 
to develop hypertension (Rethink Mental Illness, 2013), three times more likely to 
die from coronary heart disease (Osborn, 2007), ten times more likely to die from 
respiratory disease (Joukamaa et al. 2001), four times more likely to die prematurely 
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(Newman & Bland, 1991), and on average die twenty years earlier than the general 
population (Brown, Kim, Mitchell & Inskip, 2010). Public Health England have re-
cently reported a systematic review of evidence of obesity in mental health units. A 
key finding of this review was that obesity is extremely prevalent amongst in-patients 
with levels at around 80% (Public Health England, 2017). Research indicates that 
this is linked to poor diet and a lack of active lifestyle within these settings (Rough, 
2014). Recent government policy has stressed the need for interventions to address 
these issues in line with the National Institute for Health and Clinical Excellence 
(NICE) guidelines (Stegenga, Haines, Jones, & Wilding, 2014). This intervention 
therefore involved working alongside mental health professionals to deliver a healthy 
eating intervention for individuals diagnosed with schizophrenia. 
 
 
Addressing behaviour change around health eating remains an imperative objective, 
as individuals suffering from schizophrenia often have little or no insight into their 
illness (Appelbaum & Grisso, 1995). They may not consent to treatment, and this 
can lead to sectioning under the Mental Health Act (1983), resulting in a lack of en-
gagement and trust towards health care professionals, due to this, their overall well-
being and physical health can often be overlooked (Acil et al., 2008). 
 
Intervention component selection and theoretical underpinnings  
As a consequence of this unmet need Senior Management within the intervention 
setting made the decision to adapt the NHS Health Trainer Scheme (Michie et al., 
2008) in order to improve healthy eating in this client group. Health Trainers are 
recruited from the local community and their role includes supporting individuals from 
“hard to reach groups” to change their behaviour as they are marginalized from 
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health care services (Department of Health, 2008). The goal of Health Trainers is to 
provide equitable healthcare to these groups. The Health Trainer Scheme has been 
successfully implementing since 2004 (Michie et al., 2008), the organisation that I 
work for were eager to pioneer the application of this scheme, as it had not been 
implemented or evaluated within a mental health setting before. In order to deliver 
the intervention effectively I spent four days shadowing Health Trainers from West-
way Trust’s Westminster, Kensington & Chelsea boroughs. This expertise was ex-
tremely valuable when I attempted to deliver the intervention within my workplace.  
 
Health psychology theory should be utilised to encourage mental health inpatients 
to improve their health and well-being (Wearden, 2014). The support that Health 
Trainers provide, is based on behaviour change techniques grounded in Health Psy-
chology theory (Michie, et al 2008). Michie et al (2008) researched the evidence 
pertaining to the most effective techniques that help people change their behaviour, 
providing an essential framework of techniques to include in the intervention:   
 
  Deciding to change (Rollnick et al., 1999) 
  Goal setting (Carver and Scheier, 1998) 
  Action planning (Sniehotta, Scholz & Schwarzer, 2005) 
  Contracts (Kanfer & Goldstein, 1991) 
  Self-monitoring (Bandura, 1998) 
  Getting support (Wing, & Jeffrey,1999) 
  Increasing confidence to change (self-efficacy) (Schwarzer & Fuchs, 1995).  
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  Rewards (Skinner, 1969) 
  Setbacks (Prochaska, Norcross & Diclemente, 1994). 
  Realistic outcome expectancies (Rothman, 2000) 
  Coping with difficult situations and ‘if-ten’ plans (Marlatt, 1996; Gollwitzer, 
1999; Webb & Sheeran, 2006).  
  Building habits (Aarts, Paulussen & Schaalma, 1997).  
 
The NHS Health Trainer model also integrates motivational interviewing (Miller & 
Rollnick, 1991) techniques, as a means to assess clients and encouraging people 
to change. Motivational interviewing is an evidence based, client-centred form of 
counselling initially developed to change behaviour in relation to alcohol addiction 
and substance misuse (Rollnick, Mason & Butler, 1999). Motivational interviewing 
denotes the way in which practitioners engage in conversations with their clients 
(Miller & Rollnick, 2002), by providing an awareness of the importance of working 
with the individual rather than imposing ideas and beliefs upon them. Systematic 
reviews, across a range of health domains, have highlighted the effectiveness of 
motivational interviewing in helping to facilitate positive behaviour change. For 
example, Rubak et al. (2005) found that motivational interviewing is more effective 
than traditional advice giving and psycho-education when targeting behaviour 
change in a wide range of long-term conditions, including psychiatric disorders, 
addiction and obesity. As the manager of a community based mental health ward I 
had over 8 years of experience in applying motivational interviewing techniques. 
This experience was supplemented by the motivational interviewing training 
provided on the professional doctorate at City, University of London.  
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I was able to utilise and expand upon the techniques listed above, adapting them 
for application in a mental health setting. The additional approaches integrated into 
the NHS Health Trainer Scheme included a cost-benefit analysis of eating more 
healthily and skills training in meal preparation. My experience of working in mental 
health had raised my awareness of the importance of Activities of Daily Living 
(ADL) skills in this setting. Here ADL skills refer to the tasks adults routinely carry 
out during daily living, including any activity performed as part of self-care (such as 
feeding, bathing and dressing oneself) and leisure (Noelker & Browdie, 2013). 
Schizophrenia is characterised by a cyclical pattern of symptoms causing relapses 
and remissions. These symptoms can impact the ability of self-care and functioning 
and thus impact upon ADL skills (Tungpunkom, Maayan & Soares-Weiser, 2012). 
Individuals diagnosed with schizophrenia often experience challenges when 
selecting and preparing meals (Connolly & Kelly, 2005) and my professional role 
involves managing and overseeing attempts to enhance ADL skills. I therefore felt 
it was important to integrate skills training into the intervention in order to provide 
clients with the practical skills required to prepare a health meal independently.  
 
To further expand the intervention and enable discussions about healthy eating 
and the costs and benefits of doing so, an additional model of behaviour change 
was selected – the health belief model (Rosenstock, 1966, 1974). The health belief 
model is an attitudinal model of health decision making with it roots based in a 
socio-cognitive perspective. It posits that individuals will take action to avoid health 
risks based upon specific beliefs that include their perceived susceptibility to the 
risk and the perceived benefits and barriers to taking action. When perceptions of 
barriers are faint while severity, susceptibility and benefits are high, a prompt is 
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needed in order for the individual to take action, this can be referred to as cues to 
action (Michie, West, Campbell, Brown & Gainforth, 2014). Cues to action can be 
either internal, such as perceptions of weight gain or external, such as interacting 
with mental health professionals about the issue. Later versions of the theory 
incorporated the element of self-efficacy, which refers to the individual’s belief in 
their own ability to take the required action (Rosenstock, Strecher, Becker & 
Marshall, 1988). An element which is already integrated into the NHS Health 
Trainer Scheme. 
 
This health belief model has been applied across a number of health-related 
behaviours successfully, including screening (Tanner-Smith & Brown, 2010), 
diabetes (Wdowik et al. 2001) and diet and exercise (Wallace, 2002). Research 
applying the model within mental health settings is however, relatively scarce with 
much of the prevailing literature focusing on use of the model in predicting 
adherence (Perkins, 2002). This research suggests that the health belief model 
may be an expedient framework for conducting research in this area (Henshaw & 
Freedman-Doan, 2009). Critics have however, suggested that it is displays 
inadequate distinctive rules, weak effect sizes of its components, reduced 
predictive capacity and uneven application when compared to alternative social 
cognition models (Armitage & Conner 2000). Furthermore, although the HBM can 
be used to derive interventions to change health beliefs and behaviours, it does not 
provide clear guidance as to how interventions can be best structured (Yarbrough 
& Braden 2001).  Despite this the directors of the organisation remained eager for 
the intervention to utilise the HBM, as they felt it was an appropriate model for this 
population.  
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In addition to using health psychology theory to select appropriate behaviour 
change techniques, all clients had to be risk assessed and their ADL skills 
assessed. This was an essential requirement as many of the service users who 
were due to take part in the intervention where forensic patients, including those 
convicted of violent offences. The standard risk assessment utilised by the 
organisation was used to assess factors including whether a bladed instrument had 
been used during the index offence and whether the service users had recently 
attacked staff members or other service users.   
 
Planning and delivery of the intervention 
Pilot intervention 
A pilot intervention phase was conducted with six clients to assess the suitability of 
the planned intervention for this population. For a detailed description of the pilot 
intervention please refer to Appendix A. 
 
Final intervention 
An intervention pack was designed and provided to each client (Appendix b), which 
also included leaflets and materials on healthy living published by the British Heart 
Foundation. The intervention was a face-to-face, weekly 30-60 minute session, for 
six consecutive weeks, plus one face-to-face/telephone maintenance session 6 
months later. All sessions were delivered by the Trainee Health Psychologist. An 
overview of the activities included in each session can be found in Table 1. 
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Table 1. Activities within each session 
Session Content Length of time 
Session 1   Introductions and rapport building 
  Initiating discussions about the physical 
and psychological consequences of 
high weight and poor diet – cost-benefit 
analysis 
  Development of a support plan: 
o Risk assessment 
o Goal setting 
o Problem solving 
o Action planning 
o Commitment  
  Introduce the food diary 
  Baseline assessments  
60 minutes 
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Session Content Length of time 
Session 2-6   Rapport building 
  Continuing the discussions about the 
physical and psychological conse-
quences of high weight and poor diet. 
  Skills training – cooking and preparing 
healthy meals 
  Review food diary 
  Review goals 
  Problem solving 
  Action planning 
  Commitment 
  Follow-up assessment (session 6 only) 
 
30 minutes 
each.  
(session 6 – 60 
minutes) 
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Session Content Length of time 
Maintenance 
session 
  Continuing the discussions about the 
physical and psychological 
consequences of high weight and poor 
diet. 
  Review goals 
  Problem solving 
60 minutes 
 
 
 Session 1  
Much of session 1 was about building trust and rapport with the client. After baseline 
measures were taken, I set about developing support plan for each client, which 
included the risk assessment. We discussed the individuals’ current eating habits, 
using the Eat Well Plate as a prompt for the discussion. This allowed us to generate 
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a list of possible behaviours to change and goals to set. While doing so I would 
review their ADL skills and initiate discussions about their understanding and 
knowledge of healthy eating, the physical and psychological consequences of being 
overweight and having a poor diet. Combined with the risk assessment, this helped 
inform how information could be delivered in an easy and comprehensible manner, 
based on the capacity of the individual. During these discussions about healthy 
eating, an individualised cost-benefit analysis was undertaken with each patient. 
This involved the individual talking through the advantages and disadvantages of 
changing or not changing their behaviour. This was where the HBM (Rosenstock, 
1966) was integrated into the NHS Health Trainer Scheme. Discussions would focus 
on susceptibility to illness and investigate the client’s beliefs about their risk of 
developing an illness due to their unhealthy diet and the severity of the illness. The 
costs and benefits involved in carrying out the behaviour were also discussed. Cues 
to action were highlighted through discussion of the physical and psychological 
consequences of a poor diet, such as constipation and indigestion. 
I helped individuals to choose appropriate goals and set them utilising SMART goal 
techniques, an effective evidence-based, strategy for behaviour change (Swanson, 
2016). After setting a goal, I assessed how confident the individual felt about 
achieving it, using a scale from 1 to 10 (with 10 being extremely confident and 1 
being not confident). If confidence was low, we discussed the barriers to performing 
the behaviour and possible strategies to overcome them, and in some cases created 
more realistic goals. When the levels of motivation were high, I asked the individuals 
to write their goals down and sign the support plan to show commitment to change. 
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Sessions 2-6 
In sessions 2-6 we reviewed their previous goals and where appropriate I provided 
praise for achieving the goal or for any steps towards success. If the goal was not 
achieved, I asked what barriers they experienced and how they could be overcome 
in the future. We then went back to the goal and amended it to make it more 
achievable, a new support plan was then created and signed by the client. If the goal 
was fully achieved, we discussed maintenance and stayed with what had been 
working to ensure that progress was stable for that particular goal. These sessions 
also included practical elements, such as cooking workshops. This provided an 
opportunity for clients to develop their skills, but also build rapport with the facilitator. 
Discussions about healthy eating, and individualised cost-benefit analysis was also 
undertaken throughout these sessions. 
 
Maintenance session  
This session was a 6 month follow-up to the main intervention, and recapped 
information that had been provided previously.  
 
Motivational interviewing 
Throughout the intervention I used motivational interviewing techniques, such as re-
flective listening (Miller & Rollnick, 2002), to improve communication and engage-
ment levels while addressing ambivalence to change. I also incorporated the four 
guiding principles of motivational interviewing (i) resisting the righting reflex, (ii) un-
derstanding the service users own motivations, (iii) listening effectively and (iv) em-
powering the service user to feel capable of change (Rollnick, Miller & Butler, 2008). 
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A great deal of tact was required to conduct sessions in an informative and thera-
peutic way while ensuring that service users did not feel intimidated by the process. 
The majority of clients were from a forensic mental health setting and many had 
committed violent crimes and had been transferred to mental health wards from pris-
ons or other secure correctional facilities. Furthermore, if delusional thought content 
or increased psychotic symptoms are noticed by professionals involved in their care, 
this is reported and could potentially result in lengthier in-patient admissions. For 
many, this can result in increased caution and reluctance to engage with healthcare 
professionals. During the trial intervention it became apparent that a number of ser-
vice users were guarded and somewhat cautious during interactions, while others 
were suspicious and even hostile. In mental health settings professionals often per-
ceive themselves as advocates for patient’s healthcare. It can often be challenging 
to resist telling clients what to do. Traditional styles of communication can result in 
service user’s resisting or denying that there is a need to change (Lai, Cahill, Quin 
& Tang, 2010) However, mental health patients do not always enter therapeutic ses-
sions with a willingness to change, which often leads to confrontational, antagonistic 
and adversarial dynamics within mental health settings (Coffey, 1999). The role of 
motivational interviewing therefore became a vital element of the intervention. My 
experience of working within mental health allowed me to build up a rapport and 
develop a therapeutic relationship with service users. 
 
Adapting the intervention for individual clients 
This risk assessment highlighted a number pertinent challenge to the planned inter-
vention. For example, for one client all kitchen knives needed to remain locked, 
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would need to be signed out and could not be handed over directly, without an im-
mediate risk assessment being completed by his named nurse. I attempted to im-
provise the meal to one that did not require the use of a knife. It also soon became 
apparent that some patients had very limited cooking skills and thus running the 
intervention within this client group required a great deal of flexibility on my part. This 
illustrated the key practical and theoretical challenges to delivering this intervention. 
Service users that took part in the intervention included individuals with a history of 
extreme violence and the practical challenges of using cooking utensils with individ-
uals who had a history of using bladed items as weapons was something that I 
needed to remain aware of throughout each session.  
 
All of the sessions were individualised for each participant based on their perfor-
mance and ability to comprehend the information provided. For those who struggled 
in relation to their concentration spans or input capacity, I would attempt to provide 
information in a more straightforward, comprehensible form with the use of picture 
cards, cues and games.  
 
Evaluate the intervention 
The following measures were taken at the beginning of session 1, again at session 
six and 6 months post intervention: 
  Weight (kg) 
  Height (cm) 
  Body Mass Index (BMI) 
  A discussion of eating habits, physical activity levels, alcohol and nicotine in-
take  
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  Physical and emotional wellbeing using the WHO5 Wellbeing Index (WHO, 
1998) 
  General Self-efficacy (Chen, Gully & Eden, 2001).  
 
Twenty-four referrals were made for the intervention. However, sixteen individuals 
were unable to take part based on either the risk assessment, relapses to their men-
tal health and presentation, or having previously worked with the trainee. Eight indi-
viduals completed the intervention. Due to the small sample size it was not appro-
priate to conduct any statistical analysis. The results indicated that all eight individ-
uals who had taken part, had lower weight and BMI after participating in the inter-
vention. Five of the participants reported higher levels of motivation and well-being. 
Four of the participants reported higher levels of self-efficacy. Six of the participants 
reported higher levels of physical activity. At six-month follow-up, six of the eight 
individuals had maintained their weight loss, with five individuals reporting higher 
rates of self-efficacy. An overview of the results can be found in Table 2. 
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Table 2: Pre and Post intervention scores. 
 
 Participant 
1 
Participant 
2 
Participant 
3 
Participant 
4 
Participant 
5 
Participant 
6 
Participant 
7 
Participant 
8 
Baseline  
weight  
100kg 99kg 68kg 77kg 125kg 82kg 112kg 155kg 
Time 2 
weight 
94kg 98.5kg 63kg 74.5 kg 122kg 81.5kg 109.5kg 154 kg 
Baseline  
BMI 
28.3 kg/m2 30.4 kg/m2 24.1 kg/m2 25 kg/m2 39.5 kg/m2 26.6 kg/m2 32.5 kg/m2 49 kg/m2 
Time 2 BMI 26.6 kg/m2 30.3 kg/m2 22.4 kg/m2 23.7 kg/m2 38.5 kg/m2 26.5 kg/m2 31.8 kg/m2 48.7 kg/m2 
Baseline  
Well-being 
80 36 72 61.5 42 56 60 12 
Time 2 
Well-being 
88 32 80 64 48 58 60 12 
Baseline  
Self-effi-
cacy 
32 22 28 30 32 18 21 13 
Time 2  
Self-effi-
cacy 
36 20 36 14 34 22 19 08 
Baseline  
Motivation 
8 5 7 6 8 7 5 10 
Time 2 
Motivation 
10 5 9 7 10 8 5 3 
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In addition to exploring the effectiveness of the intervention in terms of clinical, psy-
chosocial and behavioural outcomes, organisational feedback was obtained from the 
directors of the service. Despite initial challenges, the overall intervention was 
viewed as a success. The Directors commented on the comprehensive and easily 
replicable nature of the intervention and as a consequence, I was asked to instruct 
other staff members in how to deliver the intervention. It was subsequently imple-
mented on a number of wards, resulting in the organisation requesting that I conduct 
additional training in motivational interviewing to all staff (refer to Teaching and Train-
ing case study A). For a detailed reflective account of the delivery and implementa-
tion of the intervention please refer to Appendix C.   
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Appendix A 
 
Pilot intervention 
 
A pilot intervention phase was conducted with six clients to assess the suitability of 
the planned intervention for this population. To facilitate participation and engage-
ment the pilot intervention consisted of the patients from my work as I had already 
developed a therapeutic relationship with them based on trust, empathy and mutual 
understanding. Barriers that could impact upon delivery and effectiveness of the in-
tervention became apparent and are exemplified by my interaction with one service 
user (AC). AC was a 42 year old male who has been residing within in-patient set-
tings since being diagnosed with schizophrenia at the age of 17. His speech was 
monosyllabic and disjointed and he often appeared to respond to possible auditory 
and visual hallucinations. AC appeared to have a complete lack of motivation re-
garding his activities of daily living. During the workshop AC was asked to demon-
strate what food he was currently able to prepare and while attempting to make 
beans on toast poured the beans into the kettle in an effort to heat them. At this stage 
it became apparent that I would need to deliver an intervention that would be con-
sistent for all that took part, but also remain flexible enough for sessions to be indi-
vidualised to take into account the vastly differing cognitive functioning for those tak-
ing part. Schizophrenia is characterised by varied symptoms for individuals diag-
nosed with the condition and these conditions can fluctuate markedly. It also con-
firmed the positive impact of motivational interviewing techniques when conducting 
the intervention, highlighting the importance of taking a collaborative, supportive and 
non-confrontational approach.  
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Appendix B   
Intervention Pack. 
 
 
Behaviour Change Intervention 
 
 
Healthy Eating Goal Setting 
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Contents 
 
Listed below are the stages of the Behaviour Change programme, these are subsequently 
detailed in full in the proceeding pages. 
  
  Consent  
  Individualised Details  
  Assessment  
o Initial Assessment  
o Wellbeing Measure 1 
o Intervention: Individualised Healthy Eating Plan  
o Progress Reviews 
o Wellbeing Measure 2 
 
o Maintenance check (after 6 months) 
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Consent 
 
Statement of Trainee Health Psychologist 
 
▪ I have explained the programme to the client.  
▪ I have explained that information will be securely stored in accordance with the Data Pro-
tection Act and BPS Guidance.  
 
 
Signed:      
   
Name:      
   
Date:      
   
Job Title:  Trainee Health Psychologist 
 
 
 
 
 
 
Statement of Client 
 
▪ I consent to participation in the Behaviour Change programme.  
▪ I understand that data will be securely stored on paper and electronically. 
 
Signed:          
     
Name:          
     
Date:          
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Service User Details 
 
Last Name   
  
  
First Name   
  
  
MHA Status   
  
  
 
Ethnicity 
   A: White – British 
   J: Asian or Asian British - Bangla-
deshi 
  
   B: White – Irish    K: Any other Asian background 
  
   C: Other White Background 
   L: Black or Black British - Carib-
bean 
  
   D: Mixed - White and Black Carib-
bean    M: Black or Black British - African 
  
   E: Mixed - White and Black African    N: Any Other Black Background 
  
   F: Mixed - White and Asian    O: Chinese 
  
   G: Mixed - Any Other Mixed Back-
ground    P: Any Other Ethnic Group 
  
   H: Asian or Asian British - Indian    Z: Not Stated 
  
   I: Asian or Asian British - Pakistani 
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Mental health  
diagnosis   
 
 
 
 
Co-morbidity 
   Yes No 
 
Physical health 
diagnosis 
  
  
Gender   
  
Ad-
dress 
  
 
 
DOB     Age    
Mobile   
  
   SMS allowed  
Additional In-
formation  
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Assessment Process 
 
Initial Assessment 
 
 
Employment status 
   Employed full-time 
   Employed part-time 
   Full-time carer 
   Response declined 
   Looking after home or family full time 
   Permanently sick/ disabled 
   Retired 
   Self-employed 
   Student 
   Unemployed 
   Volunteer 
  N/A – Offender Health 
  Other 
 
 
 
 
 
 
 
 
 
Topics discussed 
   Alcohol    Illicit substance use 
   Diet    Smoking 
   Exercise 
  Local Issue 
 
 
 
 
Additional information  
 
 
 
 
 
 
 
 
 
Physique 
 
Height  Cm/ M/ Ft  
Weight  Kg/St  
 
 
 
 
Waist Circumference  Cm / Inch  
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Exercise 
 
Number of 30 minute sessions of moderate exercise per week   
Number of 20 minute sessions of Vigorous exercise per week   
 
 
 
 
Diet 
Type of Food 
How many days last week 
did you eat this kind of 
food?  
On average, how many 
portions per day? 
    
Fruit (e.g apples, bananas, mangoes, oranges)      
Vegetables (e.g. carrots, broccoli, peas, okra, au-
bergine)      
Fried food (e.g. burgers, chips, samosas, fried 
chicken, pakoras)      
High fat dairy food (e.g. cream, ghee, full fat milk, 
cheese, butter, ice cream)      
Snacks (crisps, chocolates, cakes, sweets, bombay 
mix etc)      
 
 
Alcohol 
Do you drink alcohol (includes drink brewed at 
home)? 
   Yes, more 
than once 
weekly 
   Yes, less 
than once 
weekly 
   
No 
 
     
If ‘Yes, more than once weekly’, estimate the number of 
units of alcohol consumed each day last week... 
  Monday   Friday  
  Tuesday   Saturday  
  Wednesday    Sunday  
  Thursday   
     
 
 
Smoking 
 
Smoking status 
   Smoker 
   Non 
smoker 
   Ex 
Smoker 
 
 
 
Cigarettes per day    
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Motivation 
 
What is the issue you 
want to address? 
  
 
 
 
 
How important is this to you?  Please score 1 - 10 (1 - Not at all, 10 - Extremely)   
 
 
 
Why is this Im-
portant?    
    
   Another’s influence 
   Family/ friends beliefs about cur-
rent behaviour 
   Health risks of continuing current 
behaviour 
   Likely response of other people 
   Own beliefs about changing behaviour 
   Previous experience of addressing issue 
   Seriousness of issue 
   Other 
 
 
What would increase 
importance?   
   
   Being willing to take necessary action 
   Believing achieving goal is possible 
   Desire to achieve goal 
   Knowing that support is available 
   Knowing what to do to achieve goal 
   N/A (if importance is 10)  
  Prioritising behaviour change 
   Risk of getting worse 
   Support of family / friends 
   Other 
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How confident are you that this will be achieved?  Please score 1 - 10 
(1 - Not at all, 10 - Extremely)   
 
 
 
 
What would in-
crease confi-
dence?  
    
   Assurance of a confidential ser-
vice 
   Guaranteed support of health trainer 
   Overcoming fear of failure 
   Seeing others succeed 
   Being satisfied with progress 
   Clear, realistic goals 
   Guaranteed support of family / 
friends 
 
 
 
Notes 
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 Wellbeing Measure (prior to intervention) 
 
Section to be completed as required both before and after the programme.  
Self - efficacy 
1.    I will be able to achieve most of the goals I set for myself 
 
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
      
2.    When facing difficult tasks, I am certain that I will succeed.  
 
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
      
3.    In general, I think I can achieve outcomes that are important to me.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
      
4.    I believe I can succeed at most tasks to which I set my mind.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
 
5.    I will be able to successfully overcome many challenges.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
 
6.    I am confident that I can manage well on many different tasks.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
 
7.    Compared to other people, I can do most tasks very well.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
 
8.    Even when things are tough, I can manage quite well.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree   
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General Health  
 
9. Please rate your current state of health by placing a cross on the line. 
 
POOR  PER-
FECT 
 
  
WHO–Five Well-being 
1.    I have felt cheerful and in good spirits.    
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time o All of the time 
2.    I have felt calm and relaxed.     
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time o All of the time  
3.    I have felt active and vigorous.     
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time o All of the time  
4.    I woke up feeling fresh and rested.     
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time o All of the time  
5.    My daily life has been filled with things that 
interest me.    
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time o All of the time 
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INTERVENTION 
GOAL SETTING – Individualised Health Plan 
 
Date plan created    
 
 
 
 
Primary issue being ad-
dressed 
   Alcohol    Exercise 
   Diet    Smoking 
   Local issue  
 
 
 
 
Relevant Issues  
 
 
 
Primary goal   
  
  
  
  
  
  
  
 
 
 
 
Primary goal date   
 
 
 
 
Rewards     Acknowledgement of friends / 
family 
   Certificate for achieving 
goal 
   Feedback at each session 
about what I have achieved 
   Opportunity to encourage 
others to pursue same goal 
   Other    To be able to see results 
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Reminders     Keeping a diary    Post-event contact 
   Regular contact    Regular reminders and tips 
   Support from significant other 
(partner, friend) 
  Other 
 
 
 
Goals 
 
N
o 
Goal & Tar-
get  Action(s) Start Date 
Target 
Date Support                                  Achieved
1 
                                               Achieved, 
part 
achieved, 
not 
achieved. 
2 
            
3 
            
4 
            
5       
6 
      
 
 
 
 
2nd -5th Meeting – Progress Review(s)  
 
Review date   
 
 
 
 
What was tried?   
   Drinking less alcohol 
   Reducing intake 
of snacks 
   Reducing portion 
size 
 
   Eating more fruit and vegetables 
 
   Increasing amount of physical activity 
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   Reducing intake of fried food    Smoking less 
   Stopping smoking 
   Other  
 
   Reducing intake of high fat foods 
 
 
 
 
 
 
What was the result? 
 
   Achieved 
 
   Part Achieved 
 
   Not Achieved 
 
 
 
What were the 
benefits?  
  
  
   Feel better 
   Get on better with fam-
ily 
   Have more money 
   Look better 
   Made new friends 
   N/A 
   Other 
   
What were the 
difficulties?  
(multiple tick 
list)  
   Clashes with other ac-
tivities 
   Illness 
   NA - No difficulties 
   Not enough support from friends/family 
   Other 
   Clashes with other de-
mands 
   Did not meet expecta-
tions 
   Doesn’t seem to be 
making a difference 
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   Don’t enjoy 
   
How were they 
tackled?  
(multiple tick 
list)  
  Advice/encouragement 
from a friend 
   Advice/encouragement 
from activity leader 
  Advice from the GP/ Practice Nurse 
  Advice from book/internet 
How were they 
tackled?  
(multiple tick 
list)  
   Advice from book/inter-
net 
   Advice/encouragement 
from a friend 
   Advice/encouragement 
from activity leader 
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What have you 
learned from 
working with 
the HT?  
(multiple tick 
list)  
   Am willing to take nec-
essary action 
   Being sure about what 
to do 
   Believe achieving goal 
is desirable 
   Believe achieving goal 
is possible 
   Confidence in the ser-
vice 
   Felt good about focus-
ing on self 
   Have other issues to 
be addressed first 
   How to prioritise goals 
over other objectives 
   How to prioritise goals 
over meeting other 
needs 
   Know how to set goals 
   Know what to do to achieve goal 
   Learned about the risks of the behaviour 
   Need help to change behaviour 
   Overcame anger with self 
   Overcame envy of those without my is-
sues 
   Overcame fear of failure 
   Preferred learning style 
   Realistic expectations of progress 
What rewards 
were given / 
gained?  
(multiple tick 
list) 
  "me" time 
   Certificate of achieve-
ment 
   Feedback on progress 
   Friends / family 
acknowledgement 
  Opportunity to encourage other(s) 
  Recognition for attendance 
  Other 
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Are you confi-
dent to con-
tinue? 
  Yes   No 
Motivational 
Boost Con-
ducted? 
  Yes   No 
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Physique (optional) 
 
Height  Cm/ M/ Ft  
Weight  Kg/St  
 
 
 
 
 
Weight self reported 
   Yes    No 
 
 
 
 
Waist Circumference  Cm / Inch  
 
 
 
 
Exercise (optional) 
 
Number of 30 minute sessions of moderate exercise per week   
 
 
 
Number of 20 minute sessions of Vigorous exercise per week   
 
 
 
Diet (optional) 
Type of Food 
 
How many days last 
week did you eat this 
kind of food?  
On average, how many 
portions per day? 
    
Fruit (e.g apples, bananas, mangoes, oranges)      
Vegetables (e.g. carrots, broccoli, peas, okra, au-
bergine)      
Fried food (e.g. burgers, chips, samosas, fried 
chicken, pakoras)      
High fat dairy food (e.g. cream, ghee, full fat milk, 
cheese, butter, ice cream)      
Snacks (crisps, chocolates, cakes, sweets, bom-
bay mix etc)      
 
 
 
 
 
 
Alcohol (optional) 
Do you drink alcohol (includes drink brewed at 
home)? 
   Yes, more 
than once 
weekly 
   Yes, less 
than once 
weekly 
   
N
o 
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If ‘Yes, more than once weekly’, Estimate the number of 
units of alcohol consumed each day last week... 
  Monday   Friday  
  Tuesday   Saturday  
  Wednesday    Sunday  
  Thursday   
     
 
 
 
Smoking (optional) 
 
Smoking status 
   
Smok
er 
   Non 
smok
er 
   Ex Smoker 
 
 
 
Cigarettes per day    
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5th Meeting Maintaining Change 
Maintaining change 
by  
   Changing habits of current friends    Other 
   Changing habits of family    Plan carefully before change 
   Changing travel arrangements    Prepare before going out 
   Finding different interests    Putting money aside for new activity 
   Finding friends who share goal 
 
 
Positive conse-
quences 
   Feel better    Learning something new 
 
   Feel more confident    Look better 
 
   Have more money    Make new friends 
 
   Improve relationships    Other 
 
 
 
Potential barriers     Can’t understand what is being 
said    Have to miss a meeting & find it  
   Childcare    Difficult to restart 
   Clashes with other activities    Holidays 
   Cost    Illness 
   Doesn’t seem to be making a dif-
ference 
   Insufficient support from family/ 
friends 
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   Don’t enjoy    Stress 
   Family / friends still engage in be-
haviour    Work 
   Fear of failing    Not applicable 
 
 
 
How overcome 
problems? 
  Advice from activity leader 
   Get more info. from internet/ li-
brary 
  Assert yourself   Talk to a friend  
  Contact health trainer for advice    Other 
 
 
 
Difficult situations     Ask health psychologist to help restart 
   Consider alternatives to chosen activity 
 
 
 
 
Who might help?    Activity leader    Partner 
   Friend    Relative 
   Health trainer    Religious adviser 
   Other    Workmate 
   Other people on programme 
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How might they 
help? 
   Regular reminders of benefits     Staying in contact 
   Accompanying to activity    Taking an interest in progress  
   Other    Trying out changes together 
   Practical Advice  
 
 
 
 
Review com-
ments             
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Wellbeing Measure (AFTER INTERVENTION) 
 
Self - efficacy 
 
1.    I will be able to achieve most of the goals I set for myself 
 
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
      
2.    When facing difficult tasks, I am certain that I will succeed.  
 
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
      
3.    In general, I think I can achieve outcomes that are important to me.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
      
4.    I believe I can succeed at most tasks to which I set my mind.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
 
5.    I will be able to successfully overcome many challenges.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
 
6.    I am confident that I can manage well on many different tasks.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
 
7.    Compared to other people, I can do most tasks very well.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree  
 
8.    Even when things are tough, I can manage quite well.  
o Strongly disagree o Disagree o No preference o Agree o Strongly agree   
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General Health  
 
9. Please rate your current state of health by placing a cross on the line. 
 
POOR  PER-
FECT 
 
 
WHO–Five Well-being 
1.    I have felt cheerful and in good spirits.   
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time 
o All of the 
time 
2.    I have felt calm and relaxed.                          
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time 
o All of the 
time 
3.    I have felt active and vigorous.    
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time 
o All of the 
time 
4.    I woke up feeling fresh and rested.    
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time 
o All of the 
time 
5.    My daily life has been filled with things that in-
terest me.    
o At no 
time  
o Some of the 
time  
o Less than half of the 
time  
o More than half of the 
time 
o Most of the 
time 
o All of the 
time 
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Results  
 
Completion date    
 
 
 
 
Programme outcome     ACHIEVED    NOT ACHIEVED 
     PART ACHIEVED    OUTCOME UNKNOWN 
 
 
 
 
 
 
 
 
 
Signpost To 
 
 
 
 
 
Notes 
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Completion- Post Assessment Measures 
 
 
 
Physique 
 
Height  Cm/ M/ Ft  
Weight  Kg/St  
 
 
 
 
 
   
 
 
 
 
Waist Circumference  Cm / Inch  
 
 
 
Exercise 
 
Number of 30 minute sessions of moderate exercise per week   
 
 
 
Number of 20 minute sessions of Vigorous exercise per week   
 
 
 
Diet 
Type of Food 
How many days last 
week did you eat this 
kind of food?  
On average, how many 
portions per day? 
    
Fruit (e.g apples, bananas, mangoes, oranges)      
    
Vegetables (e.g. carrots, broccoli, peas, okra, 
aubergine)      
    
Fried food (e.g. burgers, chips, samosas, fried 
chicken, pakoras)      
    
High fat dairy food (e.g. cream, ghee, full fat milk, 
cheese, butter, ice cream)      
    
Snacks (crisps, chocolates, cakes, sweets, bom-
bay mix etc)      
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Alcohol 
Do you drink alcohol (includes drink brewed at 
home)? 
   Yes, more 
than once 
weekly 
   Yes, less 
than once 
weekly 
   
N
o 
 
 
 
 
     
If ‘Yes, more than once weekly’, Estimate the number 
of units of alcohol consumed each day last week... 
  Monday   Friday  
  Tuesday   Saturday  
  Wednesday    Sunday  
  Thursday   
     
 
 
Smoking 
 
Smoking status 
   
Smo
ker 
   Non 
smo
ker 
   Ex 
Smoker 
 
 
 
Cigarettes per day    
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Proposed 6 months follow up assessment –Maintenance 
Check(s) 
Maintenance date    
 
 
  
Programme out-
come 
If a full Programme; 
  Yes, Maintained 
  No, not maintained 
  Client not contactable 
  Not applicable 
If not a full Programme; 
  Attended: Considered useful 
  Attended: Not considered useful 
  Not attended 
 
   
Notes   
  
   
  
 
  
Physique (optional) 
 
Height  Cm/ M/ Ft 
Weight  Kg/St 
 
 
 
 
 
 
 
Waist Circumference  Cm / Inch 
 
 
 
 
Exercise (optional) 
 
Number of 30 minute sessions of moderate exercise per week   
 
 
 
Number of 20 minute sessions of Vigorous exercise per week   
 
 
 
Diet (optional) 
Type of Food 
How many days last 
week did you eat this 
kind of food?  
On average, how many 
portions per day? 
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Fruit (e.g apples, bananas, mangoes, oranges)      
Vegetables (e.g. carrots, broccoli, peas, okra, 
aubergine)      
Fried food (e.g. burgers, chips, samosas, fried 
chicken, pakoras)      
High fat dairy food (e.g. cream, ghee, full fat milk, 
cheese, butter, ice cream)      
Snacks (crisps, chocolates, cakes, sweets, bom-
bay mix etc)      
 
 
 
 
 
Alcohol (optional) 
Do you drink alcohol (includes drink brewed at home)? 
   Yes, more 
than once 
weekly 
   Yes, less 
than once 
weekly 
    
 
  
 
     
If ‘Yes, more than once weekly’, Estimate the number of 
units of alcohol consumed each day last week... 
  Monday   Friday  
  Tuesday   Saturday  
  Wednesday    Sunday  
  Thursday   
     
 
 
Smoking (optional) 
 
Smoking status 
   
Smoker 
   Non 
smoke
r 
   Ex Smoker 
 
 
 
Cigarettes per day    
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Appendix 
Programme Goal & Target Options... 
 
Goal Target ✓ 
Alcohol Reduce To 3 units or less (women) ‐ To 4 units or less (men) ‐ 
By half ‐     
By more than half ‐     
Quit ‐     
Diet Change Complete a food diary ‐  Reduce evening food intake ‐ 
Eat breakfast regularly ‐  Reduce salt intake ‐ 
Eat more regular meals ‐  Reduce sugar intake ‐ 
Increase starchy/wholegrain 
foods ‐  Other ‐ 
Increase Fruit & Veg-
etable intake by 1 portion per day  ‐  to five portions per day ‐ 
by 2 portions per day ‐     
by 3 portions per day  ‐     
by 4 portions per day  ‐   
Increase Healthy 
Snacks by 1 portion per day  ‐     
by 2 portions per day  ‐     
by 3 portions per day  ‐     
by 4 portions per day  ‐     
Increase intake of 
water by 1 glasses per day  ‐     
by 2 glasses per day  ‐     
by 3 glasses per day  ‐     
Reduce fatty food in-
take by 1 meal per week ‐ to 0 meals per week  ‐ 
by 2 meals per week ‐ to less than 3 meals per week ‐ 
by 3 meals per week ‐   
Reduce fizzy drink in-
take by 1 glass per day ‐ to 0 glasses / 0 cans per day ‐ 
by 2 glasses / 1 can per day ‐ 
to less than 2 glasses / 1 can 
per day ‐ 
by 1 meal per week ‐     
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Reduce fried food in-
take by 2 meals per week ‐  to 0 meals per week ‐ 
by 3 meals per week ‐  to less than 3 meals per week ‐ 
Reduce portion size by one quarter (25%) ‐     
Reduce unhealthy 
snack intake by 1 portion per day  ‐  to 0 portions per week ‐ 
by 2 portions per day ‐     
by 3 portions per day  ‐     
by 4 portions per day ‐   
Reduce tea / coffee 
intake by 1 cup per day ‐  to less than 2 cups per day ‐ 
by 2 cups per day ‐   
Exer-
cise 
Increase – Light * by 1 (10 Minute) session per 
week ‐ 
to 1 (10 Minute) session per 
week ‐ 
by 2 (10 Minute) session per 
week ‐ 
to 2 (10 Minute) session per 
week ‐ 
by 3 (10 Minute) session per 
week ‐ 
to 3 (10 Minute) session per 
week ‐ 
by 4 (10 Minute) session per 
week ‐ 
to 4 (10 Minute) session per 
week ‐ 
Increase – Moderate * by 1 (30 Minute) session per 
week ‐ 
to 1 (30 Minute) session per 
week ‐ 
by 2 (30 Minute) session per 
week ‐ 
to 2 (30 Minute) session per 
week ‐ 
by 3 (30 Minute) session per 
week ‐ 
to 3 (30 Minute) session per 
week ‐ 
by 4 (30 Minute) session per 
week ‐ 
to 4 (30 Minute) session per 
week ‐ 
    
to 5 (30 Minute) session per 
week  ‐ 
Increase – Vigorous * by 1 (20 Minute) session per 
week ‐ 
to 1 (20 Minute) session per 
week ‐ 
by 2 (20 Minute) session per 
week ‐ 
to 2 (20 Minute) session per 
week ‐ 
by 3 (20 Minute) session per 
week ‐ 
to 3 (20 Minute) session per 
week ‐ 
by 4 (20 Minute) session per 
week ‐ 
to 4 (20 Minute) session per 
week ‐ 
Smok-
ing 
Reduce by half ‐ to less than 10 per day ‐ 
    to less than 5 per day ‐ 
Stop Quit ‐     
Other    -- ‐   
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Appendix C 
 
 
Reflections on the intervention delivery and implementation. 
 
This was the first competency undertaken as part of the doctorate, and I was inex-
perienced in my role as a trainee. I believe that I was hindered by the practical chal-
lenges of implementing an intervention that not only fit the requirements of the com-
petence, but also met the timescales and requirements of the directors and the clin-
ical lead of the organisation. I believe that I was extremely ambitious in attempting 
to run the intervention within a forensic mental health setting. Although I had been 
proactive in arranging workplace supervision with an experienced and RMN there 
were no other Health Psychologists at the organisation that I could discuss issues 
with and I believe that the lack of awareness of Health Psychology within my work 
setting negatively impacted the initial stage of my training.   
 
If I was to run the intervention again I would consider an alternative setting with more 
traditional health psychology input, where I would be able to receive work place su-
pervision more familiar with the concepts involved. However, in the long-term I felt 
that these limitations helped strengthened my resolve and motivated me to be more 
exacting, methodological and thorough during the planning and implementation of 
future interventions. I believe that as my training progressed the experience of im-
plementing the intervention raised my awareness of the challenges faced by a prac-
titioner health psychologist and the key differences of delivering an intervention 
within this role. It also helped highlight the physical health issues faced by service 
users and illustrated the benefits of Health Psychology in optimising overall well-
being for patients with mental health settings for the organisation. The experience 
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helped me to develop an altered perspective on the approach required to deliver an 
intervention and raised my awareness of the research implementation gap. Profes-
sionals who work in mental health frequently have to contend with extreme circum-
stances and symptoms, in often challenging situations and environments. This can 
occasionally lead to a rather insular approach and dismissive stance towards other 
health care professionals and their input. Delivering this intervention helped me rec-
ognise that although an intervention targeting healthy eating and balanced diet may 
not seem particularly extreme, it can have a tremendous impact on an individual’s 
overall well-being and is thus, no less important. 
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SECTION D 
 
SYSTEMATIC REVIEW 
 
 
 
Psychological and social impact 
of auto-immune alopecia 
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Abstract  
 
Background 
Alopecia is a common and distressing condition. It can have serious psychosocial 
consequences, causing severe emotional suffering as well as personal, social and 
work-related problems. There is a paucity of research exploring the psychosocial 
impact of the condition.  
 
Objectives 
The review looks to investigate the psychological and social impact of autoimmune 
alopecia and the factors associated with psychosocial well-being.  
 
Method 
Search strategy: Electronic searches were conducted using EBSCO and OVID 
platforms, for studies published from January 2007 until December 2017. 
Reference lists of included studies were also searched.  
Selection criteria: Studies which investigated the psychosocial impact of alopecia 
areata, alopecia totalis and alopecia universalis, using controlled observational 
studies, observational studies without a control group and qualitative study 
designs. 
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Data collection and analysis: The quality of the studies was assessed and data 
was synthesised using narrative synthesis. 
Results 
Fourteen studies were included in the review, with a total of 4415 participants from 
10 different countries. The age range of participants was from 0 to 77 years and 
the duration of the disease varied from 1 week to 49 years. Twelve studies were 
quantitative and two were qualitative. The evidence suggested that alopecia is 
linked with psychological disorders and impacts upon the quality of life of those 
diagnosed. The negative impact of alopecia may be amplified for females, caused 
by societal pressure to be attractive.  
 
Conclusion 
Recognising the evident psychosocial impact of hair loss when treating patients 
with alopecia is critical. Research exploring the psychological treatments that may 
be effective in helping people adjust is required. Individual factors such as coping 
styles, age, gender and severity of the condition, which are associated with the 
course of psychosocial wellbeing in alopecia should also be considered. 
Practitioners need to be aware of the psychosocial effects to enable holistic 
management of the disease.  
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Background 
Alopecia is a general medical term for hair loss (Hon, Leung, & Ng, 2008). Hair 
loss may take various forms such as androgenetic alopecia, mediated by systemic 
androgens and genetic factors (Karaman, Dereboy, Dereboy, & Çarman, 2006), 
anagen effluvium, which is triggered by cancer treatment, telogen effluvium, 
caused by hormonal changes, severe stress, infections or certain medications 
(Shrivastava, 2009) and trichotillomania, initiated by a compulsive pulling out of 
one’s own hair (Hon et al., 2008). In most cases hair loss is temporary. For 
instance, in anagen effluvium hair should start to grow back a few months after 
chemotherapy has ceased. In telogen effluvium hair will stop falling out and begin 
to regrow within six months (Han & Mirmirani, 2006).  
 
The word alopecia is of Latin origin and literally translates as “hair loss”. It is often 
used as a blanket term to cover all forms of hair loss including those that are a by-
product of another illness. However, there are cases when the loss of hair is purely 
a condition in itself. This is referred to as autoimmune alopecia, which is a chronic 
dermatological condition, whereby hair follicles are attacked by the individuals own 
immune system and is manifested as patches of non-scarring hair loss (Alfani et 
al., 2012). There are three main subgroups of the illness, depending on the degree 
of hair loss; alopecia areata (AA) which refers to the partial loss of hair from the 
head in the form of patches, alopecia totalis (AT) referring to entire hair loss of all 
hair on the head and alopecia universalis (AU), which includes complete loss of all 
head, face and body hair (Wasserman, Guzman-Sanchez, Scott, & McMichael, 
2007).  
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It has been suggested that 60% of cases of alopecia are individuals between the 
ages of 5 to 20 years old (Galán-Gutiérrez, Rodríguez-Bujaldón, & Moreno-
Giménez, 2009). Nonetheless, it is argued that the condition can affect men and 
women at any point in their life, regardless of a person’s ethnic or racial 
background (Bolduc & Shapiro, 2001). Its prevalence in the United Kingdom is 
estimated to be one to two people in every 1,000 (Hunt & McHale, 2005a). 
 
The aetiology and subsequent development of alopecia are unclear. In the past, 
many researchers pointed to stress as a determining factor. However, it is now 
believed that while stress may be an aggravating factor, it is not the direct cause 
(Elkin, Hilker, & Drabman, 2006). Other factors that are linked to alopecia’s 
development include abnormalities of the immune mechanism, anomalies in 
endocrine systems, genetic predisposition, infections and psychological 
disturbances (Ruiz-Doblado, Carrizosa, & García-Hernández, 2003).  
 
A fundamental feature of autoimmune alopecia is the level of unpredictability 
regarding periods of remission and exacerbation. It is not yet possible to predict 
when hair will fall out, begin to grow, or to identify the relationship between 
alopecia and other medical conditions (Thompson & Shapiro, 1996). Given the 
seemingly random nature of alopecia, its management may be severely 
challenging (Bolduc & Shapiro, 2001). It is believed that out of the three types of 
autoimmune alopecia, AA sufferers are most likely to experience remission; yet 
may still go through repeated episodes of the illness throughout their lives (Meidan 
& Touitou, 2001). AT and AU are argued to be less responsive to medical 
treatment and in some cases not even possible to treat (Hunt & McHale, 2005b). 
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Additional factors linked with a less favourable prognosis are childhood onset, 
family history and when the hair loss is particularly severe (Van den Biggelaar, 
Smolders, & Jansen, 2010). 
 
In terms of its physical impact, alopecia is non-life threatening and does not involve 
loss of mobility or physical pain. However, its unpredictability and visibility is 
thought to have a profound negative impact on one’s psychological health 
(Williamson, Gonzalez, & Finlay, 2001). While being a medically benign condition, 
since hair is often considered to be a vital aspect of one’s identity, alopecia can be 
perceived as a disfiguring disorder and therefore its psychological impact can be 
profound. It is frequently emotionally painful and damaging and may be destructive 
to one’s personal and marital relationships, social wellbeing and career (Hunt & 
McHale, 2005b). In a review of 19 studies by Tucker (2009), alopecia areata was 
associated with impaired psychological well-being, occupational functioning, 
relationships and social interactions (Tucker, 2009). This could be explained by the 
fact that hair and facial hair convey messages about the individual’s culture, 
gender, age, social class, economic status or religion (Batchelor, 2001). The 
importance placed on hair, body image, and beauty in our society is reflected in 
hair care products, magazines and other media. Hair is often perceived as a 
symbol of one’s attractiveness, youth, good health or sexuality and its lack can be 
seen as a failure to fit into the norm of appearance within society (Kalabokes & 
Besta, 2001). 
 
This review will update that of Tucker (2009), by drawing on the most recent 
literature (2007-2017), broadening the inclusion criteria to include all three types of 
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autoimmune alopecia and using systematic methodology. As well as investigate 
the factors associated with its psychosocial impact.  
 
Aims 
The aims of this systematic review were to examine the most recent literature on 
the psychological and social impact of autoimmune alopecia, and the demographic, 
clinical or psychological factors associated with this impact.  
Method 
Inclusion and exclusion criteria 
Types of studies: 
Both, quantitative and qualitative studies investigating the social and psychological 
impact of AA, AT and AU were included. Observational and qualitative studies 
were included. Commentaries, letters to editors, books, book chapters and studies 
of low quality methodological designs (refer to the Result section) were removed, 
as were those written in a language other than English,  
Types of participants: 
Participants with a diagnosis of autoimmune alopecia including AA, AT and AU, 
regardless of age, sex, race or ethnicity. 
Types of outcomes: 
Studies investigating the social or psychological impact of AA, AT, AU. Thus, 
studies exploring the consequences of the illness on one’s psychological wellbeing 
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and the impact the illness has on one's ability to form satisfying relationships with 
others and to adapt to different social situations. 
 
Search strategy for identification of studies: 
Computerised searches were conducted using the EBSCO (CINAHL Plus with Full 
Text, E-Journals, Health and Psychosocial Instruments, MEDLINE Complete and 
PsychINFO) and OVID (Cochrane Central Register of Controlled Trials (CCTR) 
and EMBASE) platforms, in December 2017 for studies published from January 
2007 to December 2017. The same strategy was used for all databases. An 
example of the search terms used is provided in Appendix A. The reference lists of 
included studies were also searched for relevant papers. 
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Study selection 
All identified records were initially screened by their titles and abstracts by the 
author. Following the exclusion of records based on their titles and abstracts, a 
number of full text studies was investigated and those fulfilling the inclusion criteria 
were selected for the synthesis. 
Data extraction 
The data extraction form (Refer to figure 1) recorded the following features from 
the studies: 
1. The condition. 
2. Aims. 
3. Study type and design. 
4. Participant characteristics - age, gender, duration of the condition and 
severity of the condition. 
5. Sample size and representativeness of the sample. 
6. Sampling methods. 
7. Outcome measures used - whether the researchers used validated and 
reliable measures to define outcomes. 
8. Results and conclusions.    
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 Table 1.  Data Extraction  
 
 
ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
1 Aghaei, S., Saki, 
N., Daneshmand, 
E., & and Kardeh, 
B.  (2014), Iran.  
  
Aim: to assess 
the frequency of 
psychological dis-
orders in patients 
with AA in com-
parison with nor-
mal subjects. 
   
40 patients (18 
males; 22 fe-
males). 
  
Mean age: NS. 
  
Duration of con-
dition: NS. 
  
40 healthy con-
trols (age-sex 
matched). 
  
Quantitative 
 
Case-control 
study 
  
  
  
  
  
Beck Depression 
Inventory (1961) 
  
Beck Anxiety In-
ventory (1988) 
  
Eysenck Personal-
ity Questionnaire 
(EPQ) 
  
  
  There was significant difference between patient and 
control group regarding depression (p= 0.008), anxiety 
(p= 0.003) and neurosis (p= 0.05).  
  There was no significant difference regarding 
extraversion (p=0.249), psychosis (p=0.147) and lying 
(p=0.899). 
  There was no significant correlation between duration 
of the disease, age of onset, number of relapses and 
intensity of the disease with anxiety, extraversion, 
neurosis, psychosis or lying (p> 0.05). 
  There were significantly higher rates of neuroticism 
(p= 0.045) and lying (p= 0.005) in AA involving the 
scalp. 
  There was significantly higher rate of depression (p= 
0.020), anxiety (p= 0.019), and neurosis (p= 0.029) in 
AA involving face.  
  There was no significant higher rate of psychological 
illness (p> 0.05) in AA involving eyebrows. 
 
 
 
68% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
 
2 
 
Alfani, S., Anti-
none, V.,  Moz-
zetta, A., Di 
Pietro,  C.,  Maz-
zantp, C., Stella, 
P., Raskovich, D., 
& Abeni, D. 
(2012), Italy. 
 
Aim: to assess 
psychological sta-
tus and the per-
sonality traits of 
patients with Alo-
pecia Areata. 
  
  
  
 
73 patients (33 
males; 40 
females). 
  
Mean age: 35.2 
years (age range 
18-73 years). 
Duration of con-
dition: less than 
one year for 
54.8%. 
  
73 healthy con-
trols (age-sex 
matched). 
 
Quantitative 
  
Case-control 
study 
  
  
  
  
 
Minnesota Multi-
phasic 
Personality In-
ventory (MMPI-2) 
  
  
  
  
  
 
  They were significant differences between the case 
and control groups regarding depression (p= 0.001), 
hysteria (p= 0.006), psychopathic deviance (p= 0.017), 
psychasthenia (p= 0.006), schizophrenia (p= 0.028), 
anxiety (p= 0.001), health concerns (p= 0.002), bizarre 
thoughts (p= 0.028) and family problems (p=0.028).  
  The highest scores for the disease duration were 
observed for durations between 6 and 11 months. 
Statistically significant difference is seen respectively 
on paranoia and schizophrenia (p< 0.01), hysteria, 
psychasthenia and anger (p< 0.05), depression, 
antisocial practices and family problems (p< 0.10) 
scales. 
  The results suggest that males had significantly higher 
scores than females on psychopathic deviance, 
antisocial practices and family problems scales (p< 
0.10). 
 
 
 
 
 
 
 
55% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
3 Al-Mutairi, N. & 
Nour Eldin, O. 
(2011), Kuwait. 
  
Aim: to study the 
clinical profile of 
AA patients and 
impact of AA on 
the quality of life 
of patients with 
severe forms of 
the disease. 
  
  
2962 patients 
(1926 
males; 1036 fe-
males). 
  
Mean age: NS. 
  
Age range 0- >50; 
58.03% of pa-
tients 21-40 
years. 
  
Duration of con-
dition: 2 weeks – 
several years. 
Quantitative 
  
Case-control 
study 
  
  
  
  
  
Dermatology Life 
Quality Index 
Questionnaire 
(DLQI) 
  The mean DLQI score in patients (age>21 years) with 
severe forms of AA was found to be 13.54 as compared 
to 1.24 in control group.  
  The DLQI scores increased with the severity of AA and 
were the highest in patients with AU. 
  There was no significant difference in the mean DLQI 
scores of males and females. 
  There was no significant correlation in the mean DLQI 
scores and the duration of illness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
4 Arbabi, N., Sa-
lami, F., Forouz-
esh, F., Ghare-
hbebeglou, M., 
Riyahin, A. A., & 
Shahrzad, M. E.  
(2013), Iran.  
  
Aim: to consider 
the effects of 
stressors in AA. 
  
60 patients with 
AA (43 males; 17 
females). 
  
Mean age: 29.45 
(males) 30.48 (fe-
males). 
  
Duration of con-
dition: NS. 
  
60 controls with 
unspecific hair 
loss. 
Quantitative 
  
  
Case-control 
study 
 
  
Stress Question-
naire 
  52 AA patients had experienced a stressful event 3 
months before appearance of the disease as compared 
to 18 controls, p=0.001. 
  The majority of AA patients (30) had two stressful 
events while most patients of the control group (9) 
mostly experienced one stressful event, p=0.001. 
  The frequency of patients with severe stress in AA was 
significantly higher (70%) compared to control group 
(31.7%), p< 0.05.  
  With regards to stress perception, 93.1% of patients 
with AA and 15% of controls believed in the effects of 
stress on the process of their disease (p= 0.005). 
 
 
 
 
 
 
 
 
 
 
 
 
64% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
5 Ataseven, A., 
Saral, Y., & 
Godekmerdan, A.  
(2011), Turkey. 
  
Aim: to investi-
gate the associa-
tion between AA 
and depression, 
anxiety and cyto-
kines. 
  
  
  
  
43 patients with 
AA (31 males; 12 
females). 
  
Mean age: 23.42. 
  
Duration of con-
dition: 15.54 
months (ranged 
from 1 month to 
19 years). 
  
30 age and sex 
matched healthy 
controls. 
Quantitative 
 
 
Case-control 
study 
  
  
  
  
  
Hamilton Rating 
Scale for Depres-
sion (HAM-D) 
  
Hamilton Rating 
Scale for Anxiety 
(HAM-A) 
  
Children’s De-
pression Invento-
ries (CDIs) for 
children between 
7 and 16 years 
old. 
  Some degree of depression was observed in 50% of the 
AA patients as compared to 30% of the controls 
(p<0.05). 
  Anxiety was found in 63% of AA patients over 16 years 
old as compared to 23% of the controls (p<0.05). 
  No significant differences were observed between 
patients and controls with respect to serum cytokine 
levels (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
6 Baghestani, S., 
Zare, S., Seddigh, 
S. H. (2015), Iran. 
  
Aim: to investi-
gate severity of 
depression and 
anxiety in pa-
tients with AA.  
  
68 patients with 
AA (49 males; 19 
females). 
  
Mean age: 35.4. 
  
Duration of con-
dition: 22.7 
months. 
  
68 age, sex and 
education level 
matched healthy 
controls. 
  
Quantitative 
 
Case-control 
study 
  
  
  
  
  
  
  
Hamilton Anxiety 
Rating Scale 
(Ham-A) 
  
Hamilton Depres-
sion Rating Scale 
(Ham-D) 
  
  
  
  
  
  
  47% AA patients suffered from anxiety 
  The mean of anxiety scale in case group was 
significantly higher than that of control group (12.76 vs 
8.54; P=0.003). 
  56% AA patients suffered from depression. 
  The mean of depression scale in case group was 
significantly higher than that of control group (12.84 vs 
6.22; P=0.001). 
  Patients with AA were exposed to depression 
approximately 5 times more than normal people. 
  Patients with AA were exposed to anxiety about 3 times 
more than normal people. 
 
 
 
 
 
 
 
 
64% 
ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
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7 Cartwright, T., 
Endean, N., & 
Porter, A. (2009), 
U.K. 
 
Aim:  to investi-
gate the relation-
ships between ill-
ness perceptions, 
coping and Qual-
ity of Life in pa-
tients with Alope-
cia. 
  
  
  
  
  
  
  
  
  
  
  
  
214 patients 
(43 males; 171 fe-
males). 
  
Mean age: 35 
years. 
  
Duration of con-
dition: 13.7 years 
(the mean). 
  
  
  
  
  
  
  
  
  
Quantitative 
  
A cross-sectional 
design 
  
  
  
  
  
  
  
  
  
  
  
  
The Revised Ill-
ness Perception 
Questionnaire 
  
The Dermatology 
Life Quality Index  
  
The brief COPE 
  
  Alopecia perceived to have major consequences on 
participants’ lives (IPQ-R 3.56). 
  Alopecia perceived to have considerable emotional 
impact (IPQ-R 3.76).  
  The QOL in the sample was impaired (DLQI 12.49, 
p<0.05). 
  QOL was significantly poorer for women with Alopecia 
(DLQI 13.01; p<0.05) compared to men (DLQI 10.42, 
p<0.05) 
  Women significantly more likely to feel Alopecia 
interfering with leisure activities (DLQI 3.32, P<0.01) 
than men (DLQI 2.23, p<0.01). 
  Women significantly more likely to feel Alopecia 
interfering with personal relationships (DLQI 2.01, 
p<0.01) than men (DLQI 1.28, p<0.01)  
  Men significantly more likely to feel that Alopecia 
affected their work (DLQI 1.56, p<0.05) than women 
(DLQI 1.22, p<0.05). 
  DLQI was positively correlated with: psychological 
attributions (DLQI 0.150, p<0.05), belief in the serious 
consequences of Alopecia (DLQI 0.589, p<0.01), 
emotional interpretations of the condition (DLQI 0.545, 
p<0.01) and illness identity (DLQI 0.377, p<0.01). 
  QOL was negatively correlated with illness coherence 
(DLQI -0.161, p<0.05). 
55% 
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  Impaired QOL was associated with problem focused 
coping (DLQI 0.374, p<0.01) and avoidant coping (DLQI 
0.519, p<0.01). 
  Age at onset, number of hair losses and duration of the 
condition were not associated with Quality of Life. 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
8 Ghajarzadeh, M., 
Ghiasi, M., & 
Kheirkhah, S.  
(2011), Iran. 
  
Aim: to deter-
mine QOL impair-
ment and depres-
sion in Iranian pa-
tients with AA. 
 
  
100 patients 
(69 males; 31 fe-
males). 
  
Mean age: 23 
years. 
  
The mean dura-
tion of condition: 
12.8 months. 
  
  
Quantitative 
  
Cross-sectional 
study 
  
  
  
  
  
Beck Depression 
Inventory (BDI) 
  
Short Form 
Health Survey SF-
36 
  
Dermatology Life 
Quality Index 
questionnaire 
(DLQI)  
  
  There was no significant association between DLQI and 
the duration of the disease (p=0.6). 
  There was no significant association between DLQI and 
age (p=0.1). 
  There was significant association between DLQI and 
BDI score (p<0.001). 
  61% of participants experienced some form of 
depression.  
  BDI scores were significantly different for male (12.7) 
and female (18.1) participants (p=0.01). 
  SF-36 and DLQI did not significantly differ between two 
groups (DLQL 6.4 vs. 6.2, p=0.8; SF-36 68.1 vs.67.7, 
p=0.8). 
 
 
 
 
 
 
 
 
 
 
 
64% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
9 Masmoudi, J., 
Sellami, R., Ouali, 
U., Mnif, L., Feki, 
I., Amouri, M., 
Turki, H., & 
Jaoua, A. (2013), 
Tunisia. 
  
Aim: to examine 
the impact of AA 
on the different 
dimensions of 
QOL and to de-
termine factors 
related to an al-
tered QOL.  
   
  
50 patients (24 
males; 26 
females). 
  
Mean age: 32.92 
years (range 18  
- 60 years)  
  
Duration of the 
condition: NS 
  
80% had patchy 
Alopecia with less 
than 50% involve-
ment, 
12% had patchy 
Alopecia with 50–
99% involvement, 
and 8% had AT. 
  
50 age and sex 
matched healthy 
controls. 
Quantitative 
  
Case-control 
study. 
  
  
  
  
  
  
  
  
  
The Short Form 
Health Survey 
(SF36). 
  Compared with the general population, AA patients 
presented a significantly altered quality of life, found 
in the global score (SF-36 68.95, p<0.001) and in five 
sub-scores of the SF-36: mental health (SF-36 63.64, 
p<0.001), role emotional (SF-36 33.33, p<0.001), social 
functioning (SF-36 54.60, p<0.001), vitality (SF-36 
62.40, p<0.001) and general health (SF-36 68.95, 
p<0.001). 
  Females scored lower on the SF-36 than males in 
global score (p=0.007), physical functioning (p=0.028), 
general health (p=0.012) and role emotional (p=0.018). 
  The younger the patient, the more their mental health 
is negatively affected by AA (p=0.017).  
  Unmarried patients had significantly lower scores in 
the dimension of mental health compared to married 
patients (p=0.050). 
  There is a relationship between poorer QOL and 
severity of AA. The relationship was significant in the 
SF-36 subscale of mental health (p=0.07) and social 
functioning (p=0.009). 
 
 
 
 
73% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
10 Qi, S., Xu, F., 
Sheng, Y., & Yang, 
Q. (2015), China. 
  
Aim: to assess 
QOL of AA pa-
tients in China 
and determine 
the relationship 
of DLQI scores to 
demographic and 
clinical variables. 
698 patients with 
AA (349 males; 
349 females) 
  
Mean age: 38.8 
years. 
  
Duration of con-
dition: 16.9 years. 
  
  
Quantitative 
  
Cross-sectional 
  
  
  
  
Dermatology Life 
Quality Index 
Questionnaire 
(DLQI) 
  QOL of 40.9% patients was moderately to extremely 
affected by AA. 
  QOL was impaired significantly in severe AA patients 
(p<0.001). 
  Duration longer than 12 months, disease recurrence 
and presence of scalp symptoms were associated a 
higher DLQI score (p<0.001). 
  Younger patients exhibited higher DLQI score (p<0.05). 
  There was no effect on QOL by sex. 
59% 
11 Rafique, R., Hunt, 
N. (2015), Paki-
stan. 
  
Aim: to investi-
gate experiences 
and coping be-
haviours of ado-
lescents with AA. 
8 AA patients (3 
males; 5 females) 
  
Mean age: 17.5 
years. 
  
Duration of con-
dition: 1-3 years. 
  
  
Qualitative. Semi-structured 
interviews 
  
IPA 
  
  
  
  
  
  
  
Four main keys were identified: 
1.  Loss (self/social). 
2.  Concerns (physical/future). 
3.  Negative (emotions/thoughts). 
4.  Coping styles (adaptive/maladaptive). 
  Females experienced greater feeling of loss, were 
more concerned about their looks/future and reported 
more negative thoughts/emotions.  
  Females felt angry and blamed God; males blamed 
their fate and luck. 
  Action-oriented and practical coping styles adopted by 
all. 
80% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
12 Rocha de Hol-
landa, T.,  Sodré, 
C.T., Brasil, M. A., 
& 
RamoseSilva, M.  
(2014), Brazil. 
  
Aim: to assess 
QOL in AA pa-
tients in Brazil. 
  
37 AA patients 
(14 males; 23 fe-
males). 
  
Mean age: 35.89 
years. 
  
Duration of con-
dition: not stated. 
  
49 and sex 
matched blood 
donors controls. 
Quantitative 
  
Case-control 
study 
  
  
  
  
The Short Form 
Health Survey 
(SF36)  
  The impairment in QOL in AA patients on social 
functioning (p=0.001), emotional role functioning 
(p=0.019), and mental health (p=0.000) scales 
displayed statistically significant difference in relation 
to the control group. 
  In the AA group the mental health subscale’s score was 
not influenced by sex (p=0.139), age (p=0.603) and 
severity of Alopecia (p=0.130). 
  AA seems to greatly affect patients worldwide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
13 Sellami, R., 
Masmoudi, J., 
Ouali, U., Mnif, L., 
Amouri, M., 
Turki, H, & Jaoua, 
A. (2013), Tunisia. 
  
Aim: to investi-
gate a possible 
relationship be-
tween AA and 
Alexithymia, Anx-
iety and Depres-
sion. 
50 patients (24 
males; 26 fe-
males). 
  
Mean age: 32.92 
years (range 18-
60 years). 
  
Duration of the 
condition: 69.28 
days (range 1-400 
days). 
  
50 healthy con-
trols  
Quantitative 
  
Case control 
study 
  
Cross sectional 
  
  
Hospital Anxiety 
and Depression 
Scale (HADS). 
  
The Toronto Alex-
ithymia Scale 
(TAS) 
  
  
  
  
  There was no significant difference between AA 
patients and controls in terms of alexithymia 
prevalence (p=0.683). 
  Anxiety (p=0.005) and depression (p=0.047) were 
significantly higher in the patient group in comparison 
with controls.  
  Unmarried patients showed significantly more signs of 
depression compared to healthy controls (p=0.024). 
  Female patients are differentiated from males by 
higher levels of anxiety and depression (p=0.016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82% 
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ID Author, date, lo-
cation & aim 
Sample charac-
teristics 
Study Type and 
Study Design 
Psychosocial out-
come 
Findings Quality 
14 Welsh, N. & Guy, 
A. (2009), U.K. 
  
Aim: to capture 
respondent’s on-
going lived expe-
rience of AA. 
  
  
  
  
  
  
  
  
  
  
  
  
12 patients 
(5 males; 7 fe-
males). 
  
Mean age: 45 
(men), 37 
(women); (range 
from 31 to 59 
years). 
  
The mean dura-
tion of condition: 
14.6 years (men), 
20.7 (women); 
(range from 2 -49 
years). 
  
Qualitative 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Semi-structure 
interviews 
 
IPA 
IPA generated 2 superordinate themes and 6 subthemes:  
  Coping with the initial impact of Alopecia 
• social dimensions, treatments 
• social support 
  Living with unpredictability of Alopecia.  
• time to adjust 
• pragmatic coping 
• putting things into perspective  
• positive thinking 
  
An IPA also found that: 
  Adjustment is related to a range of psychosocial 
factors and coping techniques change and improve 
with time. 
  AA is considered to have a disruptive impact on self-
image and self-esteem. 
  Women reported higher concern regarding their 
appearance than men. 
  Women reported using support groups whereas men 
did not. 
70% 
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Quality assessment 
This review included a number of study designs and different sample sizes so in 
order to effectively evaluate the quality of the studies reviewed, several quality tools 
were considered. This included QUADAS (Whiting, Rutjes, Reitsma, Bossuyt, & 
Kleijnen, 2003), COSMIN (Mokkink at al. 2010), AMSTAR (Shea, et al., 2007) and 
QualSyst (Kmet, Lee, & Cook, 2004). Upon reviewing various checklists, it was 
decided that QualSyst was most appropriate for the current review. QualSyst is a 
standardised review tool for assessing the quality of qualitative and quantitative 
studies. Its scoring system draws upon existing published tools for quantitative and 
qualitative research and the systematic review tool implements both systems 
(Kmet, Lee, & Cook, 2004) (Appendix C & D). The checklist for quantitative studies 
consists of 14 items that are scored ‘yes’=2, ‘partial’=1, ‘no’=0, determined by the 
degree to which particular criteria are fulfilled. Items ‘not applicable’ to a specific 
study design are excluded from the calculation. A summary score was calculated 
for each study by adding the total score obtained from the relevant items and 
dividing by the total possible score (28). The checklist for qualitative studies 
consists of 10 items that are also scored ‘yes’=2, ‘partial’=1, ‘no’=0. There was no 
’n/a' option and the summary score was calculated for each study by adding the 
total score obtained from each item and dividing by the total possible score (20). 
Quality was evaluated independently by two assessors. Where disagreement 
occurred within an item, these were discussed and the checklists were reviewed 
until consensus was reached. 
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Data synthesis 
The study follows PRISMA guidelines on how to conduct and report systematic 
reviews (Moher, Liberati, Tetzlaff, & Altman, 2009). In-line with guidance from 
Popay et al., (2006), a narrative synthesis was used to summarise the data and to 
reflect critically on the synthesis process.  
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Results 
Study selection 
The search initially identified 3,568 studies, after duplicates had been removed 
(Refer to figure 2). These 3568 records were screened and 3501 records excluded 
based on their titles and abstracts. After checking the full texts, 53 records were 
excluded and in total 14 studies met the inclusion criteria of this review. 
Figure 1: PRISMA Flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
Sc
re
en
in
g 
In
clu
de
d 
El
ig
ib
ili
ty
 
Id
en
tif
ica
tio
n 
Records identified through 
database searching  
(n = 3988) 
Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed  
(n = 3568) 
Titles and abstracts 
screened  
(n = 3568) 
Records excluded  
(n = 3501) 
Full-text articles 
assessed for eligibility  
(n = 67) 
Full-text articles 
excluded 
(n = 53) 
 
Study quality (n=2) 
Not investigating 
alopecia (n=9) 
Pharmacological 
treatment of alopecia 
(n=15) 
Non-English (n=2) 
Commentaries, letters 
to editors, books, 
book chapters (n=25)  
Studies included in 
qualitative synthesis  
(n = 14) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0) 
 427 
Quality assessment 
Quantitative and qualitative studies were assessed for quality separately. For 
quantitative studies, inter-rater agreement in scoring by item ranged from 57% to 
100% (Appendix E). The overall scores assigned by the Reviewer 1 ranged from 
0.55 to 0.86 and by the Reviewer 2 from 0.55 to 0.82 (Appendix G). The reviewers 
assigned the same overall score to three studies. For the remaining eleven studies, 
discrepancies in the overall scores ranged from 0.04 to 0.05. For the qualitative 
studies, inter-rater agreement in scoring by item ranged from 50% to 100% 
(Appendix G). The overall scores assigned by Reviewer 1 ranged from 0.70 to 0.85 
and by Reviewer 2 from 0.75 to 0.80 (Appendix H). The discrepancy in the overall 
score was 0.05.  
The overall quality of the quantitative studies varied from 55% to 86%. The weakest 
studies had design flaws, for example, they lacked conclusions, insufficiently 
described their objectives and had no control group. The overall quality of the two 
qualitative studies varied from 70% to 85%. The weaker studies included 
insufficient descriptions of their theoretical framework and lacked conclusions. 
 
Study characteristics 
The 14 included studies represented 4415 participants from 10 different countries 
(Belgium, Brazil, China, Italy, Iran, Kuwait, Pakistan, Tunisia, Turkey and the 
United Kingdom). Twelve studies were quantitative (8 case-control design; 4 cross-
sectional design) and 2 were qualitative. The size of the samples varied from 8 to 
2962 participants. Of the 8 case control studies, 5 of those had an equal number of 
patients and age-sex matched controls (Aghaei et al., 2014; Alfani et al., 2012; 
 428 
Arbabi et al., 2013; Baghestani et al., 2015; Sellami et al., 2013). 
 
Participant characteristics 
Participants included 2631 males and 1784 females from 10 different countries. 
The age range of participants was from 0 to 77 years and the duration of the 
disease varied from 1 week to 49 years. The youngest age of onset was less than 
1. The studies included participants with AA, AT, AU. The severity of the illness 
varied from small patches on the scalp and loss of facial hair to the complete loss 
of all facial and body hair.  
 
Psychosocial impact of alopecia 
Depression 
Six of the 14 studies measured depression, using a validated scale. Five studies 
were case-control studies, one was a cross-sectional study. The control groups 
consisted of healthy age-sex matched controls. The studies’ quality score ranged 
from 0.55 to 0.82. Of these 6 studies, all found that the rates of depression (Aghaei, 
Saki, Daneshmand, & Kardeh, 2014; Alfani et al., 2012; Ataseven, Saral, & 
Godekmerdan, 2011; Baghestani, Zar & Seddigh, 2015; Ghajarzadeh, Ghiasi, & 
Kheirkhan, 2011; Sellami, et al. 2013) were statistically, significantly higher for 
those with alopecia compared to controls not diagnosed with the condition. 
Additionally, Ghajarzadeh, Ghiasi and Kheirkhah (2011) found a statistically 
significant negative association between quality of life and depression scores. 
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Anxiety 
Five of the 14 studies measured anxiety, using a validated scale. All 5 were case-
control studies and again the control groups consisted of healthy age-sex matched 
controls. The studies’ quality score ranged from 0.55 to 0.82. Of these 5 studies, all 
found that the rates of anxiety (Aghaei, Saki, Daneshmand, & Kardeh, 2014;  Alfani 
et al., 2012; Ataseven, Saral, & Godekmerdan, 2011; Baghestani, Zar  & Seddigh, 
2015; Sellami, et al. 2013;) were statistically significantly higher, for those with 
alopecia compared to healthy controls.  
 
Psychiatric morbidity 
One of the 14 studies measured psychiatric comorbidity, using a validated scale. 
This case-control study, with healthy age-sex matched controls had a quality score 
of 0.55. This study found that rates of schizophrenia and psychopathic deviance 
(Alfani et al., 2012) were significantly higher for those with alopecia than controls, 
but no significant differences were found between cases and controls on levels of 
paranoia or hypomania (Alfani et al., 2012).  
 
Quality of life 
The 6 studies included in this systematic review that measured this outcome 
suggest a strong association between alopecia and quality of life, using validated 
scales.  
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Disease-specific quality of life 
Four studies used the validated Dermatology Life Quality Index Questionnaire 
(DLQI) (Finlay & Khan, 1994). Al-Mutairi and Eldin (2011) argued that mean scores 
were statistically poorer in patients with alopecia than in the healthy age and sex 
matched control group. Using established criteria for the scale, Cartwright, Endean 
and Porter (2009) found low mean scores on DLQI scale, which indicated that the 
quality of life of patients with alopecia was significantly impaired. Qi, Xu, Sheng and 
Yang (2015) also suggested that quality of life was affected moderately to 
extremely impaired in 41% of alopecia patients. 
 
Generic quality of life 
Two studies measured generic quality of life. When compared with the general 
population, people with alopecia presented with significantly poorer quality of life on 
the global score of the 36-Item Short Form Health Survey (SF-36) (Masmoudi et al. 
2013) and in its mental health (Masmoudi et al. 2013; Rocha de Hollanda, Sodré, 
Brasil, & Ramos-e-Silva, 2014), social functioning (Masmoudi et al. 2013; Rocha de 
Hollanda, Sodré, Brasil, & Ramos-e-Silva, 2014), role emotional, vitality and 
general health subscales (Masmoudi et al., 2013). 
  
Stress 
Arbabi et al. (2013) found that 87% of alopecia patients had experienced a 
stressful event 3 months before the appearance of the disease, as compared to 
30% of controls, who experienced un-specific hair loss. Similarly, Alfani et al (2012) 
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found that 24.6% of the sample reported stressful events at the onset or before the 
exacerbation of alopecia, 10 reported family problems, five reported work problems 
and three reported mourning. 
 
Factors associated with psychosocial well-being 
 
Gender 
According to the majority of the reviewed studies gender is a factor associated with 
psychosocial adjustment. Masmoudi et al. (2013) found that females scored lower 
than males on global quality of life, physical functioning, general health and 
emotional role functioning using a generic quality of life measure. Using a 
dermatology specific measure, Cartwright et al. (2009) found that quality of life was 
poorer for women with alopecia compared to men and women were more likely to 
feel that alopecia interfered with personal relationships. On the contrary, 
Ghajarzadeh et al. (2011) and Qi et al. (2015) found no effect on quality of life for 
gender. 
 
Significantly higher rates of depression (Ghajarzadeh et al., 2011; Sellami et al., 
2013; Baghestani et al., 2015) and anxiety (Sellami et al., 2013; Baghestani et al., 
2015) were found for female participants as compared to males. Alfani et al. (2012) 
also suggested that males scored significantly higher than females on psychopathic 
deviance. 
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In the two qualitative studies, Welsh and Guy (2009) found that alopecia had a 
disruptive impact on self-image and self-esteem; females reported higher concern 
regarding their appearance than males and consequently reported using support 
groups, whereas males did not. Similarly, Rafique and Hunt (2015) claimed that 
there were differences in the way men and women perceive loss. Consequently, as 
a result of the condition females reported loss of self-esteem and loss of 
confidence, whereas men reported loss of confidence and loss of love from friends. 
In addition, men were more likely than women to express concerns about looking 
older and women were more likely to report concerns about looking less attractive 
(Rafique & Hunt, 2015). Only female patients reported negative emotions, for 
example, feelings of guilt and depression (Rafique & Hunt, 2015). The researchers 
also suggested that coping techniques may differ between men and women, for 
instance with regards to intropunitive avoidance, women reported withdrawing from 
social life and men starting smoking. As for self-distraction males reported playing 
more sports and women reported spending more time studying. Support seeking 
was mostly evident in women's reports and using humour was typical to males 
(Rafique & Hunt, 2015).  
 
Age 
Both Qi et al. (2015) and Masmoudi et al. (2013) found that being younger was 
associated with poorer quality of life. In Qi et al. (2015) this was found for those 
under 40 years of age and was regardless of disease severity. Whereas, 
Ghajarzadeh et al. (2011) did not find a significant association between quality of 
life and age and Baghestani et al. (2015) failed to find a significant association 
between age and severity of anxiety or depression in alopecia. 
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Education level 
Baghestani et al. (2015) found a statistically significant relationship between those 
with primary and secondary education level and prevalence of depression and 
anxiety, levels of anxiety and depression were higher in patients with secondary 
education compared to patients with primary education levels. 
  
Marital status 
Although Masmoudi et al. (2013) concluded that unmarried patients had 
significantly lower scores in mental health quality of life compared to married 
patients, the p value of 0.05 suggests that this is non-significant. Whilst Sellami et 
al. (2013) found that unmarried patients with higher depression scores had a 
significantly greater risk for having AA compared to those with lower depression 
scores. In their qualitative study, Rafique and Hunt (2015) reported that female 
patients feared not being able to experience love and not getting married. 
 
Family history 
Qi et al. (2015) failed to find any relationship between quality of life and family 
history of alopecia. 
 
Age of onset 
No significant relationships were found between quality of life (Qi et al., 2015), 
anxiety, neurosis or psychosis (Aghaei et al., 2014) and age of onset. 
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Disease type, severity and location 
Several studies looked at the impact of alopecia disease type on psychosocial well-
being, the results were somewhat inconsistent. Whilst Al-Mutairi and Eldin (2011) 
found that patients with complete facial and body hair loss, that is AU, had poorer 
quality of life compared to patients with AA and AT. Qi et al. (2015) found that 
presence of scalp symptoms (AA), were associated with poorer quality of life when 
compared with AT and AU. Ghajarzadeh et al. (2011) however, found that the 
poorest quality of life was found for patients whose eyebrows were moderately 
involved compared to eyelash or beard involvement.  
Masmoudi et al. (2013) found that those with 51-75% hair loss had significantly 
poorer mental health and social functioning quality of life than those with less than 
25% hair loss. Patients with 100% hair loss also scored poorer on mental health 
quality of life compared to those with 51-75% hair loss. Significantly higher rates of 
depression, anxiety and neurosis were also found in AT, which involves losing 
facial hair (Aghaei et al., 2014), but no association with eyebrow involvement. 
Whereas, Baghestani et al. (2015) did not find significant differences in anxiety and 
depression scores based on severity or the onset location of the disease. Similarly, 
Sellami et al. (2014) found no relationship between the severity of alopecia and 
depression. 
 
Disease duration 
Qi et al. (2015) found that disease recurrence and an illness duration of longer than 
12 months, compared to a shorter duration, was associated with poorer quality of 
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life. However, Ghajarzadeh et al. (2011) did not find significant relationship 
between quality of life and the duration of the illness. Whilst Alfani et al. (2012) 
reported the highest rates of psychopathic deviance, paranoia, schizophrenia and 
depression if the duration of the disease was between 6-11 months, compared to 
less than 6 months or more than 11 months. There was however, no association 
between disease duration and rates of anxiety, hypomania or social discomfort. 
According to Baghestani et al. (2015) there was no significant association between 
anxiety and depression scores and disease duration.  
 
Coping strategies 
Two qualitative studies explored coping strategies and how people use these to 
manage the psychosocial consequences of living with alopecia. In a group of 
adolescents with alopecia areata Rafique and Hunt (2015) identified 4 themes 
linked to psychosocial impact on alopecia patients: loss, concerns, negative 
emotions (discussed in the gender section) and coping styles. The researchers 
argued that patients can be characterised by maladaptive coping, such as blaming 
or intropunitive coping, as well as adaptive coping behaviours, for example action-
oriented, practical, religious, self-distraction, support seeking, acceptance, future 
planning and humorous coping. The data indicated that coping mechanisms 
change and improve over time and initial maladaptive coping behaviours are 
replaced by more adaptive ones as disease duration increases. Similarly, in a 
qualitative study of 12 people with AA or AU, Welsh and Guy (2009) found that 
adjustment is related to a range of coping techniques, which change and improve 
with time. Pragmatic coping, putting things into perspective and positive thinking 
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are the most common coping strategies to deal with the psychological burden of 
the condition. 
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Discussion 
The aims of the systematic review were to evaluate the psychological and social 
impact of autoimmune alopecia, and the factors associated with this impact. In 
agreement with a previous review (Tucker, 2009), all 14 papers included observed 
adverse psychosocial consequences to having alopecia and extending the findings 
of Tucker (2009) this impact was associated with a number of demographic, clinical 
and psychological factors.  
 
Supporting the findings of Tucker (2009), a majority of the studies included in the 
current review reported poorer quality of life and higher rates of depression and 
anxiety amongst patients with alopecia compared to those not affected by the 
condition. There was less robust evidence to suggest a link between alopecia and 
diagnosed psychiatric morbidities, but a potential role for stressful life events as a 
trigger for alopecia. This finding could be explained by the fact that levels of 
depression and anxiety in patients with alopecia maybe high enough to make 
stress perception more pronounced (Arbabi et al., 2013). 
 
A number of factors were found to play a potential role in people’s reports of 
psychosocial wellbeing, including disease severity and location, disease duration, 
gender, age and marital status. Overall, quality of life declined with the severity of 
alopecia, with hair loss involving the scalp and eyebrows being particularly 
problematic for quality of life and loss of facial hair for anxiety and depression. The 
significance of facial and scalp hair loss suggests that it may be the visibility of the 
disorder that is having the greatest impact on wellbeing. In support of this, Kacar et 
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al. (2016) argued that the inability to conceal an illness may lead to self-
stigmatisation and consequently individuals with alopecia report more stigma 
compared to patients with mental health disorders. Strategies to hide alopecia differ 
according to the extent of hair loss and the stage of the illness. Welsh and Guy 
(2009) argued that people often tried to conceal the initial patches by wearing 
scarves, hats, headbands, using sprays, covering patches with the remaining hair 
or make up. At later stages people alter the type of clothing they wear and try to 
cover their heads (Masmoudi et al., 2013). Women often use veils and wigs, men 
tend to use hair pieces, caps or they shave their hair (Rafique & Hun, 2015). The 
ability to hide one’s alopecia, reportedly helped people to regain their confidence 
and reinstate their social and professional roles (Welsh & Guy, 2009). 
 
Overall, the impact of disease duration on wellbeing was mixed. Qualitative 
research suggested that the coping mechanisms people utilise to manage the 
consequences of their alopecia may improve over time and initially maladaptive 
coping behaviours are replaced with more adaptive ones (Rafique and Hunt, 2015). 
Early disease seemed to also be related to poorer quality life and higher levels of 
depression and psychiatric morbidity, although these findings were not consistent. 
This implies that the patient’s experiences amplified depression and anxiety in the 
first episode of the illness and over time, they start to accept the condition as a part 
of their lives and adopt more effective coping strategies. It could however, also 
indicate that pre-existing psychological disorders may initiate or aggravate the 
disease or that alopecia can result from a stressful life event.  
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Being female was also associated with poorer quality of life and higher rates of 
anxiety and depression in the majority of the included studies. Qualitative research 
by Welsh and Guy (2009) also argued that alopecia had a more disruptive impact 
on female self-image and self-esteem and on male self-confidence. These findings 
suggest that psychological interventions may need to be adapted to target different 
areas for men compared to women. Hair has traditionally been viewed as essential 
to the identity of many women as femininity, sexuality and attractiveness are 
symbolically linked to a woman’s hair (Wolf, 1991). In a study of cancer patients 
with Alopecia, hair loss was ranked amongst the most worrisome side effects and it 
was often described as distressing, and having a negative impact on the body 
image (Lemieux, Maunsell, & Provencher, 2008).  
 
For some women, the loss of hair is reported as being psychologically more difficult 
than the loss of a breast through breast cancer (Freedman, 1994). Alopecia can 
clearly have serious psychosocial consequences, causing intense emotional 
suffering, as well as personal, social and work-related difficulties. Surveys have 
shown that around 40% of women with alopecia have had marital problems, and 
around 63% claimed to have career-related problems (Hunt & McHale, 2005a). 
Supporting the marital and relational effects of alopecia found within this review. 
Results suggest that an un-established social life in unmarried patients may lead 
them to worry about their future, resulting in increased anxiety. Hair loss could be 
viewed as an abnormality and as a failure to conform to society’s norms of ideal 
physical appearance, which has the potential to set people apart in their own 
estimation and in the estimation of others. Rafique and Hunt (2015) also noted 
differences in coping strategies, suggesting a tendency for women to withdraw from 
 440 
social life and for men to take up smoking. This qualitative work also noted that in 
order to distract themselves from thinking about the illness, men used humour and 
tended to take part in more sports and women spent a greater amount of their time 
studying. Females are also most likely than males to seek support from others 
(Welsh and Guy, 2009; Rafique & Hunt, 2015). According to these researchers, 
coping mechanisms change and improve over time and initial maladaptive coping 
behaviours may be replaced by more adaptive ones. 
 
Being younger was associated with poorer quality of life, particularly for those 
under 40 years of age, but was not associated with mood. This suggests that 
younger patients, of working age, may feel more pressure due to scenarios such as 
applying for a job or seeking a partner than older patients. Data on psychosocial 
consequences of alopecia in children and adolescents was found to be very limited, 
adolescents were only researched in one study (Rafique & Hunt, 2015). This 
concept should be studied more adequately as although age of onset was not 
found to impact on psychosocial wellbeing in this review approximately 60% of 
patients with alopecia develop the illness before the age of 20 (Kakourou, 
Karachristou, & Chrousos, 2007). The condition may severely impact identity 
formation in children and adolescents (Hunt & McHale, 2005a) and impair 
psychosocial and physical areas of children’s and adolescents’ quality of life (Bilgiç, 
et al. 2014). Consequently, further research exploring the link between alopecia 
and its psychosocial impact in children and adolescents is recommended. 
 
 
 441 
Strengths and limitations of the review 
Strengths of the current review include a systematic and thorough literature search, 
the high number of good quality studies, incorporating the most recent research, 
the use of studies from a variety of countries, the use of validated scales and 
double quality assessment checks. Limitations of the review include lack of double 
study selection, the majority of studies not utilising large samples, most participants 
being recruited from hair clinics and therefore samples being prone to selection 
bias, providing less evidence for causal inference than longitudinal or experimental 
designs, although the later would have been less appropriate for this research 
question.  
 
  
 442 
Conclusions 
Recognising the psychosocial impact of hair loss is critical when caring for patients 
with alopecia. It seems clear that alopecia can have a profound psychological 
impact on those affected by the condition and hence further research exploring the 
psychological treatments that may be effective in helping people adjust is required. 
Individual factors, such as coping styles, age, gender and severity of the condition, 
that are associated with the course of psychosocial wellbeing in alopecia should 
also be considered. Practitioners should recognise that alopecia is a medical rather 
than cosmetic condition and should be aware of the various psychosocial effects to 
enable holistic management of the disease.   
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APPENDIX A. Search Strategy 
S1 (MH “Alopecia+”) 
S2 (MH “Alopecia+”) 20070101-20171231 
S3 Alopecia areata OR Alopecia Totalis OR Alopecia Universalis 
S4 S2 OR S3 
S5 S4 NOT (Chemotherapy OR Cancer OR Effluvium OR Androgen* OR Cicatrical 
OR Trichotillomania) 
S6 “psycho*” 
S7 “emotion*” OR “adjust*” OR “adapt*” OR “cop*” OR “self*” OR “depress*” 
OR “anx*” OR “stress*” OR (MM “Quality of Life”) 
S8 S5 AND S6 AND S7 
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Appendix B. Quality Assessment Tool for quantitative studies (Kmet, Lee, & 
Cook, 2004). 
 
Criteria Yes 
(2) 
Partial 
(1) 
No 
(0) 
N/A 
1 Question/objective sufficiently 
described? 
    
2 Study design evident and appropriate?     
3 Method of subject/comparison group 
selection or source of information/input 
variables described and appropriate? 
    
4 Subject (and comparison group, if 
applicable) characteristics sufficiently 
described? 
    
5 If interventional and random allocation 
was possible, was it reported? 
    
6 If interventional and blinding of 
investigators was possible, was it 
reported? 
    
7 If interventional and blinding of subjects 
was possible, was it reported? 
    
8 Outcome and (if applicable) exposure 
measure(s) well defined and robust to 
measurement/misclassification bias? 
Means of assessment reported? 
    
9 Sample size appropriate?     
10 Analytic methods described/justified and 
appropriate? 
    
11 Some estimate of variant is reported for 
the main results? 
    
12 Controlled for confounding?     
13 Results reported in sufficient detail?     
14 Conclusions supported by the results?     
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Appendix C. Quality Assessment Tool for qualitative studies (Kmet, Lee, & 
Cook, 2004). 
Criteria Yes 
(2) 
Partial 
(1) 
No 
(0) 
N/A 
1 Question/objective sufficiently described?     
2 Study design evident and appropriate?     
3 Context for the study clear?     
4 Connection to a theoretical 
framework/wider body of knowledge? 
    
5 Sampling strategy described, relevant and 
justified? 
    
6 Data collection methods clearly described 
and systematic? 
    
7 Data analysis clearly described and 
systematic? 
    
8 Use of verification procedure(s) to 
establish credibility? 
    
9 Conclusions supported by the results?     
10 Reflexivity of the account?     
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Appendix D. Inter-rater agreement by item for quantitative studies. 
 
Checklist Item Observed Agreement for Each Checklist Item (%) 
1 79% 
2 86% 
3 71% 
4 57% 
5 100% 
6 100% 
7 100% 
8 100% 
9 93% 
10 86% 
11 100% 
12 79% 
13 64% 
14 71% 
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Appendix E. Inter-rater agreement by item for qualitative studies. 
 
Checklist Item Observed Agreement for Each Checklist Item (%) 
1 100% 
2 50% 
3 100% 
4 100% 
5 100% 
6 100% 
7 50% 
8 100% 
9 100% 
10 100% 
 
 
 
 
 
 
 
 
 
 
  
Appendix F. Inter-rater agreement for overall scores of quantitative studies. 
 
Research 
Paper 
Rater 1 Rater 2 Agreed score 
1. Aghaei et 
al. (2014) 
0.72 (72%)  0.68 (68%) 0.68 
2. Alfani et 
al. (2012) 
0.55 (55%) 0.59 (59%) 0.55 
3. Al-Mutairi 
& Nour Eldin 
(2011) 
0.77 (78%) 0.73 (73%) 0.73 
4. Arbabi et 
al., (2013) 
0.64 (64%) 0.64 (64%) 0.64 
5. Ataseven 
et al. (2011) 
0.73 (73%) 0.73 (73%) 0.73 
6. 
Baghestani 
et al. (2015) 
0.68 (68%) 0.64 (64%) 0.64 
7. Cartwright 
et al. (2009) 
0.59 (59%) 0.55 (55%) 0.55 
8. 
Ghajarzadeh 
et al. (2011) 
0.68 (68%) 0.64 (64%) 0.64 
9. Masmoudi 
et al. (2013) 
0.77 (77%) 0.73 (73%) 0.73 
10. Qi et al. 
(2015) 
0.64 (64%) 0.59 (59%) 0.59 
12. Rocha 
de Hollanda 
et al. (2014) 
0.68 (68%) 0.68 (64%) 0.68 
13. Sellami 
et al. (2013) 
0.86 (86%) 0.82 (82%) 0.82 
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Appendix G. Inter-rater agreement for overall scores of qualitative studies. 
 
Research 
Paper 
Rater 1 Rater 2 Agreed Score 
11. Rafique 
& Hunt 
(2015) 
0.85 (85%) 0.80 (80%) 0.80 
14. Welsh & 
Guy (2009) 
0.70 (70%) 0.75 (75%) 0.70 
 
 
 
 
